about the book… This unique new text delivers a solid foundation for understanding the role of genomics in human health ...
230 downloads
4880 Views
11MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
about the book… This unique new text delivers a solid foundation for understanding the role of genomics in human health and in advances that promise to help improve the quality of human life. Unlike other works that focus mainly on toxicogenomic techniques, Genomics presents a thorough overview of the field in four major sections: 1) fundamentals of genes and genome structure, function, expression, variations, and genomic technology platforms; 2) applications of genomics in drug discovery and drug development, safety evaluation, genomic database maintenance, mining, and analysis, food safety monitoring, and translational toxicogenomics; 3) how regulatory agencies such as the FDA and EPA use genomic data in their safety evaluation; and 4) a summary of the current state and the future prospect of the science of genomics. With an international perspective and practical case studies, Genomics is the first resource to present essential discussion of theory and application for: � eukaryotic genomes � epigenomics � translational genomics and biomarker development about the editors... SUPRATIM CHOUDHURI is a toxicologist in the Division of Biotechnology and GRAS notice review, Office of Food Additive Safety, U.S. Food and Drug Administration (FDA), College Park, Maryland, USA, and Adjunct Associate Professor at the Department of Pharmacology and Toxicology, University of Kansas Medical Center, Kansas City, KS. Dr. Choudhuri received his Ph.D. and M.Sc. both from the University of Calcutta, Calcutta, India. Dr. Choudhuri is a member of several professional organizations, including a full member of the U.S. Society of Toxicology. Dr. Choudhuri has been a guest reviewer of a number of toxicology and biochemistry journals, and has taught and trained undergraduate and graduate students, and postdoctoral researchers. Dr. Choudhuri has extensively published in the fields of molecular toxicology, genomics and metabolism; his teaching, research, and regulatory expertise includes molecular mechanisms of toxicity, toxicogenomics, comparative toxicology, metabolism and transporters, and regulatory safety assessment. Dr. Choudhuri has been invited to speak and chair sessions at various national and international meetings, and he is the recipient of numerous FDA awards. DAVID B. CARLSON is a toxicologist in the Division of Metabolism and Endocrinology Products, Office of New Drugs, U.S. Food and Drug Administration, Silver Spring, Maryland, and an Adjunct Assistant Professor of Biotechnology, University of Maryland University College, Adelphi, MD. Dr. Carlson received a B.S. from Duke University and a Ph.D. from Oregon State University. Dr. Carlson is an active member of several professional organizations, including the Society of Toxicology and the Society of Environmental Toxicology and Chemistry. Dr. Carlson has extensive publication and peer-review experience in scholarly journals and he has been invited to speak at national and international professional meetings in his area of expertise. Dr. Carlson’s teaching, research, and regulatory expertise includes mechanisms of endocrine disruption and nuclear receptor signaling, comparative toxicology and carcinogenesis, and safety assessment of drugs and food additives. Dr. Carlson is the recipient of numerous academic and FDA scholarships and awards. Printed in the United States of America
d838003.cva.indd d838003_cva.indd 1 1
�����
Genomics Fundamentals and Applications
Genomics
Choudhuri � Carlson
Genomics Fundamentals and Applications
Edited by
Supratim Choudhuri David B. Carlson
9/17/2008 9/16/200812:57:16 5:39:15 PM PM
Genomics
Choudhuri_978-1420067057_TP.indd 1
9/15/08 11:40:39 AM
Genomics Fundamentals and Applications Edited by
Supratim Choudhuri FDA/CFSAN College Park, Maryland, USA
David B. Carlson
FDA/CDER Silver Spring, Maryland, USA
Choudhuri_978-1420067057_TP.indd 2
9/15/08 11:40:39 AM
Informa Healthcare USA, Inc. 52 Vanderbilt Avenue New York, NY 10017 © 2009 by Informa Healthcare USA, Inc. Informa Healthcare is an Informa business No claim to original U.S. Government works Printed in the United States of America on acid-free paper 10 9 8 7 6 5 4 3 2 1 International Standard Book Number-10: 1-4200-6705-2 (Hardcover) International Standard Book Number-13: 978-1-4200-6705-7 (Hardcover) This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequence of their use. No part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers. For permission to photocopy or use material electronically from this work, please access www.copyright.com (http://www.copyright.com/) or contact the Copyright Clearance Center, Inc. (CCC) 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged. Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.
Library of Congress Cataloging-in-Publication Data Genomics: fundamentals and applications/edited by Supratim Choudhuri, David B. Carlson. p.; cm. Includes bibliographical references and index. ISBN-13: 978-1-4200-6705-7 (hardcover : alk. paper) ISBN-10: 1-4200-6705-2 (hardcover : alk. paper) 1. Genomics. I. Choudhuri, Supratim. II. Carlson, David B. (David Byron), 1970[DNLM: 1. Genomics--United States. 2. Drug Toxicity--genetics--United States. 3. Pharmacogenetics--United States. QU 58.5 G3351 2008] QH447.G4653485 2008 616’.042--dc22 2008026281 For Corporate Sales and Reprint Permissions call 212-520-2700 or write to: Sales Department, 52 Vanderbilt Avenue, 7th floor, New York, NY 10017. Visit the Informa Web site at www.informa.com and the Informa Healthcare Web site at www.informahealthcare.com
Preface
In a span of 100 years between 1900 and 2000, three landmark discoveries almost equally spaced apart in time revolutionized the scope of the study of the molecular basis of life. These were: the rediscovery of Mendelism and the laws of heredity in 1900, the discovery of DNA structure in 1953, and the completion of the first draft sequence of the human genome in 2000 (published in 2001). Each of these discoveries represents a major breakthrough that paved the way for further progress in a new direction. With the elucidation of DNA structure in 1953 by James Watson and Francis Crick, and the subsequent deluge of discoveries on DNA replication, genetic code, mRNA synthesis, protein synthesis, and gene regulation, the findings of classical genetics could be explained in terms of molecular biology principles. Thus, the discovery of DNA structure paved the way for the merger of two apparently disparate disciplines—classical genetics and molecular biology, and the birth of molecular genetics.a,b Within another 50 years, the science of molecular biology/molecular genetics has undergone another phase of transformation into the science of genomics, which is much more global in scope and approach. Knowledge of the genomes of humans and other species as well as scientific advances in genome research in general will presumably help us understand the genetic instructions that make us human. From a clinical perspective, by learning about the gene sequences and the functional dynamics of the genome as well as individual genetic differences, scientists hope to understand the molecular basis of the normal state and the diseased state of life on one hand, and develop ways to individualize medicine and nutrition on the other hand. However, the enormous wealth of knowledge that has been accumulated through genome sequencing and genome research has created a new challenge for scientists. The new challenge is to learn how to integrate and interpret the enormous body of genomic data to determine cause-and-effect relationships and how to predict the occurrence and progression of diseases before there are any symptoms. Parallel developments in the science of bioinformatics, genomic regulatory networks, and systems biology will presumably help us add meaning to the enormous body of genomic data, and in so doing will help us understand the molecular basis of biological diversity, organismal complexity, and life in general. a b
Choudhuri S. Tox Mech Meth 16, 2006, 137-159. Choudhuri S. Bull Sci Tech Soc 23, 2003, 360-367.
iii
iv
Preface
Nevertheless, despite real technological progress and much journalistic hyperbole about the promise of genomics, recent advances in research have not yet radically changed the practice of medicine and nutrition. The disconnect between the hope of quick returns from advances in genomics and the reality of the long-drawn path of developing products that will improve the quality of human life may lead to under-appreciation of the progress and achievements of genomics. In this new era, the terms “genome” and “genomics” have gone beyond the boundaries of the laboratory into public life and thus we all need to know something about genomics. The current book is an attempt to present to the reader, a thorough overview of the progress of genomics to its current level. EDITORS’ DISCLAIMER The editorial work on this book was outside the normal duties of the editors’ work at the FDA. The views and opinions expressed by the editors in the articles of this book are the editors’ personal opinions and they do not necessarily reflect those of the FDA, DHHS, or Federal Government. ACKNOWLEDGEMENT We would like to express our sincere appreciation and thanks to all who contributed chapters for the book, thereby making the project successful. We would like to acknowledge our colleagues who provided encouragement to tackle this project, and for stimulating discussion on various aspects of genomics. Thanks are also due to Carolyn Honour, Sherri Niziolek, and all of their colleagues at Informa Healthcare for helping us bring this project to a successful conclusion. Most importantly, we thank our families for their unwavering support throughout this process and to this small contribution to advance science! Supratim Choudhuri David B. Carlson
Contents
Preface . . . . iii Contributors . . . . xi Introduction . . . . xv PART 1: GENES AND GENOMES 1. Fundamentals of Structure–Function Analysis of Eukaryotic Protein-Coding Genes . . . . . . . . . . . . . . . . . . . 3 Supratim Choudhuri Introduction . . . . 5 Structure and Function of Typical Eukaryotic Protein-Coding Gene . . . . 6 Concluding Remarks . . . . 43 References . . . . 44 2. The Eukaryotic Genome: A Brief Overview of Structure, Function, and Evolution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49 Supratim Choudhuri Introduction—The Scope of Genomics . . . . 51 Nucleoprotein Organization of the Genome . . . . 55 Genomic DNA as a Mosaic of Isochores . . . . 63 Genomic Landscape as Revealed by Genome Sequencing . . . . 67 Chromosomal Synteny and Syntenic Maps in Comparative Genomics . . . . 94 Concluding Remarks . . . . 94 References . . . . 95 3. Epigenetic Regulation of Gene and Genome Expression . . . . . . . . . Supratim Choudhuri Introduction . . . . 102 Molecular Basis of Epigenetic Regulation . . . . 102
101
*Disclaimer: The views and opinions expressed in the articles of this book are the authors’ personal opinions and they do not necessarily reflect those of EPA, FDA, DHHS, or the Federal Government.
v
vi
Contents
Examples of Epigenetic Regulation of Gene and Genome Expression . . . . 111 Conclusion . . . . 124 References . . . . 125
4. Principles of Functional Genomic Analysis . . . . . . . . . . . . . . . . . . . . 129 Scott A. Jackson, Isha Patel, J. Eugene LeClerc, Thomas A. Cebula, Mark K. Mammel, Michael L. Kotewicz, Amit Mukherjee, Sushil K. Mahata, Juan L. Rodriguez Flores, Manjula Mahata, Daniel T. O’Connor, and Jannavi R. Srinivasan I. Use of High Density Gene Arrays for Gene Expression Profiling and Genotyping . . . . 131 II. Pyrosequencing in SNP Discovery and Genotyping in Prokaryotes . . . . 135 III. Use of Optical Mapping for the Rapid Construction of Ordered Restriction Maps for Entire Chromosomes from Single DNA Molecule . . . . 137 IV. Metabolic Profiling in Bacteria Using Phenotypic Microarray . . . . 139 V. From Plus–Minus Sequencing to Next Generation Sequencing with a Focus on Pyrosequencing . . . . 141 Introduction . . . . 141 Sequencing by Synthesis—Sanger Method . . . . 142 Sequencing by Chemical Cleavage—Maxam & Gilbert Method . . . . 142 Sequencing by Hybridization—ED Southern Method . . . . 142 Sequence by Synthesis—Pal Nyren’s Pyrosequencing Method . . . . 143 Applications of Pyrosequencing . . . . 150 Next Generation Sequencing—$1,000 Per Genome? . . . . 154 Concluding Remarks . . . . 156 VI. Principles of Proteomic Analysis with Special Emphasis on Mass Spectrometry . . . . 157 Introduction . . . . 157 Principles of Protein Separation . . . . 158 Principles of Protein Identification . . . . 160 Principles of Protein Structure Determination . . . . 165 Conclusion . . . . 167 References . . . . 167 PART 2: APPLICATIONS OF GENOMICS 5. Toxicogenomics in Non-Clinical Safety Studies: Models of Animal and Human Tissues to Assess Target Organ Injury . . . . Alison Vickers Introduction–Translational Research and Research Models . . . . 175 New Approaches and Models for Mechanistic Insight . . . . 176 Value of In Vitro Models . . . . 177 Toxicogenomics in Translational Research–Animal and Human Models (In Vivo and In Vitro) . . . . 178 Conclusion . . . . 185 References . . . . 185
175
Contents
vii
6. Mining of Genome Sequence Databases to Identify New Targets for Prostate and Breast Cancer Therapy. . . . . . . . . . . 191 Tapan K. Bera and Byungkook Lee Introduction . . . . 191 Identification of Disease-Related Genes by Database Mining . . . . 192 Concluding Remarks . . . . 203 References . . . . 203 7. Functional Genomic Approaches for Studying Genotoxicity and Carcinogenesis . . . . . . . . . . . . . . . . . Ebru Caba and Jiri Aubrecht Introduction . . . . 207 Transcriptomics . . . . 209 Functional Genomics . . . . 215 Summary . . . . 217 References . . . . 217
207
8. Human Genomics in Hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . 223 Pei-an Betty Shih, Daniel T. O’Connor, and Sushil K. Mahata Introduction . . . . 224 Intermediate Phenotypes and Heritability in Hypertension . . . . 224 Systematic Polymorphism Discovery at the Candidate Genetic Loci Susceptible for Hypertension . . . . 225 Genome-Wide Linkage Studies in Hypertension . . . . 228 Genome-Wide Association Studies in Hypertension . . . . 228 Gene-by-Sex Interaction in Hypertension . . . . 229 Adrenergic Pathway Polymorphisms and Hypertension . . . . 230 Renin-Angiotensin-Aldosterone System and Hypertension . . . . 232 Metabolic Syndrome and Hypertension . . . . 233 Endothelium and Vascular Dysfunction in Hypertension . . . . 233 Cardio-Renal Target Organ Susceptibility Genes and Hypertension . . . . 234 Pleiotropy and Hypertension . . . . 235 Epistasis and Hypertension . . . . 235 Heterosis and Hypertension . . . . 237 Pharmacogenetics—Antihypertensive Drugs . . . . 238 Mechanistic Studies on Trait-Associated Genetic Variants . . . . 238 Transcriptomics in Hypertension . . . . 239 Perspectives and Strategies . . . . 239 References . . . . 241 9. Immunotoxicogenomics: Gene Expression and Immunotoxicology in the Age of Genomics . . . . . . . . . . . . . . . . Dori R. Germolec, Leigh Ann Burns-Naas, G. Frank Gerberick, Gregory S. Ladics, Cindy A. Ryan, Stephen B. Pruett, Berran Yucesoy, and Robert W. Luebke Introduction . . . . 248
247
viii
Contents
Immune Suppression . . . . 249 Specific Application of Genomics Techniques as a Discovery Tool to Investigate Targeted Pathways in Immune Suppression . . . . 251 Screening for Dermal Sensitizers . . . . 254 Relating Genetic Variability and Host Susceptibility to Immune-Mediated Diseases . . . . 257 Genomics Applications in Discovery—A Tool in the Development of Immunomodulatory Therapeutics . . . . 259 Hazard Identification and Risk Characterization . . . . 262 Conclusions . . . . 263 References . . . . 264 10. Statistical Methods for Functional Analysis of ’Omics Experimental Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Zoltan Dezso, Andrej Bugrim, Richard J. Brennan, Yuri Nikolsky, and Tatiana Nikolskaya Introduction . . . . 269 Enrichment Analysis of High-Content Data . . . . 270 Analyzing Condition-Specific Networks . . . . 274 Network Measures . . . . 281 References . . . . 285 11. Toxicogenomics Data and Databases . . . . . . . . . . . . . . . . . . . . . . . . . Jennifer Fostel Introduction . . . . 289 Public Toxicogenomics Databases . . . . 290 Types of Data . . . . 293 Archiving ’Omics Data . . . . 296 Cheminformatics Data . . . . 296 Sharing Data . . . . 297 Characteristics of “Ideal” Database . . . . 300 References . . . . 301
269
289
12. Phenotypic Microarray Approaches to the Study of Prokaryotes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 305 Amit Mukherjee, J. Eugene LeClerc, and Thomas A. Cebula Introduction . . . . 305 The Phenotypic Microarray System . . . . 306 Phenotypic Microarray Studies with E. coli K-12 Mutants Deleted for all Two-Component Systems . . . . 307 Deciphering the Function of the b1012 Operon in E. Coli K-12 . . . . 307 Investigation of Phenotypic Changes in Rifampicin-Resistant rpoB Mutants of Bacillus Subtilis . . . . 309 Identifying Phenotypic Markers to Distinguish Foodborne Enteric Pathogens . . . . 310 Concluding Remarks . . . . 313 References . . . . 313
Contents
ix
13. Functional Analysis and Genomics of G-Protein-Coupled Receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 315 Kausik Ray and John K. Northup Introduction . . . . 315 GPCR Structural Features and Pharmacology . . . . 316 Receptor Functional Screening Strategies . . . . 324 Functional Genomics and Characterization of Orphan GPCRs . . . . 326 GPCR Dimerization and Allosteric Activation . . . . 329 GPCR Mutations in Human Diseases and Natural Variants . . . . 331 Conclusion . . . . 333 References . . . . 334 14. Nutrigenomics: A Genomic Approach to Human Nutrition . . . . . . Dilip Ghosh and Linda C. Tapsell Introduction . . . . 337 Applied Genomics—Pharmacogenomics and Nutrigenomics in Health Care . . . . 338 Nutrient–Gene Interactions . . . . 339 Paradigm Shift from Health-Care to Self-Care and the Current State of Personalized Nutrition . . . . 340 Public Perceptions and the Future of Nutrigenomics . . . . 341 New Applications of Genomic Technologies . . . . 342 Moving Forward . . . . 342 References . . . . 343
337
PART 3: USE OF GENOMICS DATA BY THE REGULATORY AGENCIES 15. Collaborations Lay the Critical Path to Acceptance of Genomics in Drug Safety Assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Peter G. Lord, Alex Y. Nie, and Michael K. McMillian Introduction . . . . 347 Forums for Collaboration . . . . 348 Microarray Technology Performance . . . . 351 Microarray Applications in Risk Assessment and Regulatory Concerns . . . . 353 Advancing the Science . . . . 355 References . . . . 355 16. Application of Pharmacogenetics and Pharmacogenomics in Drug Development and Regulatory Review . . . . . . . . . . . . . . . . . . . . . . . . . Shiew-Mei Huang, Myong-Jin Kim, Federico Goodsaid, Felix Frueh, and Lawrence J. Lesko Introduction . . . . 358 Drug Metabolizing Enzymes and Transporters . . . . 359 Preapproval Evaluation . . . . 361 Postapproval Evaluation . . . . 362
347
357
x
Contents
Type of Genomic Data that Qualifies as Valid Biomarkers . . . . Drug Interactions . . . . 369 Voluntary Versus Required Submissions . . . . 370 Qualification of Biomarkers . . . . 371 Genetic Tests . . . . 372 Drug/Test Codevelopment . . . . 372 Clinical Study Design . . . . 372 Labeling Implications . . . . 374 Conclusion . . . . 375 References . . . . 376
368
17. Potential Use of Microarray Technology at the U.S. Environmental Protection Agency . . . . . . . . . . . . . . . . . . 379 Kenneth M. Haymes, Susan D. Hester, William H. Benson, and J. Thomas McClintock Introduction . . . . 380 Applicability of Genomics Technology in Regulatory Application . . . . 381 The Potential of Microarray Data . . . . 383 Limitations of Microarray Technology . . . . 384 Data Submission Considerations . . . . 385 Research Utilizing Microarray Technology . . . . 388 Potential Integration of Microarray Data Into EPA’S Regulatory Applications . . . . 392 Microarray Applications and Challenges in Risk Assessment . . . . 392 Collaborations to Standardize the Field of Microarray Technology . . . . 393 Outlook on Microarray Technology . . . . 393 References . . . . 394 PART 4: THE PROMISE OF GENOMICS 18. Genomics: The State of the Science . . . . . . . . . . . . . . . . . . . . . . . . . . David B. Carlson and Supratim Choudhuri From Genes to Genomics . . . . 399 Genomic Data, Databases, and Statistical Analysis . . . . 400 Current Applications and Future Promises of Genomics . . . . 401 Genomics and Regulatory Agencies . . . . 401 Genomics—The State of the Science . . . . 402 References . . . . 403 Index . . . .
405
399
Contributors
Jiri Aubrecht U.S.A.
Pfizer Global Research and Development, Groton, Connecticut,
William H. Benson U.S. Environmental Protection Agency, Office of Research and Development, National Health and Environmental Effects Research Laboratory, Gulf Ecology Division, Gulf Breeze, Florida, U.S.A. Tapan K. Bera Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, U.S.A. Richard J. Brennan Andrej Bugrim
GeneGo, Inc., St. Joseph, Michigan, U.S.A. GeneGo, Inc., St. Joseph, Michigan, U.S.A.
Leigh Ann Burns-Naas Drug Safety Research and Development, Pfizer Global Research and Development, San Diego, California, U.S.A. Ebru Caba Pfizer Global Research and Development, Groton, Connecticut, and Vertex Pharmaceuticals, Cambridge, Massachusetts, U.S.A. David B. Carlson U.S. Food and Drug Administration, CDER, Office of New Drugs, Division of Metabolism and Endocrinology Products, Silver Spring, Maryland, U.S.A. Thomas A. Cebula* U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, Office of Applied Research and Safety Assessment, Division of Molecular Biology, Laurel, Maryland, U.S.A. Supratim Choudhuri U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, OFAS, Division of Biotechnology and GRAS Notice Review, College Park, Maryland, U.S.A. Zoltan Dezso
GeneGo, Inc., St. Joseph, Michigan, U.S.A.
*Current affiliation: Department of Biology, Johns Hopkins University, Baltimore, Maryland, U.S.A.
xi
xii
Contributors
Jennifer Fostel Laboratory of Respiratory Biology, Division of Intramural Research, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, U.S.A. Felix Frueh U.S. Food and Drug Administration, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, Silver Spring, Maryland, U.S.A. G. Frank Gerberick Central Product Safety, Procter & Gamble Company, Cincinnati, Ohio, U.S.A. Dori R. Germolec Toxicology Branch, National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, U.S.A. Dilip Ghosh Australia
Smart Foods Centre, University of Wollongong, New South Wales,
Federico Goodsaid U.S. Food and Drug Administration, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, Silver Spring, Maryland, U.S.A. Kenneth M. Haymes U.S. Environmental Protection Agency, Office of Science Coordination and Policy, Office of Prevention, Pesticides, and Toxic Substances, Washington, D.C., U.S.A. Susan D. Hester U.S. Environmental Protection Agency, Office of Research and Development, National Health and Environmental Effects Research Laboratory, Research Triangle Park, North Carolina, U.S.A. Shiew-Mei Huang U.S. Food and Drug Administration, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, Silver Spring, Maryland, U.S.A. Scott A. Jackson U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, Office of Applied Research and Safety Assessment, Division of Molecular Biology, Laurel, Maryland, U.S.A. Myong-Jin Kim U.S. Food and Drug Administration, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, Silver Spring, Maryland, U.S.A. Michael L. Kotewicz U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, Office of Applied Research and Safety Assessment, Division of Molecular Biology, Laurel, Maryland, U.S.A. Gregory S. Ladics U.S.A.
Crop Genetics, DuPont Company, Wilmington, Delaware,
J. Eugene LeClerc U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, Office of Applied Research and Safety Assessment, Division of Molecular Biology, Laurel, Maryland, U.S.A.
Contributors
xiii
Byungkook Lee Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, U.S.A. Lawrence J. Lesko U.S. Food and Drug Administration, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, Silver Spring, Maryland, U.S.A. Robert W. Luebke U.S. Environmental Protection Agency, National Health and Environmental Effects Research Laboratory, Experimental Toxicology Division, Immunotoxicology Branch, Research Triangle Park, North Carolina, U.S.A. Peter G. Lord Johnson & Johnson Pharmaceutical Research & Development, PreClinical Development, Mechanistic Toxicology, Raritan, New Jersey, U.S.A. Manjula Mahata Department of Medicine and Department of Molecular Genetics, University of California, San Diego, and VA San Diego Healthcare System, San Diego, California, U.S.A. Sushil K. Mahata Department of Medicine and Department of Molecular Genetics, University of California, San Diego, and VA San Diego Healthcare System, San Diego, California, U.S.A. Mark K. Mammel U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, Office of Applied Research and Safety Assessment, Division of Molecular Biology, Laurel, Maryland, U.S.A. J. Thomas McClintock U.S. Environmental Protection Agency, Office of Science Coordination and Policy, Office of Prevention, Pesticides, and Toxic Substances, Washington, D.C., U.S.A. Michael K. McMillian Johnson & Johnson Pharmaceutical Research & Development, PreClinical Development, Mechanistic Toxicology, Raritan, New Jersey, U.S.A. Amit Mukherjee U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, Office of Applied Research and Safety Assessment, Division of Molecular Biology, Laurel, Maryland, U.S.A. Alex Y. Nie Johnson & Johnson Pharmaceutical Research & Development, PreClinical Development, Mechanistic Toxicology, Raritan, New Jersey, U.S.A. Tatiana Nikolskaya Yuri Nikolsky
GeneGo, Inc., St. Joseph, Michigan, U.S.A.
GeneGo, Inc., St. Joseph, Michigan, U.S.A.
John K. Northup Laboratory of Cellular Biology, National Institute on Deafness and Other Communication Disorders (NIDCD), National Institutes of Health, Rockville, Maryland, U.S.A. Daniel T. O’Connor Department of Medicine and Department of Molecular Genetics, University of California, San Diego, and VA San Diego Healthcare System, San Diego, California, U.S.A.
xiv
Contributors
Isha Patel U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, Office of Applied Research and Safety Assessment, Division of Molecular Biology, Laurel, Maryland, U.S.A. Stephen B. Pruett Department of Basic Sciences, College of Veterinary Medicine, Mississippi State University, Mississippi State, Mississippi, U.S.A. Kausik Ray Laboratory of Cellular Biology, National Institute on Deafness and Other Communication Disorders (NIDCD), National Institutes of Health, Rockville, Maryland, U.S.A. Juan L. Rodriguez Flores Department of Medicine and Department of Molecular Genetics, University of California, San Diego, and VA San Diego Healthcare System, San Diego, California, U.S.A. Cindy A. Ryan Ohio, U.S.A.
Central Product Safety, Procter & Gamble Company, Cincinnati,
Pei-an Betty Shih Departments of Medicine and Pharmacology, Center for Human Genetics and Genomics, University of California at San Diego, San Diego, and VA San Diego Healthcare System, San Diego, California, U.S.A. Jannavi R. Srinivasan U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, Division of Biotechnology and GRAS Notice Review, College Park, Maryland, U.S.A. Linda C. Tapsell Australia
Smart Foods Centre, University of Wollongong, New South Wales,
Alison Vickers Allergan Inc., Investigative Sciences, Drug Safety Evaluation, Irvine, California, U.S.A. Berran Yucesoy Toxicology and Molecular Biology Branch, Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown, West Virginia, U.S.A.
Introduction
This book is an attempt to present to the reader a thorough overview of the progress of genomics to its current level. The book has four parts. Part 1 contains chapters that capture the fundamentals of gene and genome structure, function, and evolution, as well as a discussion of our understanding of epigenetic regulation of genome expression. Part 1 also includes a chapter that discusses various genomic technology platforms. Part 2 contains chapters on the applications of genomics in drug discovery and development, safety evaluation, food safety, nutritional genomics, genomic database maintenance, genomic database mining, and genomic data analysis. Part 3 contains three chapters on how regulatory agencies like FDA and EPA are collaborating with various industries and using genomic data in their safety evaluation. Part 4 contains one chapter (Chapter 18) that provides an editorial view of the state of genomics and briefly discusses how articles in Parts 2 and 3 fit into the editors’ perception of the current status of the science of genomics. The following description is a brief outline of the chapters in Parts 2 and 3. In Part 2, Vickers (Chapter 5) gives an overview of various in vitro models and discusses how toxicogenomics may be used to advance translational research. Vickers concludes that the major impacts of the new technologies include: (1) identifying the underlying molecular and biochemical mechanism(s) of specific adverse effects to better characterize and evaluate drug safety; (2) identifying specific target organ injury biomarkers that are predictive (or diagnostic) of clinically relevant pathology (specific example provided); and (3) improved comparison of differences in species sensitivity and susceptibility to drug-induced toxicity to better define and predict variability of human responses. Bera and Lee (Chapter 6) provide a glimpse of the power of genomics data mining in the identification and validation of disease-associated candidate gene targets. They provide a simple blueprint for mining genome information and identifying putative prostate and breast cancer–related genes. They targeted their search of the human EST database to identify sequences of previously unknown putative prostate and breast cancer– specific genes and then using a variety of techniques verified the expression of these genes in cancer cells. Caba and Aubrecht (Chapter 7) discuss how the identification and risk assessment of non-DNA-reactive genotoxic compounds that show non-linear, thresholded dose–response relationship may be difficult based on the current in vitro tests. They use examples to emphasize that understanding the molecular mechanism of genotoxicity and carcinogenicity using functional genomics approaches will facilitate improved risk assessment of both genotoxic and nongenotoxic carcinogens. Shih and colleagues (Chapter 8) review an extensive array of genomic approaches that have been used to characterize the genetic contributions to hypertension. They describe evidence for the genetic complexity
xv
xvi
Introduction
of hypertension and discuss the difficulties in determining the heritability of this complex disease. Germolec and colleagues (Chapter 9) provide a detailed discussion of how gene expression data is used by immunotoxicologists. Using various examples, they discuss how microarrays coupled with confirmatory RT-PCR and other mechanistic biochemistry and molecular biology tools are used to identify immune system–related genes, gene sets, and pathways that are altered in response to xenobiotic exposure, such as identification of targeted pathways in immune suppression, screening for dermal sensitizers, understanding the molecular basis of immune-mediated disease, and relating host susceptibility to immune-mediated disease. Dezso and colleagues (Chapter 10) discuss several different types, or levels, of statistical analyses from individual gene expression patterns and gene set enrichment analysis, to gene sets in pre-selected or previously unknown biological networks and sub-networks, allowing identification of “master regulators” and even small but coordinated gene expression changes. Fostel (Chapter 11) describes various publicly available databases, proprietary databases, types of toxicogenomics data, sharing toxicogenomics data, and features of an ideal database. The immense potential of the vast amount of genomic data and the utility of data-sharing for the global community was realized early on and this led to various collaborative efforts between government regulatory agencies, non-governmental science organizations, and industry interests, which solved some of the vexing issues and provided early standards (MIAME) for universal data format and submission. Mukherjee and colleagues (Chapter 12) discuss how high-throughput metabolic profiling of bacterial populations using phenotypic microarray can be used to identify metabolic differences in bacterial populations that are rooted in the genome. The authors discuss the successful use of phenotypic microarray in identifying phenotypic markers in foodborne enteric pathogens (e.g., Escherichia coli O157:H7, Salmonella, and Shigella), including characterizing a virulent mutation in the E. coli strain from a 2006 multistate spinach outbreak in the United States. Ray and Northup (Chapter 13) give an excellent overview of the importance of G-protein signaling in disease. The authors describe a ‘reverse genetics’ approach to identify ligand(s) and biological function of orphan G-proteincoupled receptors. They also note several examples of genetic variability that result in gainof-function and loss-of-function mutants, an area where pharmacogenomic analysis may provide insight into variation in drug sensitivity across populations and among individuals. Ghosh and Tapsell (Chapter 14) discuss the potential of using genomic technologies in nutrition and the future of nutrigenomics. The authors provide examples of nutrient–gene interactions, including nuclear receptor modulation (retinoic acid), epigenetic effects of gene-specific methylation, and the influence of SNPs on folate metabolism and cardiovascular responsiveness to the DASH diet. In Part 3, Lord and colleagues (Chapter 15) describe collaborative efforts between regulatory agencies and the pharmaceutical industry to use genomics to simultaneously improve drug safety assessment and expedite the development of new pharmaceuticals. The authors clearly outline the necessity of continued collaborations between regulatory and regulated communities for the successful use of genomics in drug discovery and development. Huang and colleagues (Chapter 16) describe the current state of affairs for genomic applications in drug development at the US FDA. They note the FDA hopes to use pharmacogenomics to further the FDA mission and that “The FDA has made a commitment and investment in pharmacogenomics with people, time and technology, and with increasing knowledge and the availability of novel tools, the FDA will continue to foster genomics-based research and drug development, supporting translation of the resulting scientific data to clinical practice.” Haymes and colleagues (Chapter 17) summarize the potential influence of genomics at the EPA. The authors note that environmental moni-
Introduction
xvii
toring, adverse effect reporting, and risk assessment are obvious areas that can benefit from the use of genomics (e.g., through enhanced understanding of hazards, mechanism of action, and species extrapolations). The authors provide several case-study examples of how genomic data may be used to increase knowledge of environmental agents and to complement EPA submissions. Supratim Choudhuri David B. Carlson
Part 1 Genes and Genomes
1
Fundamentals of Structure–Function Analysis of Eukaryotic Protein-Coding Genes Supratim Choudhuri U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, OFAS, Division of Biotechnology and GRAS Notice Review, College Park, Maryland, U.S.A. 1. INTRODUCTION 1.1. The Cistron Concept of Gene 1.2. The Split Gene Concept 1.3. The Split Gene Concept Remains Valid Despite the Fluidity of Eukaryotic Gene Structure 2. STRUCTURE AND FUNCTION OF TYPICAL EUKARYOTIC PROTEIN-CODING GENE 2.1. Transcribed Region of the Gene 2.1.1. Sense and Antisense Strand 2.1.2. Cap Site 2.1.3. The 5′ -Untranslated Region 2.1.3.1. 5′-UTR length 2.1.3.2. Introns may be retained in 5′-UTR after RNA processing 2.1.3.3. Role of 5′-UTR in cap-dependent and cap-independent initiation of translation 2.1.3.4. Comparison of eukaryotic and prokaryotic ribosome-binding site (RBS) 2.1.3.5. 5′-UTR and regulation of gene expression 2.1.3.5.1. Regulation of gene expression by 5′-UTR–regulatory protein interactions 2.1.3.5.2. Regulation of gene expression by 5′-UTR riboswitch–nonprotein ligand interactions 2.1.4. Translation Initiation Region 2.1.4.1. The first-AUG rule and its exceptions 2.1.4.2. Cap to first AUG, and first-AUG to second-AUG distance 2.1.4.3. Leaky scanning
5 5 6 6 6 7 8 8 10 10 10 10 11 11 11 13 13 13 13 13
The opinions expressed in this chapter are the author’s own, and they do not necessarily reflect those of the FDA, the DHHS, or the Federal Government.
3
4
Choudhuri
2.1.4.4. Reinitiation 2.1.4.5. Non-AUG initiation codons 2.1.4.6. Kozak sequence 2.1.5. The 3′-Untranslated Region and the Poly(A) Tail 2.1.5.1. 3′-UTR length 2.1.5.2. Introns may be retained in 3′-UTR after RNA processing 2.1.5.3. Various roles of 3′-UTR 2.1.5.3.1. Regulation of transcript cleavage and polyadenylation 2.1.5.3.2. Sequences in 3′-UTR determining mRNA stability and regulating gene expression 2.1.5.3.3. Riboswitch in 3′-UTR 2.1.5.3.4. The role of 3′-UTR in mRNA targeting and localization 2.1.6. Interaction Between 5′ - and 3′ -UTRs and the Circular/Closed-Loop Model of mRNA for the Regulation of mRNA Translation and Stability 2.1.7. Exon and Intron Length 2.1.8. Intron Organization, Types, Splicing, and Function 2.1.8.1. Splicing of group I introns, group II introns, and spliceosomal introns 2.1.8.2. Spliceosome composition 2.1.8.3. Splice signals of GT-AG (GU-AG in pre-mRNA) introns 2.1.8.4. Splicing mechanism for GT-AG introns 2.1.8.5. Splicing of AT-AC (AU-AC in pre-mRNA) introns needs a different splicing apparatus 2.1.8.6. Fidelity of splicing 2.1.8.7. Alternative splicing 2.1.8.8. Effect of intron phase on alternative splicing 2.1.8.9. Intronic riboswitch and the regulation of gene expression through regulation of alternative splicing 2.1.8.10. Mutations generating splice sites within introns can activate pseudoexons that are included in the mature mRNA 2.1.9. Silent Mutations in the ORF Do Not Change the Amino Acid Sequence But May Still Alter Protein Activity by Altering Conformation: A New Paradigm Challenging the Traditional Wisdom that Silent Mutations Do Not Affect the Phenotype 2.1.10. Triplet Repeat Expansion in the Gene and Its Effect 2.2. The 5′-Flanking Region of the Gene and Transcription Initiation 2.2.1. The Promoter 2.2.1.1. Core promoter 2.2.1.1.1. TATA box 2.2.1.1.2. Initiator element 2.2.1.1.3. Downstream promoter element 2.2.1.1.4. Formation of the transcription preinitiation complex (PIC) on core promoter and subsequent events
14 14 14 14 15 15 15 15 17 18 19
19 21 21 22 22 23 23 24 24 27 27 28
31
31 32 33 34 34 34 35 35 35
Eukaryotic Protein-Coding Genes
2.2.1.2. Proximal promoter 2.2.1.3. Distal promoter 2.2.1.4. Promoter-like elements in the intron 2.2.2. Enhancers, Silencers, Locus Control Regions, Insulators 2.2.2.1. Enhancers and silencers 2.2.2.2. Locus control region 2.2.2.3. Insulator 2.3. The 3′-Flanking Region of the Gene and Transcription Termination 2.3.1. Transcription Termination in Prokaryotes 2.3.2. Transcription Termination in Eukaryotes 2.3.2.1. Termination of RNA polymerase I-mediated rRNA transcription 2.3.2.2. Termination of RNA polymerase III-mediated tRNA transcription 2.3.2.3. Termination of RNA polymerase II-mediated mRNA transcription 2.3.2.3.1. The antiterminator (or allosteric) model 2.3.2.3.2. The torpedo model 2.3.2.3.3. The unified allosteric—torpedo model 2.3.2.3.4. The revised torpedo model 3. CONCLUDING REMARKS REFERENCES
5
36 37 37 37 37 38 39 40 40 40 40 41 41 41 42 43 43 43 44
1. INTRODUCTION Since the coining of the term “gene” in 1909 by the Danish botanist Wilhelm Johannsen, the concept of gene has evolved. In the beginning, gene was regarded as an abstract entity without any physical/structural connotation. It was more important to naturalists who were concerned with the inheritance of advantageous variations that would provide raw materials for evolution. 1.1. The Cistron Concept of Gene In the early 1950s, Seymour Benzer’s experiments with the rII locus of T4 bacteriophage helped define gene in terms of a unit of function, the “cistron”. The operational definition of cistron depicts it as a continuous stretch of DNA that codes for a polypeptide through the transcription of messenger RNA. Further work by Charles Yanofsky and Harvey Itano on genetic complementation in other experimental models led to the formulation of the “one-cistron-one-polypeptide” hypothesis. The concept of gene–protein colinearity demonstrated independently by Sydney Brenner and Charles Yanofsky and the operon model proposed by Francois Jacob and Jacques Monod in early 1960s were also in agreement with the cistron concept. The operon model explained how the transcription of a cistron could be regulated, whereas the gene–protein colinearity model demonstrated that a mutation in the gene (cistron) resulted in an amino acid change in the protein. Therefore, the model of regulation of cistron (gene) expression through promoter–operator interaction helped unify the structural and functional aspects of the gene into a universal gene concept.
6
Choudhuri
1.2. The Split Gene Concept This universal gene concept was again revised following independent discoveries published in 1977 by Phillip Sharp and Richard Roberts, followed by a deluge of other similar publications. These discoveries demonstrated that genes do not necessarily exist as continuous DNA stretch but can also exist as interrupted entities, the so-called “split gene concept”. The split gene concept depicts that the coding section of a gene (cistron) is interrupted by noncoding intervening sequences (introns). The gene is transcribed into a long primary transcript called “heterogeneous nuclear RNA” (hnRNA) or “pre-mRNA”, which is complementary to the entire cistron. The pre-mRNA is then processed to form the translatable mRNA. Processing of pre-mRNA involves three events: capping, polyadenylation, and splicing. Capping results in the addition of a “cap” (m7G) to the first base of mRNA at the 5′ end; polyadenylation results in the addition of a long string of adenylate nucleotides (about 200–250 in eukaryotes) to the 3′ end of mRNA; and splicing results in the removal of introns from the mature mRNA. The regions of the gene that are present in pre-mRNA but absent in mature mRNA were termed “introns”, while those that are present in mature mRNA were termed “exons”. The terms exon and intron were coined by Walter Gilbert. Development of the split gene concept did not invalidate the cistron concept; it is still valid for genes lacking introns, such as prokaryotic genes and some eukaryotic genes. The term “cistron” is now often replaced by the term “open reading frame” (ORF). 1.3. The Split Gene Concept Remains Valid Despite the Fluidity of Eukaryotic Gene Structure With an ever-increasing knowledge of gene structure and function, transcriptional, posttranscriptional, translational, and posttranslational processing and regulation, there have been many surprising findings that challenged even the universality of the split gene concept. Some of these findings such as restructured genes, alternative promoters, alternative splicing including splicing of exons flanked by introns of different phases, overlapping and nested genes, mRNA trans-splicing, RNA editing, and protein splicing have further underscored the fluidity of eukaryotic gene structure beyond the exon–intron model. The traditional idea of one-to-one correspondence between gene, mRNA, and polypeptide sequence is no longer a universal theme; it is applicable to many, but not all, eukaryotic genes (1,2). Despite many exceptions to the gene–mRNA–polypeptide sequence relationship, the exon–intron model is still central to understanding the molecular structure and function of eukaryotic genes. This chapter discusses our current understanding of eukaryotic gene structure and function analysis in light of the split gene concept. Regulation of gene expression will not be discussed; readers are referred to a brief review (1) and some recent books (3,4), for in-depth discussion on various aspects of gene regulation. 2. STRUCTURE AND FUNCTION OF TYPICAL EUKARYOTIC PROTEIN-CODING GENE The structure of a typical eukaryotic protein-coding gene is depicted in Fig. 1. There are three main sections: a 5′-flanking region (5′-flank) at the 5′ end of the gene; a transcribed region in the middle; and a 3′-flanking region (3′-flank) at the 3′ end of the gene. The 5′ end of a gene is where its promoter lies, and this always corresponds to the 5′ end of the sense
Eukaryotic Protein-Coding Genes 5′ -Flanking sequence (contains promoter, URS, etc.)
7
Transcribed region
Sense strand of DNA
TATA Box (TATAAA) (-25)
ATG 5′ 3′
STOP
GT
AG
GT
AG
CA
TC
CA
TC
Exon 1
Gene
Intron 1
Exon 2
3′ 5′
Intron 2
Exon 3
Transcription
Transcribed region but not part of exon 3 Part of the nascent transcript (downstream cleavage product) that is degraded during termination
Poly(A) signal AAUAAA AUG
hnRNA
3′ -Flanking sequence (no specific cistermination signals in most proteincoding genes) Poly(A) signal AATAAA
Transcription start site (+1)
5′
GU
Exon 1
GU
Intron 1
3′
STOP
AG
Exon 2
AG
Exon 3
Intron 2
3′
5′ Cleavage/Poly(A) site
hnRNA processing
Poly(A) signal AAUAAA AUG
Mature mRNA
STOP
5′ Cap
Poly(A) tail
-AAA…AAA 3′ 5′ -UTR
ORF
3′ -UTR
Translation
Polypeptide
NH2-
-COOH
Figure 1 The structure of a typical eukaryotic gene. The figure shows the sense strand, template strand, TATA box, cap site (transcription start site), poly(A) signal (AATAAA in DNA and AAUAAA in RNA), splice donor and acceptor sites in the intron (GT…AG in DNA; GU…AG in RNA), as well as pre-mRNA processing. The figure shows that exon 1 and a small part at the 5′ end of the exon 2 is noncoding, and thus, these form the 5′-UTR. The figure also shows that during transcription, the RNA polymerase II runs well beyond the cleavage/poly(A) site before terminating transcription.
strand (discussed below). In the following description, the transcribed region is discussed first, followed by discussions of the 5′- and 3′-flanking regions. [Note: Since the functional sequence of an mRNA is derived from gene, the structure–function relationships of a gene and its mRNA are intertwined. Therefore, the following discussion on structure and function will include both the gene and its product mRNA. The abbreviations for the bases (A, T, G, C) will be used interchangeably to indicate both the bases and the nucleotides. Whenever appropriate, comparison will be made with prokaryotic genes. The word “nucleotide” will be abbreviated as “nt” whenever necessary. To keep the number of references to a minimum, many recent reviews that include the original references and earlier important reviews have been cited.]
2.1. Transcribed Region of the Gene The transcribed region of a gene has three main sections: a 5′-untranslated region (5′-UTR), an amino acid-coding region (also called the open reading frame or ORF), and a 3′-untranslated region (3′-UTR). The expressions 5′- and 3′-UTR are associated with both mRNA and the gene. The 5′-UTR of a gene (and mRNA) refers to the entire sequence from transcription start site (cap site) to the nucleotide before the translation start codon (ATG in the sense
8
Choudhuri
strand of DNA; AUG in mRNA). Similarly, the 3′-UTR of a gene (and mRNA) refers to the entire sequence beginning after the translation stop codon (TAG/TGA/TAA in the sense strand of DNA; UAG/UGA/UAA in mRNA) to the nucleotide before the poly(A) tail (Fig. 1). Thus, 5′- and 3′-UTRs of a gene include all noncoding exons, noncoding parts of exons, and sometimes introns. 2.1.1. Sense and Antisense Strand For any given gene, one of the two DNA strands is transcribed. The transcribed strand is called “template” or “antisense strand”. The other strand that is not transcribed is called “sense strand” for two reasons: first, the sequence of bases in the nontranscribed strand is the same as that of mRNA (except for T in DNA and U in RNA) so that the sequence of codons in mRNA is reflected in the base sequence of the nontranscribed strand; second, the 5′→3′ polarity of the nontranscribed strand is the same as that of mRNA. All genes that reside in the same chromosomal DNA may not be transcribed from the same DNA strand. For some genes, one strand may serve as the template, while for other genes, the other strand may serve as the template. Because transcription always proceeds in a 5′→3′ direction, and because the template DNA strand and the RNA that is synthesized on it are antiparallel, the location of the promoter automatically determines which of the two DNA strands can serve as template for transcription.
2.1.2. Cap Site The transcription start site, that is, the first DNA base that is transcribed, is known as the “cap site” and designated + 1. The base just preceding the cap site is denoted −1. In most eukaryotic genes, transcription usually begins with a purine (A or G, mostly an A). The expression cap site applies to both the first DNA base that is transcribed and the first base of mRNA. As a result of pre-mRNA processing, the final mRNA has a 7-methyl GTP, called the “cap”, at the 5′ end through a unique 5′-5′ triphosphate linkage (Fig. 2). This is in contrast to the 5′-3′ (phosphodiester) linkage found between the nucleotides of nucleic acids. The cap is designated as m7Gppp and abbreviated as m7G or m7G. The classic m7G cap structure is called “cap0”, which is present in all eukaryotic mRNAs. Cap0 is added in a three-step reaction: first, the terminal phosphate (γ-phosphate) is hydrolyzed by RNA 5′ triphosphatase from the triphosphate of the first nucleotide of pre-mRNA, thereby leaving a diphosphate; second, RNA guanylyltransferase catalyzes the fusion of a GMP moiety from GTP to this diphosphate of the first nucleotide via a 5′-5′ linkage, thus restoring the terminal triphosphate; finally, RNA (guanine-7)-methyltransferase methylates the N7 position of the guanine. In mammals, the triphosphatase activity lies at the N-terminal end, and the guanylyltransferase activity lies at the C-terminal end of the same polypeptide, but in yeast they are catalyzed by separate enzymes. The capping enzymes are targeted to pre-mRNA by binding to phosphorylated carboxy-terminal domain (CTD) of RNA polymerase II (RNA pol II or pol II). The CTD consists of multiple repeats of an evolutionarily conserved heptapeptide with the consensus sequence Tyr-Ser-Pro-Thr-Ser-Pro-Ser (YSPTSPS). The number of repeats ranges from 26 in yeast to 52 in mammals. Five out of seven amino acids in the consensus motif are phosphate acceptors, and phosphorylation is a major posttranslational modification of the CTD in vivo. The inability of the transcripts generated by RNA polymerase I and III to undergo processing is thought to be due to the lack of CTD in these enzymes (5).
Eukaryotic Protein-Coding Genes
9
Cap0
O
7-Methylguanine N
H2N
5¢ CH2
O– HN
P
N O
CH3
5¢-5¢ triphosphate linkage
O
N
O
O P
O–
O
Methyl group at N7position
O–
Target for methylation (N6 position)
NH2
O P
N
O
N
Cap1 O
N
5¢ CH2
N Nucleotide1 ("A")
O
O
N O O
P
NH
OCH3 N
CH2
O
O–
O
P
NH2
Nucleotide 2 ("G")
O
O
N
Cap2
OCH3 O–
O
2¢-O-methylated ribose
To RNA chain
Figure 2 Various cap structures of eukaryotic mRNAs. In lower eukaryotes, the capping process only creates cap0. In higher eukaryotes, the capping process may create cap1 and cap2 by additional modifications, such as 2′-O-methylation of the ribose of nucleotides 1 and 2 of the pre-mRNA, and an additional N6-methylation of the first base of the pre-mRNA, if the first base is an adenine.
In lower eukaryotes, the capping process only creates cap0. In higher eukaryotes, it may involve additional modifications, such as 2′-O-methylation of the ribose. The 2′-O-methylation of the ribose of nucleotides 1 and 2 creates what is called “cap1” and “cap2”, respectively. There is an additional N6-methylation of the first base of premRNA, if it is an adenine (Fig. 2). The cap is added cotranscriptionally; cap0 is added when the RNA is 20–30 nt long. An interesting situation is encountered in parasitic trypanosomes. All mRNA molecules in parasitic trypanosomes are chimeras of two unrelated sequences that are encoded by different genes. The first 39-nt sequence at the 5′ end is common to all mRNAs and is
10
Choudhuri
referred to as “spliced leader” or “miniexon”. The spliced leader is derived from the 5′ end of a small nuclear RNA (snRNA), which is 120–140 nt long, and it is spliced with the 5′ end of the protein-coding exons in primary transcripts. For trans-splicing of spliced leader with the coding exon, the spliced leader has to be capped. Capping occurs by the addition of m7G followed by 2′-O-methylation of the first four nucleotides (A-A-C-U). The resultant cap (m7Gppp-Am-p-Am-p-Cm-p-Um) is known as “cap4”, and it is essential for trans-splicing to occur (1). All four modified bases of the cap4 structure are part of the 39-nt spliced leader. The cap performs two major functions: (i) it prevents premature degradation of mRNA, thereby increasing mRNA stability; and (ii) it also helps in the initiation of translation, a process called “cap-dependent initiation” (discussed below). In addition, recent findings indicate that the cap also plays a crucial role in microRNA (miRNA)-mediated translational silencing (6). This is discussed in Section 2.1.6. 2.1.3. The 5′ -Untranslated Region For most genes, the first one or two exons are fully or partially noncoding, that is, they do not code for any amino acids in the polypeptide. Sometimes, more noncoding exons can be found in a gene. For example, in mouse oatp2 (organic anion transporting polypeptide 2) gene, the first three exons are fully noncoding, whereas exon 4 is partially noncoding (7). These noncoding exons or noncoding parts of exons at 5′ end of the gene form the 5′-UTR of mature mRNA. Similarly, noncoding exons or noncoding parts of exons at 3′ end of the gene form the 3′-UTR of mature mRNA. 2.1.3.1. 5′ -UTR length A comprehensive analysis of several thousand 5′- and 3′-UTR sequences of various mRNAs and genes from a number of vertebrate, invertebrate, and fungal species revealed that the average length of 5′-UTR is about one-third to one-fifth of that of 3′-UTR, particularly in vertebrates (8). The average 5′-UTR length was found to be 210 nt in humans, 186 nt in rodents, 126 nt in birds, 221 nt in invertebrates, and 134 nt in fungi; the maximum 5′-UTR length was found to be 2,803 nt in humans, 1,786 nt in rodents, 620 nt in birds, 4,498 nt in invertebrates, and 1,088 nt in fungi; whereas the minimum 5′-UTR length was found to vary between 12 nt and 20 nt, with a median length of 16 nt. 2.1.3.2. Introns may be retained in 5′ -UTR after RNA processing Most mature mRNAs are devoid of introns, but a fraction of them contain introns either due to faulty splicing or due to regulated posttranscriptional processing. Sometimes, intron retention in 5′-UTR may increase or decrease mRNA translatability. For example, the retention of intron 1 in proinsulin mRNA in chick embryos decreases its translatability. The generation of such intron-containing proinsulin mRNA is developmentally regulated (9). In both plants and animals, there are many examples of intron retention in mature mRNA as a result of regulated posttranscriptional processing. 2.1.3.3. Role of 5′ -UTR in cap-dependent and cap-independent initiation of translation The 5′-UTR has an important role in translation. During initiation of translation in eukaryotes, the 40S ribosomal subunit, initiator methionyl-tRNA (tRNAmet), several eukaryotic initiation factors (eIFs), and GTP form the 43S complex. Independently, the mRNA becomes associated with some other eIFs. One such eIF, the eIF4F, consists of three subunits: eIF4A (helicase), eIF4E (cap-binding protein), and eIF4G (scaffolding protein).
Eukaryotic Protein-Coding Genes
11
The 43S complex binds the mRNA–eIF complex to form the 48S complex, also known as “initiation complex”. In the formation of the initiation complex, the binding of eIF4E subunit with the cap (m7G) is a crucial step because this interaction stabilizes eIF4F, which then recruits the 43S complex at the cap site with the help of eIF4G subunit. The initiation complex starts scanning the mRNA sequence in a 5′→3′ direction to find (usually) the first available AUG codon. This “scanning model” of initiation of translation is called “cap-dependent initiation”. Once the correct AUG is identified, eIF5 recruits the 60S ribosomal subunit to the initiation complex, forming the 80S complex that begins translation. Translation can also begin by “cap-independent initiation”. In this process, specific internal sequence in the 5′-UTR of mRNA is used to recruit ribosomes directly. These sequences are called “internal ribosomal entry sites” (IRESs). Some viral RNAs and cellular mRNAs have IRES in the 5′-UTR. Studies on the structure and the function of IRES elements in picornavirus RNA showed that IRES involves a large sequence (several hundred nucleotides), and IRES function requires the formation of stem-loop structures which are stabilized by various IRES-binding proteins (10,11). Noncanonical translation factors, also known as “IRES-binding trans-acting factors” (ITAFs), by virtue of their cell- and tissue-specific distribution, may determine viral translation, propagation, and pathogenesis. IRES elements differ in primary sequence and nucleotide length (˜130–460 nt), and they display different secondary structures, the only exception being a Y-shaped structure which is shared by most of them (12). Cap-independent initiation of translation of viral RNAs helps viruses to suppress cap-dependent translation of host mRNAs and use the host’s translation machinery for translating viral RNAs. In eukaryotes, many cellular mRNAs that encode proteins critical during cell stress, apoptosis, and cell cycle can be translated using IRES elements when cap-dependent translation is compromised. Under cellular stress including severe DNA damage, cap-dependent translation is globally suppressed through decapping of translatable mRNAs. Under these circumstances, these “survival” mRNAs are preferentially translated using IRES and cap-independent initiation of translation. 2.1.3.4. Comparison of eukaryotic and prokaryotic ribosome-binding site (RBS) In eukaryotes, the ribosome binding and the initiation of translation are facilitated by a combination of the cap and the Kozak sequence (discussed later), and by the interaction between cap and poly(A) tail (discussed in Section 2.1.6). In prokaryotes, the ribosome-binding for translation occurs at a specific RBS. The RBS is a short sequence (5′-AGGAGGU-3′) located 3–10 nt upstream of translation start codon and is also known as “Shine–Dalgarno sequence”. In prokaryotic polycistronic mRNA, the internal ORFs may lack RBS because the ribosomes keep translating the downstream ORFs. In such cases, only the 5′-terminal ORF possesses RBS. 2.1.3.5. 5′ -UTR and regulation of gene expression The 5′-UTR can regulate gene expression by interacting with either regulatory proteins or regulatory nonprotein ligands, as discussed below. 2.1.3.5.1. Regulation of gene expression by 5′ -UTR—regulatory protein interactions A role of the 5′-UTR in controlling gene expression through direct interactions with proteins is well illustrated by the study of iron response element (IRE). IREs are RNA stem-loop structures in the 5′-UTR of certain mRNAs whose expressions are regulated by
12
Choudhuri
iron; the conserved loop domain sequence is 5′-CAGUGX-3′, where X is usually U or C but can also be an A. Five base pairs 5′ of the loop is a bulge nucleotide region that may vary in size depending on the IRE. Many proteins involved in iron metabolism are regulated by IRE through its interaction with the IRE-binding protein (IRE-BP). There are two IRE-BPs: IRP1 and IRP2. They show equal capability of mediating translational repression by binding to IREs in vitro (13). Therefore, for simplicity, the model of translational repression is discussed in the following text using the general terminology IRE-BP. The IRE–IRE-BP interactions differentially affect translation depending on whether the IRE is located at the 5′-UTR or 3′-UTR (Fig. 3). For example, ferritin is an intracellular iron-binding protein that prevents the accumulation of toxic levels of iron (Fe2+) in cells. When intracellular iron levels are high, IRE-BP binds iron (Fe), and the IRE-BP–Fe complex cannot bind to IRE in the 5′-UTR of ferritin mRNA. This allows ferritin mRNA to be translated to ferritin, which then sequesters excess iron. When intracellular iron levels are low, the IRE-BP does not bind iron, but it binds to IRE and prevents translation of the ferritin mRNA (Fig. 3A). The IRE-BP has a dual role in the cell depending on the availability of iron. The IRE-BP is a homolog of the mitochondrial aconitase enzyme and is identical to the cytosolic form of aconitase (14). The activity of aconitase depends on a [4Fe–4S] cluster in its active site. Under conditions of high cellular iron, the IRE-BP has an intact [4Fe–4S] cluster, high aconitase activity, and no RNA-binding activity. In contrast, under conditions of low cellular iron, the IRE-BP has a disrupted Fe–S cluster, no aconitase activity, but has high RNA-binding activity. Low cytosolic iron
High cytosolic iron Ferritin
A IRE-BP
IRE-BP without Fe IRE-BP
IRE-BP without Fe IRE (in the 5′ -UTR) binds to the IRE and inhibits translation of the ferritin mRNA
IRE-BP with Fe IRE-BP with Fe cannot bind to the IRE, translation of the ferritin mRNA occurs
Fe
No translation
5′ -UTR
B
ORF
Translation
3′ -UTR
IRE-BP without Fe binds to the IRE and stabilizes the transferrin receptor mRNA which is then increasingly translated; greater amounts of transferrin receptor are produced, and cells take up more iron from transferrin receptor
3′ -UTR
ORF
5′ -UTR
IRE-BP with Fe cannot bind to the IRE; transferrin receptor mRNA is degraded; less transferrin receptor is produced; less iron is taken up by cell
Transferrin receptor
IRE-BP with Fe
IRE-BP without Fe IRE-BP IRE-BP
IRE-BP
IRE-BP
IRE-BP
IRE-BP
IRE (in the 3′-UTR) Translation
Translation
5′ -UTR
ORF
3′ -UTR
5′ -UTR
ORF
3′ -UTR
Figure 3 Interactions between the IRE and the IRE-BP result in different translational outcomes depending on whether the IREs are in the 5′-UTR or in the 3′-UTR. (A) The IRE–IRE-BP interactions in the 5′-UTR of ferritin mRNA downregulate translation, resulting in lower availability of the ferritin protein. (B) The same interactions in the 3′-UTR of transferrin receptor mRNA directly increase the half-life of transferrin receptor mRNA by stabilizing it, resulting in its increased translation and increased availability of the transferrin receptor protein.
Eukaryotic Protein-Coding Genes
13
2.1.3.5.2. Regulation of gene expression by 5′ -UTR riboswitch—nonprotein ligand interactions The binding of regulatory proteins to specific nucleic acid sequences (DNA or RNA) is an established paradigm of nucleic acid–protein interaction in controlling gene expression. The discovery of riboswitch in prokaryotes demonstrates that 5′-UTR of certain mRNAs can also directly bind nonprotein ligands to regulate gene expression. Even though the current discussion focuses on eukaryotes, a discussion of riboswitch in prokaryotic mRNA is appropriate here. The part of mRNA that binds a small molecule and acts as a genetic on–off switch for translation in response to environment is called a “riboswitch”. The domain of the riboswitch that actually senses the intracellular concentration of a specific metabolite and binds the metabolite as ligand is termed “aptamer”. Such ligand binding to 5′-UTR presumably masks the RBS, and the translation of mRNA is suppressed. When the ligand concentration falls, the binding is disrupted, and the mRNA is translated into protein. Several bacterial riboswitches were described in 2002 (1). In Escherichia coli, synthesis of the cobalamin transport protein BtuB is regulated by direct and selective binding of coenzyme B12 to a region in the 5′-UTR of BtuB mRNA, called “B12 box”. The binding of coenzyme B12 to B12 box prevents translation of BtuB mRNA. Some other examples include flavin mononucleotide (FMN)-binding mRNA riboswitch, thiamine, or thiamine pyrophosphate (TPP)-binding mRNA riboswitch. All these riboswitches supposedly act by similar mechanisms, that is, by inhibiting translation. Many more riboswitches have been described since the original discovery. The existence of metabolite-binding riboswitches was also reported in eukaryotes, such as the putative TPP-riboswitch sequence motif in Arabidopsis thaliana, bluegrass (Poa secunda), rice (Oryza sativa), and in fungi, such as Neurospora crassa and Fusarium oxysporum (15). Unlike bacterial riboswitches, which are in 5′-UTR, the plant riboswitches described are either in 3′-UTR as in A. thaliana and P. secunda, or in intron as in F. oxysporum, and will be discussed in more detail in the relevant sections.
2.1.4. Translation Initiation Region 2.1.4.1. The first-AUG rule and its exceptions For virtually all eukaryotic genes, the translation initiation codon is AUG in mRNA which corresponds to ATG in the sense strand of DNA. For the vast majority of vertebrate mRNAs, the AUG nearest to the 5′ end of mRNA is used as the initiation codon. If there are multiple in-frame AUG codons toward the 5′ end of mRNA, the “first-AUG” rule may be violated, but there are apparent rules for the violation of first-AUG rule (16), as described below. 2.1.4.2. Cap to first AUG, and first-AUG to second-AUG distance If there are fewer than 10 nucleotides between the cap and the first AUG, ribosomes may initiate translation from both the first and the second AUG codon. If the first and the second AUG codon are located very close to each other, and the first AUG is located in the context of full consensus sequence, ribosomes tend to initiate translation from the first AUG; however, even a small departure from the full consensus sequence allows the second AUG to be utilized for initiation (16,17). 2.1.4.3. Leaky scanning If the first AUG is not surrounded by a favorable sequence context (e.g., Kozak sequence), the ribosomes may skip the first AUG and initiate from the second AUG, a phenomenon
14
Choudhuri
called “leaky scanning”. Multiple upstream AUGs that are in-frame with the true AUG can support low-level translation initiated from more than one AUG through leaky scanning (18). Thus, leaky scanning can help translate two overlapping ORFs. 2.1.4.4. Reinitiation Translation from the true initiation codon can also occur through another phenomenon called “reinitiation”. When an upstream AUG, that is, upstream from the true initiation codon, lies in a favorable sequence context and is in-frame with a termination codon which is also upstream of the true initiation codon, a small upstream ORF is created in the 5′-UTR; ribosomes can translate this small upstream ORF, then resume scanning and reinitiate translation of the second ORF from the true initiation codon. 2.1.4.5. Non-AUG initiation codons In eukaryotes, AUG is the universal intiation codon in mRNA for nuclear genes, but there are exceptions. For example, in Saccharomyces cerevisiae NFS1 gene, when the first AUG (AUG1) was replaced by the triplet UUG by site-directed mutagenesis, and the product was translated in vitro using yeast lysate, initiation of translation from the second AUG (AUG2) was not increased as expected. Instead, the newly generated UUG was used as the initiation codon for translational initiation, albeit with decreased efficiency (19). The authors concluded that translation initiation at AUG2 would have led to a nonfunctional protein, and the AUG1→UUG mutation would have been lethal. In prokaryotes, AUG is the translation initiation codon in most cases, but alternative initiation codons, such as GUG, UUG, and ACG, are also used (20). 2.1.4.6. Kozak sequence An important sequence relevant for translation initiation and identification of the correct AUG codon by translation initiation complex is called “Kozak sequence” (after its discoverer Marilyn Kozak). The original functional Kozak sequence was described as 5′-GCCRCCAUGG-3′ (where R is a purine, which in most vertebrate mRNAs is an A) (16,21,22). Site-directed mutagenesis experiments confirmed the contribution of every nucleotide in positions –1 to –6, as well as the G in position + 4. A shorter and more effective version (5′-ACCAUGG-3′) of the original Kozak sequence was also described later (23). In the original analysis of 153 mRNAs, later extended to 699 mRNAs (24), it was found that most authentic initiator codons are preceded by a purine (mostly an A) in position –3 and a G in position + 4 with respect to the A (+ 1) of AUG, and most nonfunctional AUGs have a pyrimidine in –3 position. The observed asymmetry suggests that purines in positions –3 and + 4 may facilitate recognition of the AUG codon during the formation of translation initiation complex. Mutagenesis studies support this hypothesis because mutations in positions –3 and + 4 have the strongest influence on translational efficiency. Thus, an initiator codon can be designated “strong” or “weak” by considering only those two positions (24). Some mRNAs contain the consensus Kozak sequence, while many others contain some variant of it. 2.1.5. The 3′ -Untranslated Region and the Poly(A) Tail The noncoding exons or noncoding parts of exons at the 3′ end of a gene form the 3′-UTR of mature mRNA. The last exon is usually the longest, and the major part of it is usually
Eukaryotic Protein-Coding Genes
15
noncoding. The poly(A) tail in eukaryotes usually contains between 200 and 250 “A” residues. 2.1.5.1. 3′ -UTR length As mentioned above, the average length of 3′-UTR is about three to five times that of 5′-UTR, particularly in vertebrates (8). In the analysis, the average 3′-UTR length was found to be 1,028 nt in humans, 607 nt in rodents, 652 nt in birds, 445 nt in invertebrates, and 237 nt in fungi; the maximum 3′-UTR length was found to be 8,555 nt in humans, 3,354 nt in rodents, 3,990 nt in birds, 9,142 nt in invertebrates, and 1,142 nt in fungi; whereas the minimum 3′-UTR length was found to vary between 13 and 37 nt, with a median length of 21 nt. 2.1.5.2. Introns may be retained in 3′ -UTR after RNA processing Most mature mRNAs are devoid of introns, but sometimes an intron may be retained in the 3′-UTR of mature mRNA, and it may have regulatory functions. For example, migration stimulatory factor (MSF) is a truncated oncofetal isoform of fibronectin. It is expressed in fetal fibroblasts, keratinocytes, vascular endothelial cells, and also in mammary carcinoma cells, tumor-associated stromal fibroblasts, and endothelial cells. Two types of MSF mRNAs have been detected: a shorter 2.1-kb transcript and a longer 5.9-kb transcript, which differ only in the length of their 3′-UTRs. Both transcripts have 1,941 nt of coding sequence derived from the first 12 exons of the Fn1 gene, and a contiguous intron-derived 30-nt coding sequence. In the smaller transcript, the intron-derived 30-nt coding sequence is followed by a 165-nt intron-derived 3′-UTR. This makes a total of 195-nt intron-derived sequence in the smaller transcript (25). This intron-derived 3′-UTR also provides the polyadenylation signal. The smaller transcript is transported to the cytoplasm and eventually secreted, while the larger transcript is retained in the nucleus. 2.1.5.3. Various roles of 3′ -UTR The 3′-UTR plays important functions, such as regulation of transcript cleavage and polyadenylation, determination of transcript stability, regulation of mRNA targeting and localization, and regulation of translation. Recent evidence suggests that 3′-UTR also plays an important role in the regulation of the nuclear export of mRNA. 2.1.5.3.1. Regulation of transcript cleavage and polyadenylation Regulation of transcript cleavage and polyadenylation is driven by the interplay of various signal sequences in 3′-UTR and their interactions with various protein factors, as discussed below. I. Transcript cleavage and polyadenylation signal sequences in 3′ -UTR: The 3′-end processing of pre-mRNA is regulated by sequences in 3′-UTR. Among these, the polyadenylation signal sequence AAUAAA in mRNA is located 10–30 nt upstream of the transcript cleavage site, which is also the polyadenylation or poly(A) site. The polyadenylation signal sequence is highly conserved; the only functional variant known is AUUAAA (26). A second sequence, known as the “downstream element” (DSE), is usually located within the first 30 nt of the cleavage site. Due to the abundance of uracil and guanine residues in these motifs, DSEs are usually referred to as “U- or G/U-rich elements”. The cleavage site also shows a nucleotide bias in the order A > U > C >> G (27). Frequently, a 5′-CA-3′ dinucleotide is found at the cleavage site. A third element UGUA is often present in one or more copies at variable distance upstream of the cleavage site and is recognized by
16
Choudhuri
cleavage factor I (CFI; discussed below) (28). The spacing of AAUAAA and DSE, together with local sequence preference (e.g., base composition), is thought to determine the precise cleavage site. II. Cleavage and polyadenylation factors necessary for 3′ -end processing: Some crucial protein factors necessary for cleavage and polyadenylation have been identified and characterized, such as the cleavage and polyadenylation specificity factor (CPSF), cleavage stimulation factor (CstF), cleavage factor I and II (CFI and CFII), poly(A) polymerase, and poly(A) binding protein (PABP). These proteins have multiple subunits except for poly(A) polymerase and PABP, and are sufficient for 3′-end cleavage and polyadenylation in vitro (26). There are two types of PABPs in higher eukaryotes: (i) nuclear PABPs that regulate the polyadenylation of mRNAs in the nucleus and (ii) several types of cytoplasmic PABPs that regulate mRNA translation and stability in the cytoplasm, presumably by regulating polyadenylation. Yeast has one PABP that does both the jobs. The nuclear PABPs have one RNA recognition motif (RRM), whereas the cytoplasmic PABPs have four RRMs (29). III. Mechanism of cleavage and polyadenylation: During 3′-end processing in which the cleavage and the polyadenylation are tightly coupled, a cleavage and polyadenylation complex forms that includes various protein factors and the RNA substrate. The complex forms in a cooperative manner in which the CPSF and CstF first bind the RNA independently but cooperatively; CPSF binds the poly(A) signal AAUAAA and CstF binds the DSE. This is followed by the binding of other factors. Cleavage of the 3′ end is followed by polyadenylation, which requires both poly(A) polymerase and PABP. Addition of the A-residues to the 3′ end is carried out by poly(A) polymerase. Proper activity of the poly(A) polymerase depends on its interaction with CPSF. This is because the CPSF stabilizes poly(A) polymerase on the RNA template, thereby significantly increasing its processivity. Without interaction with CPSF, the poly(A) polymerase is marginally active and acts in a distributive mode, that is, it polymerizes a few nucleotides and detaches from the RNA template. Interaction with CPSF makes it processive, and it can complete the addition of the entire poly(A) tail in one catalytic cycle. The PABP can bind to the growing poly(A) tail when it is about 11 nt long, and multiple molecules bind to the same poly(A) tract covering (thus protecting) about 27 nucleotides. In mammals, the poly(A) tail contains about 200–250 A-residues, while in yeast, it contains about 70–90 A-residues. When the growing poly(A) tail reaches a critical length, poly(A) polymerase falls off the template presumably because its stabilizing interaction with CPSF is disrupted beyond this length. PABP-binding stabilizes the mRNA, and it also promotes the 5′–3′-end interactions after the mRNA exits the nucleus and enters into cytoplasm (5,26,29). The only known exception to the polyadenylation of mature mRNAs is histone mRNAs. IV. Alternative polyadenylation as a means of differential gene regulation: An mRNA may contain more than one polyadenylation signal in its 3′-UTR. Because the 3′-UTR is closely associated with the stability of mRNA, alternative polyadenylation can produce mRNAs with very different stability. Alternative polyadenylation has been reported in both viruses and eukaryotes. Alternatively polyadenylated transcripts can be observed in different tissues or different developmental stages where the mRNA half-lives can markedly vary. Alternatively polyadenylated transcripts may also be produced in response to toxic environmental stimuli. Many alternatively polyadenylated transcripts have been reported in the literature, but not all of them have been characterized (1).
Eukaryotic Protein-Coding Genes
17
V. Integration of transcription and 3′ -end processing: The current model of integrated transcription-mRNA processing depicts that during transcription preinitiation phase, the CPSF first interacts with transcription factor IID (TFIID), then it gets transferred to the CTD of pol II. During the elongation phase, CPSF rides on the CTD as pol II transcribes the template. As soon as the poly(A) signal sequence (AAUAAA) is generated on the elongating RNA, CPSF is transferred to the poly(A) signal sequence. This is followed by cleavage and polyadenylation of the RNA. Proof for this model came from several direct and indirect lines of evidence: (i) copurification of CPSF with TFIID subunits; (ii) observation that in the preinitiation complex (PIC) CPSF remains associated with TFIID, but after the start of transcription it is associated with CTD; (iii) observation that the deletion of CTD impairs cleavage and polyadenylation; and (iv) observation that transcription termination is dependent on the presence of a functional poly(A) signal sequence (5,26). 2.1.5.3.2. Sequences in 3′ -UTR determining mRNA stability and regulating gene expression The half-lives of eukaryotic mRNAs may vary widely from ˜5 min (e.g., mRNAs of early response genes, many mRNAs in yeast) to several hours (e.g., β-globin mRNA, human dystrophin mRNA, both with half-lives of ˜16 hr). Various exo- and endoribonucleases have been found to degrade RNAs. Degradation of mRNA may begin from either end. Degradation that begins from the 3′ end is initiated by shortening of the poly(A) tail; degradation of such deadenylated mRNA can be carried out by exosome. Exosome is a complex of about ten 3′→5′ exonucleases that are involved in the degradation as well as precise processing of many types of RNA in both nucleus and cytoplasm. Degradation may also be initiated at the 5′ end after the removal of the poly(A) tail. The enzyme Xrn1 (exoribonuclease 1) is thought to be the primary 5′→3′ exoribonuclease in yeast and other eukaryotes; it degrades mRNA in a 5′→3′ direction following removal of the poly(A) tail and the cap. Xrn1 is mainly cytoplasmic but is also found in nucleus. Proteins that bind to the cis-acting elements in 3′-UTR affect the degradation process from both ends. The existence of an AU-rich sequence in 3′-UTR of many mRNAs was identified by analyzing various cDNA sequences (30). The authors identified a consensus sequence (TTATTTAT; hence, UUAUUUAU in mRNA) in 3′-UTR of both human and mouse TNF mRNAs, as well as in mRNAs encoding human lymphotoxin, human colony-stimulating factor, human and mouse interleukin 1, human and rat fibronectin, and most of the sequenced human and mouse interferons. The role of this AU-rich sequence in determining mRNA stability was also experimentally demonstrated (31). The authors introduced a 51-bp-long AT sequence from a human lymphokine gene (GM-CSF ) into the 3′-UTR of rabbit β-globin gene. As a result, the β-globin mRNA, which is otherwise stable, became highly unstable in vivo. Since then, the role of the AU-rich element (ARE) in determining transcript stability has been well established. The minimal sequence motif required to increase the turnover of chimeric mRNAs was shown to be a nonamer UUAUUUA(U/A)(U/A) (32). It is important to note that although the ARE and the U-rich regions have been associated with increased transcript turnover, no unique or consensus sequence has been precisely defined yet. The regulatory function of AREs is driven by its interaction with various ARE-binding proteins (ARE-BPs), such as AUF1, TTP, and proteins of Hu family (see 33 and references therein for various ARE-BPs). In contrast to the AU-rich sequence that increases transcript turnover, there are other interactions in 3′-UTR that stabilize mRNAs, thereby increasing their half-lives. For example, IREs located in 3′-UTR of some mRNA can regulate mRNA half-life and
18
Choudhuri
expression, such as in transferrin receptor. Transferrin is a major iron transport protein in the plasma (as opposed to ferritin, which is the major iron-binding protein in the cell). Transferrin binds to transferrin receptor located on the plasma membrane. When iron levels are low, transferrin receptor mRNAs are stabilized by the binding of IRE-BP with IRE in its 3′-UTR so that more transferrin receptors can be translated and cells can take up more iron from transferrin. Unlike ferritin mRNA which has a single IRE in 5′-UTR, transferrin receptor mRNA has multiple IREs in 3′-UTR. When iron levels are high, IRE-BP binds iron and cannot interact with IREs; as a result, transferrin receptor mRNA is degraded at a faster rate to prevent over-uptake (thus, over-accumulation) of iron in the cell (Fig. 3B). Therefore, interactions between IRE and IRE-BP may have very different translational outcomes depending on whether the interaction is in 5′-UTR or in 3′-UTR. The IRE– IRE-BP interaction in 5′-UTR of ferritin mRNA directly downregulates its translation, resulting in lower availability of ferritin protein. The same interaction in 3′-UTR of transferrin receptor mRNA directly increases its half-life, resulting in its increased translation and increased availability of transferrin receptor protein. A similar example is a 106-nt GC-rich region in the 3′-UTR of glucose transporter GLUT-1 mRNA. Normally, this region facilitates the decay of GLUT-1 mRNA. Following TNF treatment, this region binds a protein complex; as a result, GLUT-1 mRNA is protected from degradation and stabilized (34). Another important example of the role of 3′-UTR in translational regulation is that of selenoproteins. Selenocysteine (Sec), the 21st amino acid, is incorporated into many proteins in eukaryotes. Selenocysteine-containing proteins are called “selenoproteins”. In humans, at least 25 selenoproteins are known. The tRNA for selenocysteine is charged with serine and then enzymatically selenylated to produce selenocysteinyl-tRNA (Sec-tRNA[Ser]Sec). During selenoprotein translation, Sec-tRNA is brought into the ribosome by a dedicated specific elongation factor known as “eEFsec”. Selenocysteine is incorporated into the protein at UGA codon, which is normally a stop codon, and this process is called “recoding”. Recoding requires Sec-tRNA[Ser]Sec, protein factors, and one cis-acting sequence. The cis-acting sequence, termed “selenocysteine insertion sequence” (SECIS), forms a specific secondary structure in the 3′-UTR of selenoprotein mRNAs. The SECIS element is about 60-nt-long stem-loop structure, which carries large or small apical loops, and binds the SECIS-binding protein 2 (SBP2). 2.1.5.3.3. Riboswitch in 3′ -UTR Riboswitch in 3′-UTR may also contribute to mRNA stability, translatability, and processing. Sudarsan et al. (15) described a putative thiamine biosynthesis gene of A. thaliana, which carries an RNA element in its 3′-UTR that conforms to the consensus TPP-binding domain. The authors obtained the TPP-riboswitch element of A. thaliana by in vitro transcription and subjected this RNA to ligand-binding analyses. They found that it binds TPP with an apparent dissociation constant (KD) of ˜50 nM, which is comparable to that of E. coli TPP-riboswitch. The authors hypothesized that TPP-riboswitch in plants may modulate the processing and stability of riboswitch-containing mRNAs. Recently, the 2.9 Å crystal structure of A. thaliana TPP-riboswitch in complex with TPP was described (35). Similar RNA elements are found in rice (O. sativa) and bluegrass (P. secunda). In plants, riboswitch domains have been found in 3′-UTR, and in fungi, they have been reported in introns. The intronic riboswitch will be discussed in Section 2.1.8.
Eukaryotic Protein-Coding Genes
19
2.1.5.3.4. The role of 3′ -UTR in mRNA targeting and localization Accurate targeting and localization of various mRNAs are necessary for the proper expression of proteins in correct cellular compartments. In some cases, mRNA localization in cells is highly polarized/compartmentalized as in neurons, but in most cases, such polarization is not very clear-cut. In many mRNAs that are targeted to a specific subcellular location, the localization and targeting signals are in 3′-UTR. An example is the localization of Oxa1 mRNA in yeast (S. cerevisiae). The Oxa1 protein (of the Oxa1 protein complex) is a ubiquitous constituent of the inner mitochondrial membrane. The Oxa1 protein is a key component in the biogenesis of the inner mitochondrial membrane because it facilitates the integration of both mitochondrial- and nuclear-encoded proteins from the matrix into the inner mitochondrial membrane. As a consequence, Oxa1 is conserved from bacteria to eukaryotes. In S. cerevisiae, a null mutation in Oxa1 gene leads to complete respiratory deficiency in yeast, but this can be rescued by the human homolog OXA1 protein. Using partial deletion analysis of the 3′-UTR of human OXA1 mRNA, it was demonstrated that the last 137 nt possesses targeting and localization signals, which are recognized by the yeast proteins (36). As a result, human OXA1 mRNA is accurately sorted to the vicinity of yeast mitochondria. Once the OXA1 mRNA is properly localized in the vicinity of mitochondria, OXA1 protein is translated and easily targeted to the inner mitochondrial membrane, thereby rescuing yeast cells from respiratory deficiency. Another example of 3′-UTR-mediated localization of mRNA is the metallothionein (MT ) mRNA. Deletion analysis and mutagenesis studies demonstrated that nt 45–86 in 3′-UTR are required for the targeting of MT-I mRNA to its perinuclear localization (37). 2.1.6. Interaction Between 5′ - and 3′ -UTRs and the Circular/Closed-Loop Model of mRNA for the Regulation of mRNA Translation and Stability Translation of mRNAs is frequently correlated with a change in the length of the poly(A) tail. That is, an increase in poly(A) tail length is usually correlated with an increase in mRNA translatability. The classical view of mRNA as an extended thread-like structure passing through the ribosomes during translation is being increasingly challenged. Recent evidence indicates the existence of a possible circular/closed-loop form of mRNA during translation. The observation by Christensen et al. (38) provided the first clue that mRNA may exist as a circular/closed-loop structure during translation. The authors observed an abundance of circular polysomes on the rough endoplasmic reticulum in somatotropes and mammotropes in the rat anterior pituitary. Somatotropes secrete growth hormone, and mammotropes secrete prolactin. It was observed that about 80% of the membrane-bound polysomes in these two cell types have an approximately circular shape, and they contain an average of seven ribosomes, which is appropriate for the translation of the polypeptide hormones produced by these cells. Interaction between the 5′ and the 3′ end of mRNA was later experimentally demonstrated (39). The authors provided evidence that the 5′-UTR contributed to rapid mRNA degradation mediated by the 3′ ARE. They generated two different types of v/c-fos (viral/ cellular-fos) hybrid transcripts, both containing the 3′ AU-rich destabilizing sequence but differing in the length of their 5′-UTRs. The full-length transcripts were found to be unstable, whereas the shorter transcripts lacking part of the 5′-UTR were stable. When the full-length v/c-fos 5′-UTR fragment was inserted into α-globin gene harboring the AU-rich destabilizing element, the splicing and degradation patterns of the heterologous transcript
20
Choudhuri
paralleled that of the v/c-fos recombinants. These observations strongly suggested that an intact 5′ end of mRNA is required for the activity of the AU-rich destabilizing element at 3′ end to cause rapid mRNA degradation. In other words, interactions between the two ends of mRNA play an important role in determining mRNA stability. It is now becoming increasingly clear that poly(A) tail and m7G cap act synergistically to stimulate translation. The PABP has been shown to interact with one or more eIFs, such as eIF4G, eIF4E, and eIF4B, particularly eIF4G (Fig. 4A). By reconstituting the eIF4E–eIF4G–PABP complex in vitro, it was demonstrated using atomic force microscopy that this complex could circularize capped, polyadenylated RNA (40). PABP is also known to interact with eukaryotic release factor 3 (eRF3). Several examples of the formation of closed-loop conformation of translatable mRNAs through 5′- and 3′-UTR interactions have been described in the literature (41–43). The formation of a closed-loop conformation also aids in determining mRNA stability by bringing together factors that either facilitate or prevent mRNA degradation. An increasing body of evidence has provided support for this model of translatable mRNAs; these include the demonstration of physical interactions between decapping enzyme Dcp1 and PABP (44) and interaction between the m7G cap and deadenylases. Many major
A
Cap 5′ -UTR
eIF4E eIF4G PABP
eIF4B ORF
eIF4A
A
AA
AA
AA
Poly(A) tail 3′ -UTR
B miRNP complex Cap 5′ -UTR
miRNP/Ago–Cap interaction and translational silencing Cap
eIF4E
PABP
eIF4G PABP
eIF4B ORF
eIF4A
3′ -UTR
A
AA AA AA
Poly(A) tail
Ago miRNA
AAA AAAA
Poly(A) tail
Figure 4 Interaction between the 5′-UTR and the 3′-UTR and the circular/closed-loop model of mRNA for the regulation of mRNA translation and stability. The poly(A) tail and the m7G cap act synergistically to stimulate translation. (A) The poly(A) binding protein (PABP) presumably interacts with one or more eIFs, such as eIF4G, eIF4E, eIF4B, particularly eIF4G, and the eIF– PABP complex plays an important role in translation. (B) The cap also plays an important role in miRNA-mediated translational silencing. Once the miRNP is positioned on the 3′-UTR, the Ago protein disrupts the eIF–elF4G–PABP complex, which is required for efficient translational initiation. The cap now interacts with the Ago proteins of the miRNP complex, which effectively inhibits cap-dependent translation.
Eukaryotic Protein-Coding Genes
21
deadenylases [the exonuclease Ccr4, Caf1, Pop2, Pan2, Pan3 in yeast, and the poly(A)specific ribonuclease (PARN), CCR4, PAN in vertebrates] were shown to be stimulated by the presence of m7G cap. During deadenylation, when the poly(A) tail length falls below ˜12–15 residues, PABP is released (42,43,45,46). Therefore, the maintenance of a closed-loop conformation of mRNAs during degradation may be necessary so that PABP, various 3′-UTR binding factors, decapping enzymes, and the deadenylases can all interact. Interactions between the two ends of mRNA during degradation may also help flag the decaying mRNAs so that they are prevented from competing with intact translatable mRNAs. The closed-loop conformation of mRNA also helps in RNA splicing. Components that bind to the cap cooperate with the splicing machinery to facilitate recognition of the first exon, and components of the polyadenylation machinery interact with the splicing machinery to define the last exon (discussed in Section 2.1.8). As mentioned under “cap site” earlier in this chapter, the cap plays a crucial role in microRNA (miRNA)-mediated translational silencing. This apparently involves a circular/ closed-loop conformation of mRNA. The miRNAs constitute a class of small noncoding RNAs (ncRNAs) that play important roles in gene silencing (discussed in more detail in Chapter 3). Following transcription and processing, the final functional miRNA is ˜22-nt long which interacts with various proteins including members of the Argonaute (Ago) family to form miRNA-protein (miRNP) complex. The miRNA binds to the 3′-UTR of mRNA and thus positions the miRNP on the 3′-UTR. Efficient miRNA-mediated translational silencing requires functional m7G. In the circular/closed-loop conformation of mRNA, once the miRNP is positioned on 3′-UTR, the Ago protein disrupts the eIF4E–eIF4G–PABP complex, which is required for efficient translational initiation. This disrupts the interaction between the cap and eIF4E. The cap now interacts with Ago proteins of the miRNP complex, which effectively inhibits cap-dependent translation of the mRNA (6) (Fig. 4B). 2.1.7. Exon and Intron Length A detailed study on exon and intron length in various eukaryotes demonstrated that the majority of internal exons in vertebrate genes are less than 300 bp with an average length of 135 bp, and exons larger than 800 bp are rare (47). In vitro studies showed that vertebrate internal exons greater than 300 bp have increased probability of faulty splicing (48,49). Likewise, decreasing the size of an internal exon to less than 51 bp also increases the probability of faulty splicing by exon skipping (50). The first (5′) noncoding exon can be as small as 20 bp. The last (3′ ) exon is usually the longest, and can be well over 1 kb depending on the gene. A major part of the last exon is usually noncoding. In general, exon/intron lengths vary across eukaryotic species. In vertebrates, large intron and small exon seem to be the rule, but in lower eukaryotes, the opposite seems to be true (49). Exon definition and intron definition models that explain the apparent fidelity in splice site selection during splicing together predict that exons and introns of a gene cannot be large at the same time; introns can be large if exons are small and exons can be large if introns are small (discussed in Section 2.1.8.6). 2.1.8. Intron Organization, Types, Splicing, and Function Introns or intervening sequences (IVSs) are common in eukaryotic genes of all types. Three main groups of introns are known: group I introns, group II introns, and spliceosomal (nuclear) introns. In addition, there are group III introns, which are similar to group II introns but smaller and have different three-dimensional structure. Sometimes, one or more
22
Choudhuri
introns can be embedded in an intron. This complex intron is called “ twintron”. Several twintrons have been reported in Euglena and Drosophila. Group I introns are found in rRNA, tRNA, and mRNA of organelles in fungi, plants, and protists; in tRNA and mRNA of bacteria/bacteriophage; in rRNA of protists and fungi; and in mRNA of animal (sea anemone) mitochondria. Group II introns are found in rRNA, tRNA, and mRNA of organelles in fungi, plants, and protists, and in mRNA in bacteria. Group III introns are very short group II-like introns found in mRNA of plastids of euglenoid protists (51). In total, around 1,500 group I and 200 group II introns have been identified (52). The spliceosomal introns are found in the nuclear genomes of all eukaryotes and are therefore most numerous and ubiquitous. The following discussion will focus on the spliceosomal introns. 2.1.8.1. Splicing of group I introns, group II introns, and spliceosomal introns Group I and group II (and also group III) introns are self-splicing. The RNA itself possesses enzyme activity, hence acting as a ribozyme. No proteins are needed for splicing reactions. For splicing, a series of stem-loop structures that can bring the splice sites together are necessary. Group I introns need free guanine nucleotide for splicing, which attacks the 5′-splice site. Following splicing, group I introns are released as linear introns. In contrast, group II introns are spliced by the lariat pathway and are released as lariat structure. In this respect, the splicing of group II introns shows similarities to that of spliceosomal introns. Both group I and group II introns have distinct RNA structures that facilitate their self-splicing activity. They also contain internal ORFs which facilitate their propagation to intronless sites through reverse transcription. 2.1.8.2. Spliceosome composition Introns that are spliced by spliceosomes are called “spliceosomal introns”. Such splicing takes place through the interactions of various protein factors and cis-acting signals in the substrate pre-mRNA. Spliceosomes are composed of many proteins (splicing factors) and small RNA molecules. More than 100 splicing factors with known functions have been identified so far (53). The RNA component contains several small RNA molecules (less than 200 nt) found only in the nucleus, which are called “small nuclear RNA” (snRNA). The snRNAs important for the splicing of GT-AG introns are U1, U2, U4, U5, and U6. The name U-RNA owes its origin to the modified uridine content of these snRNAs. The combination of proteins and snRNAs forms small nuclear ribonucleoprotein (snRNP) or snurp; thus, U1–U6 snRNAs in combination with the proteins form U1–U6 snRNPs. The core snRNPs include a group of seven proteins known as “Sm proteins” (Sm B/B′, D1, D2, D3, E1, F1, and G1), and seven LSm proteins (LSm = Like Sm; LSm2 through eight) (53). Sm proteins were first identified through precipitation from nuclear extracts by anti-Sm antibodies from patients with the autoimmune disorder systemic lupus erythematosus. Whereas Sm proteins are part of U1, U2, U4, and U5 snRNPs, LSm proteins are part of U6 snRNPs. The seven Sm proteins form a seven-member-ring core structure that encircles the pre-mRNA. The Sm core is essential for the function of snRNP particles. There are many more protein splicing factors that are part of specific snRNPs (53). One such important group of proteins necessary for both constitutive and alternative splicing are the SR proteins (serine-arginine-rich proteins). The SR proteins are so named because their C-terminal ends contain a region rich in arginine and serine. The arginine-serine-rich
Eukaryotic Protein-Coding Genes
23
region is called the “RS domain”. In addition to the RS domain, the SR proteins also contain one or two RRMs at the N-terminal end. More than a dozen SR proteins are known in humans, such as SF2/ASF, SC35, 9G8, SRp20, SRp30c, SRp40, SRp46, SRp54, SRp55, SRp75, SFRS10, SRm160, and SRm300 (53,54). Another essential splicing factor is U2AF (U2 snRNP auxiliary factor). It is a heterodimer composed of two subunits, U2AF65 and U2AF35, and is essential for splicing. Both subunits of U2AF are SR-related proteins because they contain RS domains. 2.1.8.3. Splice signals of GT-AG (GU-AG in pre-mRNA) introns Certain splice signals facilitate proper identification of intron sequences and their accurate removal. Most introns in a gene have GT at the 5′-splice site (splice donor site) and AG at the 3′-splice site (splice acceptor site), giving rise to the so-called GT-AG rule for introns (GU-AG in pre-mRNA). There are exceptions to GT-AG introns, such as GC-AG introns and AT-AC introns. The following discussion focuses on GT-AG introns. In most eukaryotic genes, the nucleotides surrounding splice donor and acceptor sites show a great degree of conservation. For example, the last two nucleotides of an exon preceding the intronic splice donor site are usually AG, and the nucleotide following the splice donor site is a purine, mostly an A. Likewise, the nucleotide immediately before the splice acceptor site is a pyrimidine, mostly a C. Upstream from the splice acceptor site, the intronic sequence is rich in pyrimidines. The usual nucleotide distribution around the splice sites is as follows: 5′-splice site: 5′-…NNNAGgtannn…-3′ (gt = splice donor site; N and n = any nucleotide in the exon and intron, respectively. According to convention, when exon and intron sequences are written together, exon sequence is written in capital letters, whereas intron sequence is written in small letters). 3′-splice site: 5′-…nnncagNNN…-3′ (ag = splice acceptor site; N and n = any nucleotide in the exon and intron, respectively). In addition to the signals at the splice donor and acceptor sites, there are other elements, such as exonic splicing enhancer (ESE), intronic splicing enhancer (ISE), exonic splicing silencer (ESS), and intronic splicing silencer (ISS). Other important signals are the branch site located 20–50 nt upstream of the acceptor site, and the polypyrimidine tract (y)n located downstream of the branch site. The consensus sequence of the branch site in the gene is (C/T)(T/C)(A/G)A(C/T) [hence (C/U)(U/C)(A/G)A(C/U) in the pre-mRNA], where the A-residue is conserved in all genes. 2.1.8.4. Splicing mechanism for GT-AG introns Following recognition of the exon to be spliced, there are overall three steps in splicing: (i) the 5′ end of the intron is excised and is covalently attached to the A-residue of the branch site through a 5′-2′ phosphodiester linkage (first transesterification reaction); (ii) the 3′ end of the intron is excised and the exons are joined (second transesterification reaction); and (iii) the intron thus released as a lariat structure is degraded. Splicing reactions are initiated by the following interactions: (i) the U1 snRNP binds to the 5′-splice site—base-pairing between U1 snRNA and the pre-mRNA aids in stabilizing this interaction; (ii) the U2AF binds to the polypyrimidine tract so that the larger subunit (U2AF65) is bound to the polypyrimidine tract, and the smaller subunit (U2AF35) is bound to the 3′-splice site; and (iii) the U2 snRNP binds to the branch site with the help of U2AF—base-pairing between U2 snRNA and the pre-mRNA aids in stabilizing this interaction. Before the binding of U2, the branch site is occupied by another splicing factor called “SF1” in mammals and BBP (branch site-binding protein) in yeast; U2 binding
24
Choudhuri
displaces SF1/BBP from the branch site. The complex of U1 snRNP, U2 snRNP, and U2AF with the pre-mRNA is called “complex A”. In complex A, the base-pairing between U2 snRNA and branch site excludes the A-residue. As a result, the A-residue bulges out and is positioned as the nucleophile for the first transesterification reaction. The presence of a pseudouridine (ψ) in U2 snRNA results in an altered conformation of the U2 snRNA–pre-mRNA duplex; such altered conformation of the duplex places the 2′-OH of the bulged A-residue in a favorable position as the transesterification reaction center. Next, the complex A undergoes rearrangement to bring all three splice signal sites (5′-splice site, 3′-splice site, and branch site) together. This is achieved through the involvement of U4/U5/U6 tri-snRNP particle. The recruitment of U4/U5/U6 tri-snRNP to complex A turns it into “complex B”. In complex B, the pre-mRNA loops upon recruitment of U4/U5/U6 tri-snRNP. This is followed by the release of U1 from the 5′-splice site, which is then occupied by U6. During the initial binding, U5 snRNP binds to the downstream exon. At this stage of complex B, U4 is in contact with U2. Next, U4 is released from the complex allowing U6 to interact with U2 through RNA–RNA base-pairing interactions. This arrangement is called “complex C”, and it brings the 5′-splice site close to the branch site through U6–U2 interaction. At this phase, U5 snRNP is shifted to the intron to be excised. Splicing then proceeds in two steps: first, the intron and the exon are cut apart at the 5′-splice site; the free 5′ end of the intron loops around and is joined to the A-residue of the branch site (first transesterification); second, the free 3′ end of the exon displaces the intron from 3′-splice site, and the two exons are joined together (second transesterification). The second reaction is aided by U5 snRNP, which helps bring the two exons together. The intron is released as a lariat structure and is subsequently degraded, and the snRNPs get recycled. Fig. 5 shows the principles of splicing, and Fig. 6 shows the sequence of binding and release of various U-snRNPs during splicing. 2.1.8.5. Splicing of AT-AC (AU-AC in pre-mRNA) introns needs a different splicing apparatus Both GT-AG and GC-AG introns are processed by the major or lariat pathway, while most AT-AC introns are processed by a different pathway, the minor pathway. The AT-AC introns have unique and highly conserved 5′-splice site and branch site elements. These are recognized by some unique sets of minor snRNAs, such as U11, U12, U4atac, and U6atac, which play roles analogous to that of U1, U2, U4, and U6, respectively. The only snRNA shared by both pathways is U5 (55). 2.1.8.6. Fidelity of splicing The requirement for multiple splice signal sequences for splicing provides one mechanism of ensuring the accuracy of splicing. However, splice site signal sequences are part of vast intronic sequences, and it is possible for an intron to have multiple splice site consensus sequences. Thus, there may still be errors in splice site recognition, which may result in skipping of legitimate splice site or recognition of illegitimate or cryptic splice sites. The other challenge of splicing is joining all exons in proper order without skipping any exons. To ensure the fidelity of splicing, additional mechanisms have evolved. One such mechanism was termed “exon definition” (48). Exon definition proposes that in pre-mRNAs with large introns, the splicing machinery searches for a pair of closely spaced splice sites in an exonic polarity. When such a pair is recognized, the exon is defined by the binding of U1 and U2 snRNPs and their associated splicing factors. The assembly of U2AF
Eukaryotic Protein-Coding Genes
25
SR proteins
SR proteins i
n
t
p-G-U
5′
o
n yyyyy
A
ESE 5′ Exon
r
First transesterification reaction
2′ -OH
A-G-p
Branch point
SR proteins
5′ Exon
ESE
3′ Exon
SR proteins i n t r o n
— 3′ -OH
5′
3′
ESE
3′
A-G-p
A G U
ESE
3′ Exon
Second transesterification reaction
AG A G Intron released as U a lariat structure
5′
3′ Two exons spliced in proper order
Figure 5 Essential reactions in the splicing of spliceosomal intron. The splicing reaction involves two stepwise transesterification reactions. The branch site A-residue plays a critical role in the enzymatic reaction. Following recognition of the exon to be spliced, there are three overall steps: (i) the 5′ end of the intron is excised and is covalently attached to the A-residue of the branch site through a 5′-2′ phosphodiester linkage (first transesterification reaction); (ii) the 3′ end of the intron is excised and the exons are joined (second transesterification reaction); and (iii) finally, the intron thus released as a lariat structure is degraded.
at the 3′-splice site is enhanced by the presence of downstream 5′-splice site even though the downstream 5′-splice site will not be spliced by the same spliceosome (56). The exon definition model derives further support from the circular/closed-loop model of mRNA. Components that bind to the 5′ cap cooperate with the splicing machinery to facilitate recognition of the first exon, and components of the polyadenylation machinery interact with the splicing machinery to define the last exon (55). Therefore, the exon definition model stipulates that when the gene is composed of large introns and small exons, sequences within large introns need not be recognized. In contrast, if the gene is composed of small introns and large exons, the mechanism appears to work through intron definition (57), where a pair of splice sites is recognized at the ends of short introns. Together, the exon definition and intron definition models predict that exons and introns of a gene cannot be large at the same time; introns can be large if exons are small and exons can be large if introns are small. Another mechanism that contributes to the fidelity of splicing is the coupling of transcription and splicing. Many splicing factors, such as the SR proteins and snRNPs, ride on the CTD of RNA pol II (58). When a 5′-splice site is recognized in the newly synthesized RNA, these factors are transferred to the RNA. These factors are then ready to interact with
26
Choudhuri U2AF U1
Complex A
U2
Exon 1
Exon 2 U6
Complex B
U5 (bound to exon) U4
U1 Exon 1
U5 Exon 2 E
U2
U1 U6
Complex B Exon 1
U4
U5 Exon 2
U2
U4 Complex C Exon 1
U5 (shifted to intron) U6
U5
Exon 2
U2
Exon 1 U5 U2 U6
Exon 2 U5
Exon 1
Exon 2
Exons spliced
U2
U6 Intron released as a lariat
Figure 6 Sequence of association and dissociation of U-snRNPs with the pre-mRNA during splicing. Splicing reactions are initiated by the following interactions: (i) U1 snRNP binds to the 5′-splice site; (ii) U2AF binds to the polypyrimidine tract so that the larger subunit (U2AF 65) is bound to the polypyrimidine tract and the smaller subunit (U2AF 35) is bound to the 3′-splice site; and (iii) U2 snRNP binds to the branch site with the help of U2AF. Next, this complex undergoes rearrangement to bring all three splice signal sites (5′-splice site, 3′-splice site, and the branch site) together. This is achieved through the involvement of the U4/U5/U6 tri-snRNP particle and looping of the premRNA. This is followed by the release of U1 from the 5′-splice site, which is then occupied by U6. Next, U4 is released from the complex allowing U6 to interact with U2. This arrangement brings the 5′-splice site close to the branch site through U6–U2 interaction. Splicing then proceeds in two steps, as indicated in Fig. 5.
3′-splice site factors which will be transferred to the 3′-splice site as soon as it is synthesized. Thus, the correct 3′-splice site will be recognized before any other similar sites are synthesized by the advancing RNA pol II. Additionally, there are many nonsplice site sequence elements that serve to define exons, such as the ESE, ESS, ISE, and ISS elements mentioned earlier. Each of these elements binds splicing factors that positively or negatively affect spliceosome assembly. The most studied of these splicing factors are the SR proteins. The SR proteins bind ESE elements within exons (Fig. 5), and they interact with the components of the splicing
Eukaryotic Protein-Coding Genes
27
machinery, such as U2AF of the upstream intron and U1 snRNP of the downstream intron. Most exons contain ESEs, which are loosely conserved purine-rich sequences that bind one or more SR proteins. The SR proteins seem to be essential in defining the exon. A recent report (59) suggests that the SR proteins and the ESEs also play a crucial role in the maintenance of exon order during splicing by preventing exon skipping. Several lines of evidence point to such a role for the ESEs and the SR proteins. For example, deletion of ESEs from an exon results in the skipping of the exon during splicing. Since the ESEs are SR protein-binding sites, progressive loss of SR protein-binding to the exon seems to be an important factor in exon skipping. Inactivation of the 3′-splice site alone does not result in skipping of the immediately downstream exon even though the distal 3′-splice sites are intact. In order for this exon to be skipped during splicing, further deletion of ESEs in the upstream exon is necessary. Because the disruption of the SR proteins– spliceosomal machinery interactions seems to be responsible for exon skipping, it strongly suggests an important role of the ESE–SR protein complex in maintaining exon order during splicing. However, exceptions to this paradigm also exist. There are reports of exon skipping in vertebrate genes including in humans as a result of splice site mutations. 2.1.8.7. Alternative splicing Alternative splicing is achieved through the combinatorial interplay of cooperative and competitive binding of various splicing factors to various cis-acting positive and negative regulatory signals in the pre-mRNA substrate. Some of these interactions may cause masking of splice sites resulting in exon skipping. The cis-acting sequences are the ESE or ISE and ESS or ISS elements mentioned above. The splicing factors involved are various members of the hnRNP and SR protein families. After being synthesized, the pre-mRNA associates with a family of polypeptides to form densely packed ribonucleoprotein complex known as “heterogeneous nuclear ribonucleoprotein” (hnRNP). There are many different kinds of hnRNPs, such as hnRNPA1, hnRNPF, hnRNPH, and hnRNPI (PTB). A model that explains the experimental results depicts that exon skipping and alternative splicing may be primarily driven by a balance between SR proteins and hnRNPs. Under limiting concentrations of the SR protein called “alternative splicing factor/splicing factor 2” (ASF/SF2), U1 snRNP binds only to functionally stronger splice sites, whereas higher levels of ASF/SF2 promote full occupancy of all 5′-splice sites. Because the binding of U1 snRNP to 5′-splice site is the first step in a series of splicing reactions, lack of U1 snRNP-binding to certain 5′-splice sites can be an important determinant of which exon will be skipped. The action of ASF/SF2 can be antagonized by hnRNPA1, which binds to the exonic silencer elements. Thus, tissue-specific differences in the relative concentrations of splicing factors and hnRNPs may modulate splice site choice resulting in tissue-specific pattern of alternative splicing. The regulation of alternative splicing can also be sex-specific and developmental stage-specific. Sex-lethal (Sxl) protein in Drosophila is produced only in female flies. It induces a female-specific pattern of alternative splicing. The role of Sxl in mediating alternative splicing involves its interaction with the polypyrimidine tract and prevention of U2AF from binding to this site. Like hnRNPA1, Sxl also promotes exonskipping in its own pre-mRNA by binding to both of the flanking introns (60). 2.1.8.8. Effect of intron phase on alternative splicing Whereas the regulation of alternative splicing may be driven by a balance between SR proteins and hnRNPs, the choice of exons that can be skipped during alternative splicing is driven by intron phase, as explained below.
28
Choudhuri
Spliceosomal introns can be divided into three types based on “phase”, such as phase 0, phase 1, and phase 2 introns. A phase 0 intron does not disrupt a codon; a phase 1 intron disrupts a codon in between the first and second base; and a phase 2 intron disrupts a codon in between the second and third base. An exon flanked by the same-phase introns at both ends is called a “symmetrical exon”, while an exon flanked by different phase introns is called an “asymmetrical exon”. Thus, a symmetrical exon flanked by phase 1 introns at both ends is designated class 1,1, while an asymmetrical exon flanked by phase 1 intron at the 5′ end and phase 2 intron at the 3′ end, for example, is designated class 1,2. Normally, an exon has to be flanked by the same-phase introns in order to be inserted, deleted, or duplicated without altering the rest of the ORF from the 3′-splice site. Hence, legitimate alternative splicing involves symmetrical exons. Alternative splicing involving an entire asymmetrical exon will lead to a frameshift in the ORF beyond the 3′-splice site (Fig. 7A and B). If the phases of introns in a gene are known, then it can be predicted which exons are expected (or not expected) to be alternatively spliced. An unusual phenomenon of alternative splicing involving an exon flanked by introns of two different phases was reported for rat liver-specific organic anion transporter-1 (lst-1/Oatp-4), a xenobiotic and endobiotic transporter (61). The authors cloned the full-length mRNA of lst-1/Oatp-4 as well as two splice variants. One of the splice variants termed rlst-1c is a normal splice variant that has a deletion of the entire exon 7 which is a symmetrical exon (class 1,1). Thus, the generation of rlst-1c obeys the rule of intron phase limitation of alternative splicing. The other splice variant termed rlst-1b is an unusual splice variant because it involves partial deletion of exon 10. Since exon 10 is an asymmetrical exon (class 1,2), deletion of the entire exon 10 would have caused a frameshift in the ORF beyond the 3′-splice site. This phase limitation is overcome by the use of an alternative splice donor site from within exon 10. As a result, 91 bp from the 5′ end of exon 10 is retained in the final mRNA. The final transcript thus produced is constitutively expressed and is functional albeit with somewhat different substrate specificity compared with the full-length transcript (62). Fig. 7A and B explains the intron phase limitation rule during alternative splicing. The regulation of intron phase limitation, however, is not known yet. 2.1.8.9. Intronic riboswitch and the regulation of gene expression through regulation of alternative splicing Exogenous thiamine, added to growth medium, was shown to reduce thiA gene expression in the fungus Aspergillus oryzae (63). The thiA gene is involved in thiamine (vitamin B1) biosynthesis. The authors identified through sequence analysis that the second intron in the 5′-UTR of thiA mRNA contains the TPP aptamer. The TPP aptamer is highly conserved among the fungal thiamine biosynthesis genes. Deletion experiments with constructs containing GUS reporter gene revealed that the TPP aptamer is involved in thiamine-dependent repression of thiA gene expression. The authors also concluded that splicing of the riboswitch-containing intron is crucial to the thiamine-regulated gene expression. The mechanism of the action of intronic TPP-riboswitch was studied in further detail in N. crassa (64). The authors studied genes known to be involved in thiamine metabolism, NMT1, THI4, and a third gene whose function is unknown. When the concentration of thiamine in the growth medium of N. crassa was high, there was a marked increase in one type of mRNA splice variant. In contrast, less thiamine in the growth medium resulted in a marked increase in another type of mRNA splice variant. Translation of these two splice variants produced different protein products. To understand the mechanism, the authors subsequently focused on NMT1 pre-mRNA splicing mechanism.
Phase 0 Intron Asn Asp … Asp Gly
Phase 0 Intron Leu Thr … Val A
Phase 1 Intron la
Thr … Val
Ar
Phase 2 Intron g Arg … Pro Ala
Exon 2
Exon 3 Transcription
Exon 4
Exon 5
Phase 0 Intron Asn Asp … Asp Gly
Phase 0 Intron Leu Thr … Val A
Phase 1 Intron la Thr
Arg … Pro
…
Ala
C AGG…CCU GCC
Val Ar
Phase 2 Intron g Arg
mRNA (No frameshift)
…
Pro Ala
DNA
Asn Asp … Asp Gly
Exon 2
Exon 3
Leu Thr … Val A
Transcription la Thr
…
Exon 4
Val Ar
g Arg
…
Pro Ala
pre-mRNA
Exon 5
Asn Asp … Asp Gly
Arg Pro … Arg Gln
Gln Ala … Pro Cys ...
CAG GC…CCC UGC C..
mRNA (frameshift)
Alternative splicing involving asymmetrical exon
Figure 7 The effect of intron phase on alternative splicing. (A) Exon 2 (AAU GAU…GAC GGA) is a symmetrical exon (class 0,0, i.e., flanked by phase 0 introns). Alternative splicing involving its removal does not cause a frameshift in the ORF except the deletion of Asn-Asp…Asp-Gly amino acids encoded by it. All other amino acids are maintained in proper order. (B) Exon 3 (CUA ACC GUG G) is an asymmetrical exon (class 0,1, i.e., flanked by phase 0 intron at the 5′ end and by phase 1 intron at the 3′ end). Alternative splicing involving its removal causes a frameshift in the ORF. All amino acids beyond the Gly residues are new (underlined by a parenthesis) and not part of the original ORF.
Leu Pro … Met Val
CUU CCC…AUG GUC AAU GAU…GAC GGA CGA CCG …CGU CAG
Exon 3 (class 0,1) spliced out
CUU CCC…AUG GUC gu…ag AAU GAU…GAC GGA gu…ag CUA ACC…GUG G gu…ag CG ACC G…CC GUC AG gu…ag C AGG C…CC CCU GCC
Leu Pro … Met Val
Exon 1
CTT CCC… ATG GTC gt…ag AAT GAT…GAC GGA gt…ag CTA ACC…GTG G gt…ag CG ACC G…CC GTC AG gt…ag C AGG C…CC CCT GCC
Leu Pro … Met Val
B
CG ACC…GUC AG
Ala Thr … Val Arg
Leu Pro … Met Val
Leu Thr … Val
CUU CCC … AUG GUC CUA ACC…GUG G
Leu Pro … Met Val Asn Asp … Asp Gly Leu Thr … Val A la Thr … Val Ar g Arg … Pro Ala preCUU CCC…AUG GUC gu…ag AAU GAU…GAC GGA gu…ag CUA ACC…GUG G gu…ag CG ACC …GUC AG gu…ag C AGG…CCU GCC mRNA Exon 2 (class 0,0) spliced out Alternative splicing involving symmetrical exon
Exon 1
CTT CCC…ATG GTC gt…ag AAT GAT…GAC GGA gt…ag CTA ACC…GTG G gt…ag CG ACC…GTC AG gt…ag C AGG…CCT GCC DNA
Leu Pro … Met Val
A
Eukaryotic Protein-Coding Genes 29
30
Choudhuri
On the basis of their data, the authors have proposed a model to explain the mechanism of generation of such alternatively spliced variants. The model is depicted in Fig. 8. In NMT1 pre-mRNA, there is an intron at the 5′ end of NMT1 ORF. This intron contains the TPP aptamer, and upstream from the aptamer are two splice donor sites (5′-splice sites) that are 60 nt apart. The authors noted that part of the TPP aptamer sequence (the P4 and P5 elements), which is required to bind TPP, is also complementary to most of the nucleotides of the second 5′-splice site. When TPP is low in the medium, the second 5′-splice site is sequestered by TPP aptamer and is not available to the splicing machinery. Therefore, the first 5′-splice site (upstream splice donor site) is preferentially used by splicing machinery, and more NMT1 mRNA with functional NMT1 ORF is produced (Fig. 8A). In contrast, when TPP is high in the medium, it binds to TPP aptamer causing allosteric changes to RNA folding. Under such altered conformation of the pre-mRNA, the splicing machinery preferentially uses the second 5′-splice site. This results in the inclusion of a small 5′ end of the intron (bordered) that contains two splice donor sites and an ORF (uORF)
A
Intron
5′ -UTR
NMT1 ORF GU * * GU
NMT1 pre-mRNA
AG
Upstream 5′ -splice site is used 5′ -UTR
Low TPP concentration NMT 1 ORF translation (TPP aptamer has been drawn arbitrarily)
TPP aptamer without the ligand (TPP) blocks the downstream 5′ -splice site
NMT1 ORF NMT1 mRNA NMT1 ORF translated
Putative translation start codons in the intron represented by (∗)
B GU* *
GU
AG
T Upstream 5′ -splice site is not used
NMT1 mRNA
GU* *
High TPP concentration uORF translation (TPP aptamer has been drawn arbitrarily)
NMT1 pre-mRNA TPP aptamer with the bound ligand (TPP) makes the downstream 5′ -splice site available
uORF translated
NMT1 ORF translation repressed
Figure 8 Regulation of alternative splicing and gene expression by intronic riboswitch in eukaryotes. The figure depicts a model to explain the mechanism of generation of alternatively spliced variants of NMT1 mRNA in Neurospora crassa. The intron upstream of the NMT1 ORF contains the TPP aptamer and two splice donor sites that are both located upstream of the aptamer. (A) When the TPP concentration is low in the medium, the second 5′-splice site (downstream splice donor site) is presumably sequestered by the aptamer and is not available to the splicing machinery. Therefore, the first 5′-splice site (upstream splice donor site) is preferentially used by the splicing machinery, and more NMT1 mRNA with functional NMT1 ORF is produced. (B) In contrast, when the TPP concentration is high in the medium, the binding of TPP to the TPP aptamer causes allosteric changes to RNA folding. Under such altered conformation of the pre-mRNA, the splicing machinery preferentially uses the second 5′-splice site. This results in the inclusion of a small upstream fragment of the intron in the final NMT1 mRNA. This intronic fragment contains two AUG codons and creates a short upstream ORF (uORF). This uORF competes with the NMT1 ORF for translation, resulting in the repression of NMT1 expression.
Eukaryotic Protein-Coding Genes
31
upstream fragment of the intron in the final NMT1 mRNA. This intronic fragment contains two AUG codons and creates a short upstream ORF (uORF). This uORF competes with NMT1 ORF for translation resulting in the repression of NMT1 expression (Fig. 8B). 2.1.8.10. Mutations generating splice sites within introns can activate pseudoexons that are included in the mature mRNA Despite all the safeguards to ensure the fidelity of splicing, errors do happen. An increasing number of evidence show that single-nucleotide changes in a gene in places other than splice sites can also affect the splicing process. Potential exonic sequences (pseudoexons) are frequently found within introns, but they are normally not included in mature mRNA because they are not recognized by the splicing machinery. Mutations creating or activating a strong splice site may result in the inclusion of pseudoexon in processed mRNA. Such pseudoexon insertion in various mature mRNAs has been reported in connection with human diseases. For example, an A→G transition within intron 6 of the human growth hormone receptor (GHR) gene results in the insertion of a pseudoexon in mature GHR mRNA. This pseudoexon encodes 36 additional amino acids in the protein. This aberrant protein is associated with atypical growth hormone insensitivity (65). Pseudoexon activation in Duchenne muscular dystrophy (DMD) gene apparently also causes Becker muscular dystrophy (BMD) (66). The authors characterized two intronic mutations in the DMD gene from two unrelated BMD patients. One of these pseudoexons was a 58-bp insertion between exon 62 and exon 63. The activation of this pseudoexon was due to an A→G transition in intron 62, which resulted in the creation of a high quality splice donor site. The other pseudoexon was created by an A→G transition in intron 25, and this resulted in the inclusion of a 95-bp segment in mature mRNA. The insertion of both these pseudoexons leads to truncation of the ORF and premature translational termination. The authors observed some degree of normal splicing in both patients, and they concluded that the detection of these residual full-length transcripts is consistent with the clinical presentation and dystrophin analyses. 2.1.9. Silent Mutations in the ORF Do Not Change the Amino Acid Sequence But May Still Alter Protein Activity by Altering Conformation: A New Paradigm Challenging the Traditional Wisdom that Silent Mutations Do Not Affect the Phenotype Mutations in the gene that do not change the amino acid sequence and function of the protein are known as “silent” or “synonymous mutations”. The traditional wisdom in molecular biology is that silent mutations do not affect the phenotype because they do not alter protein function. If the frequency of a mutation in the population is 1% or greater, it is called a “single-nucleotide polymorphism” (SNP). An exception to this well-accepted paradigm was reported from Michael Gottesman’s laboratory (67). They reported that a synonymous SNP in exon 26 (C3435T; C at position 3435 replaced by T) in human Multidrug Resistance 1 (MDR1) gene resulted in the production of protein with an altered ability to interact with drugs and inhibitors. This SNP (C3435T) had been reported before to be associated with altered P-glycoprotein (P-gp) activity and also with reduced functionality. The authors found that the mutation did not change the levels of mRNA or protein expression, but the expressed protein had altered conformation. MDR1 gene in humans is expressed in small intestine, liver, kidney and brain, and its protein product is known as “P-glycoprotein (P-gp)”. P-gp is an efflux transporter responsible for the tissue elimination of a variety of xenobiotics including pharmacologically distinct drugs used in cancer chemotherapy, hypertension, allergy, infection, immunosuppression,
32
Choudhuri
neurology, and inflammation (68). The finding of such a profound effect of silent mutation on the protein activity provides a very important clue about the importance of silent mutations in determining individual susceptibilities to drugs and other xenobiotics even when the protein sequence is not altered. The authors hypothesized that the presence of a rare codon affected the timing of cotranslational folding and insertion of the P-gp into the membrane, thereby altering the structure of substrate and inhibitor interaction sites. Thus, a general mechanism how silent mutations might affect protein function may be due to the creation of rare codons that alter the rate of translation. This could be due to limiting concentration of the specific tRNA that would recognize the rare codon, resulting in transient ribosomal pause during polypeptide elongation. Since protein folding is a cotranslational process, altered rate and timing of synthesis may affect the cotranslational folding, leading to altered conformation and altered binding ability for substrates and inhibitors. 2.1.10. Triplet Repeat Expansion in the Gene and Its Effect Even though DNA replication is a high fidelity process, mistakes do occur. Long stretches of repeat sequences sometimes form internal loops during replication. This phenomenon causes “replication slippage” or “slipped strand mispairing” (Fig. 9). Long stretches of
-
-
-
A CG G C A A Slippage and mispairing C G G C A A C G 5¢-CAG-CAG-CAG CAG-CAG-CAG-CAG Direction of new strand synthesis 3¢-GTC-GTC-GTC-GTC-GTC-GTC-GTC-5¢ Parent strand (template) with seven triplet repeats 5¢-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-3¢ 3¢-GTC-GTC-GTC-GTC-GTC-GTC-GTC-5¢
This strand replicates normally
This strand with expanded number of triplet repeats (12) will serve as the template during next replication cycle leading to an increase in the number of triplet repeats in the gene
Newly synthesized strand with 12 triplet repeats
5¢-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-3¢ 3¢-GTC-GTC-GTC-GTC-GTC-GTC-GTC-GTC-GTC-GTC-GTC-GTC-5¢
Further replication slippage can cause further triplet expansion. When hnRNA is synthesized on these templates and processed to mRNA, the mRNA will contain these expanded triplet repeats
Figure 9 Mechanism of replication slippage. The slippage and mispairing of the newly synthesized DNA strand during replication results in an increase in the number of repeats. During the next replication cycle, when the strand with the increased number of repeats serves as a template strand, it results in a permanent increase in the repeat length of the gene.
Eukaryotic Protein-Coding Genes 5′
33 3′ 3′
5′
5′
3′
5′
3′ Repeat expanded in this strand
Misalignment of two DNA strands from two nonsister chromatids and unequal crossing-over
At the molecular level = CAG-CAG-CAG-CAG-CAG
At the molecular level
N = Any nucleotide
5′ -CAG-CAG-CAG-CAG-CAG-NNNNN-CAG-CAG-CAG-CAG-CAG-NNNNN-CAG-CAG-CAG-CAG-CAG-3′
X
5′ -CAG-CAG-CAG-CAG-CAG-NNNNN-CAG-CAG-CAG-CAG-CAG-NNNNN-CAG-CAG-CAG-CAG-CAG-3′
5′ -CAG-CAG-CAG-CAG-CAG-NNNNN-CAG-CAG-CAG-CAG-CAG-NNNNN-CAG-CAG-CAG-CAG-CAG-NNNNN-CAG-CAG-CAG-CAG-CAG-3′ 5′ -CAG-CAG-CAG-CAG-CAG-NNNNN-CAG-CAG-CAG-CAG-CAG-3′
Strand with expanded repeats
Figure 10 Mechanism of unequal crossing-over. The existence of long repeat sequences may sometimes result in misalignment of the two DNA strands from two nonsister chromatids involved in crossing-over. As a result, one strand gains part of the repeat sequence from the other strand. Subsequent replication process fixes this increased length in the gene, as described above.
repeat sequences may also cause unequal crossing-over (Fig. 10). In both situations, there is a net increase in the repeat sequence in one strand. Replication slippage seems to be more important for repeat expansion. The expandable repeat sequences can be located in exons, introns, or even in untranslated regions. Altered number of trinucleotide repeats (triplet repeats) are a unique class of mutations associated with a number of heritable genetic disorders in humans. For example, there are 6–35 CAG repeats in human HD gene. When the number of repeats starts increasing, the result is Huntington’s disease (HD). The number of repeats found in various patients of HD varies from 36 to 121. In general, the greater the number of repeats, the earlier the onset, and the more severe the disease. There are many other trinucleotide repeat disorders, such as fragile X syndrome, myotonic dystrophy, and spinal and bulbar muscular atrophy. Transcriptional disruption appears to be associated with such triplet repeat-mediated disease. In HD, the mutated huntingtin protein contains expanded glutamine-rich domain (because CAG codes for glutamine) compared with that of its normal counterpart, and this glutamine expansion in huntingtin protein disrupts transcriptional activation by Sp1 and TAFII130. In the nucleus, the mutant protein accumulates and associates with Sp1 and TAFII130. This prevents the binding of Sp1 to the GC box and also disrupts the interaction between Sp1 and TAFII130. Such disruption presumably leads to specific and pleiotropic dysregulation of transcription. A similar mechanism may be responsible for other diseases such as dentatorubralpallidoluysian atrophy (DRPLA), a neurodegenerative disease similar to HD (69). 2.2. The 5′ -Flanking Region of the Gene and Transcription Initiation The 5′-flanking region of the gene is the long region upstream of the transcription start site (+ 1). It contains most of the cis-acting transcription regulatory sequence elements, the most fundamental of which is the promoter.
34
Choudhuri
2.2.1. The Promoter The operon model proposed by Jacob and Monod introduced the concept of promoter as an integral part of gene/transcriptional unit to which RNA polymerase binds. With the advances in molecular cloning techniques, various promoter elements (sequences) have been analyzed and defined through deletion analysis. The most salient features of the promoter elements are that they control the initiation of transcription of a specific gene, and their locations are relatively fixed with respect to the transcription start site. Since transcription proceeds in a 5′→3′ direction, and newly synthesized RNA is in antiparallel orientation with the template DNA strand, the location of the promoter automatically determines which of the two DNA strands of a gene will be transcribed. Various regions of the promoter have been termed the “core (or basal) promoter”, “proximal promoter”, and “distal promoter”, based on their functions and distance from the transcription start site. Sometimes, transcriptional regulatory sequences located upstream of the core promoter are collectively referred to as “upstream promoter elements”. In addition to the promoter, other cis-acting DNA sequences that regulate gene expression include enhancer, silencer, locus control region (LCR), and insulator elements. In general, the transcription start site is determined by TATA box and initiator element, or in the case of TATA-less promoters, by initiator element and downstream promoter element, all located within core promoter. Core promoter elements facilitate the formation of transcription preinitiation complex (PIC) close to the transcription start site. The PIC is composed of RNA polymerase and general (basal) transcription factors (GTFs); the GTFs are so named because of their universal requirement in transcription initiation by RNA pol II. However, the efficiency and the specificity with which a promoter is recognized depend on several other sequences (and their interacting proteins) that are located further upstream in the proximal promoter. These proximal promoter elements bind a different group of transcription factors called “transcriptional activators”. These activator proteins interact with the basal apparatus. Some of the activators can be tissue-specific and are called “specific transcription factors or tissue-specific activators”. 2.2.1.1. Core promoter The core promoter is the minimal contiguous sequence that is sufficient to direct the accurate initiation of transcription by RNA pol II. It is the binding site for RNA pol II and the GTFs. Typically, the core promoter is about 35 bp long, and can extend either upstream or downstream of the transcription start site (–35 to + 35). The core promoter may contain two or more of the following sequence motifs: TATA box, initiator (Inr) element, and downstream promotor element (DPE) (70). 2.2.1.1.1. TATA box The TATA box is responsible for the accurate positioning of RNA pol II. It has a consensus sequence TATAAA, which has been highly conserved through evolution. In most eukaryotic genes, TATA box is located approximately 25 nt upstream (usually between –30 and –25) from the transcription start site. In yeast (S. cerevisiae), the location of TATA box may range from 40 to 100 nt upstream of the transcription start site (70). Certain variations of the consensus TATA sequence, such as TATATA, are also present in many genes. The TATA box is usually followed by a few more (˜3) A-residues. This AT-rich sequence facilitates easy melting of the DNA duplex during transcription.
Eukaryotic Protein-Coding Genes
35
2.2.1.1.2. Initiator element Even though the TATA box plays an important role in transcription, nearly half of all known gene promoters lack a TATA box (TATA-less promoters). Accurate positioning of RNA pol II in these genes is thought to be mediated by Inr element and DPE. The Inr encompasses transcription start site between –2 and + 5, and it can be found in both TATA-containing and TATA-less promoters. Its consensus sequence in mammals is PyPy-+1-N-T/A-Py-Py, where Py is pyrimidine, + 1 is transcription start site, and N is any nucleotide. However, Inr is not absolutely conserved, and there are variations of this consensus motif. For example, the promoter of rat liver-specific organic anion transporter 1 (rlst-1/Oatp-4/Slc21a10) is a TATA-less promoter, and it contains a noncanonical Inr motif in which the half-site (+ 1-N-T/A-Py) matches that of the consensus sequence. A similar situation was described for mouse lst-1 and human MRP3 (ABCC3) genes (71). The Inr is apparently recognized by various transcription factors, such as TFIID, TFII-I, YY1, as well as RNA pol II itself (see 70 and references therein). The Inr element and the TATA box, when present in the core promoter, usually act synergistically. 2.2.1.1.3. Downstream promoter element The DPE was originally identified as a downstream basal promoter element in some Drosophila TATA-less promoters, and could bind purified Drosophila TFIID (72). In TATAless core promoters, TFIID was found to bind cooperatively to Inr and DPE, and mutation in either Inr or DPE abolished TFIID-binding to the core promoter (72). Thus, DPE-dependent promoters also need Inr for activity. Studies in Drosophila demonstrated that Inr-to-DPE spacing is strictly maintained, and a single-nucleotide alteration in the spacing reduces core promoter activity and TFIID binding (73). The consensus DPE spans between + 28 and + 32 with respect to transcription start site, and the estimated consensus sequence is (A/G)+28G(A/T) (C/T)(G/A/C)+32 (70). The DPE is conserved from Drosophila to humans and is mostly found in TATA-less promoters; however, it has been most well studied in Drosophila (73). 2.2.1.1.4. Formation of the transcription preinitiation complex (PIC) on core promoter and subsequent events Transcription PIC that forms on the core promoter is composed of RNA pol II and multiple GTFs, such as TFIIA, IIB, IID, IIE, IIF, and IIH (TFII = transcription factor for RNA pol II). The sequence of events that goes on the core promoter during transcription initiation can be summarized as follows: PIC formation→Promoter melting→Transcription initiation→Promoter clearance→Transcript elongation→Transcription termination. I. PIC formation: TFIID is the first transcription factor to bind TATA box. This is followed by the binding of other factors in the following order: TFIIA, TFIIB, RNA pol II–TFIIF, TFIIE, and THIIH. TFIID, which is the first one to bind TATA box, is a multiprotein complex composed of TATA-binding protein (TBP) and about 13 other proteins called “TBP-associated factors” (TAFs or TAFIIs). The TBP actually binds the TATA box and it makes contact with the DNA like a saddle so that the inner surface is bound to DNA, and the larger outer surface is available to make contacts with other proteins. The TBP is a universal component of the PIC for all three types of RNA polymerases. Recent evidence suggests that trimethylated lysine 4 of histone H3 (H3K4me3), which is regarded as the hallmark of transcriptionally active promoters, provides a direct binding site for TFIID. The exact protein component of TFIID involved in this interaction is TAF3 (or TAFII3; TBP-associated factor 3), which binds H3K4me3 via its plant
36
Choudhuri
homeodomain (PHD) finger. Acetylation of H3K9 and H3K14 potentiates TFIID interaction with H3K4me3 (74). TFIIA binds to the upstream part of TFIID, whereas TFIIB binds to TFIIB recognition element (BRE). The BRE is located immediately upstream of TATA box and has a consensus sequence (G/C)(G/C)(G/A)CGCC. Both TFIIA and TFIIB directly interact with TBP. The recruitment of TFIIB is accompanied by dramatic conformational rearrangements; as a result, TFIIB contacts DNA both upstream and downstream of TATA box. After binding, TFIIB provides the platform for recruiting RNA pol II, thereby acting as a bridge between RNA pol II and the rest of the PIC. The interaction between TFIIB and RNA pol II is partially mediated by TFIIF, which is complexed with RNA pol II. TFIIF is also important for elongation. The recruitment of RNA pol II is followed by the binding of TFIIE and TFIIH. Thus, TFIIH is the last factor to bind the complex. II. Promoter melting, transcription initiation, promoter clearance, and elongation: TFIIH, which is the last factor to bind the preinitiation complex, is also involved in DNA repair (nucleotide excision repair). TFIIH has both helicase and kinase activity; it has nine subunits, of which the XPB subunit is a 3′→5′ helicase, the XPD subunit is a 5′→3′ helicase, and the cdk7 subunit is a kinase. TFIIH recruitment to the PIC is facilitated by TFIIE. Using ATP, the helicase activity of TFIIH disrupts base-pairing and helps in promoter melting. This creates an open complex due to the separation of two DNA strands so that RNA pol II and other factors gain access to the bases of the template strand and starts polymerizing a few complementary nucleotides (initiation). Initiation is defined by the formation of the first phosphodiester bond. The PIC can now be called the “initiation complex”. Following initiation, the kinase activity of TFIIH phosphorylates the CTD of RNA pol II (75). Phosphorylation of CTD makes RNA pol II elongation-competent. Without CTD phosphorylation, RNA pol II does not get promoter clearance, and it cycles in the stuttering synthesis mode in which it polymerizes about 8–10 ribonucleotides, aborts the elongation, and then starts the cycle all over again. Once transcription is initiated, CTD phosphorylation by TFIIH helps RNA pol II to undergo promoter clearance by dissociating from all the transcription factors in the initiation complex except TFIIF, escape the promoter, and begin productive synthesis of the RNA chain (elongation). After the beginning of elongation, TFIIH dissociates from pol II. Once RNA pol II begins elongation, TFIIF remains associated with it. Also, various elongation factors, such as SII (TFIIS), SIII (elongin), P-TEFb, and ELL, become associated with pol II and enhance its elongation activity by suppressing its pausing and arrest on the DNA template. In addition, the advancing polymerase also becomes associated with many other factors, such as FACT that facilitate transcription through chromatin. After transcription termination, a TFIIF-associating C-terminal domain phosphatase (FCP1) dephosphorylates the C-terminal domain of RNA pol II, making it available for new PIC. 2.2.1.2. Proximal promoter The proximal promoter is about 250 bp long and can extend either upstream or downstream of the transcription start site (–250 to + 250) (70). In the literature, however, sequences far upstream of –250 have also been referred to as “proximal promoter sequences” (e.g., see 76,77). The proximal promoter typically binds activators/specific transcription factors. Two transcription activating elements found in proximal promoter are the CAAT box and the GC box. The CAAT box binds transcription factor NF-I (nuclear factor I, also known as NF-Y, CTF, and CBF); it is located about 75 nt upstream from the transcription start site and has a consensus sequence GG(T/C)CAATCT. The GC box has a consensus
Eukaryotic Protein-Coding Genes
37
sequence GGGCGG; it is located about 90 nt upstream from the transcription start site, and it binds the transcription factor Sp1 (specificity protein 1). The CAAT box and the GC box operate as enhancer elements because they can activate transcription when placed in either orientation in the proximal promoter (hence, orientation-independent). 2.2.1.3. Distal promoter The term “distal promoter” is used to mean sequences that are further upstream of the proximal promoter elements. There are many examples of cooperation between proximal and distal promoter elements in regulating transcription. The proximal and the distal promoters of genes that show tissue-specific expression contain many more unique transcription regulatory elements that are recognized by tissue-specific transcription factors. 2.2.1.4. Promoter-like elements in the intron Sometimes, promoter-like elements in the intron are indispensable in upregulating transcription. For example, maize ubiquitin 1 promoter cassette includes the promoter, exon 1, and intron 1 (promoter–exon 1–intron 1 cassette) (78). Using different combinations of the elements of the cassette, the authors made various constructs and determined the relative effectiveness of each combination in driving the expression of GUS reporter gene. The authors demonstrated that the complete promoter cassette (promoter– exon 1–intron 1) was the most effective in driving maximal GUS expression. The combination of 40 bp of exon1 and complete intron 1 could also drive GUS expression without the promoter. However, the promoter and the 44 bp of exon 1 combination alone (without intron 1) could not drive GUS expression. In other words, the intronic sequence elements were essential for transcription. The authors suggested that the intron has promoter-like features, such as a TATA-like sequence, a canonical CAAT box, and opaque-2 binding motif that may play a role in the promotion of GUS activity without the promoter. 2.2.2. Enhancers, Silencers, Locus Control Regions, Insulators Many transcription regulatory elements can be located several kilobases away from the gene, either upstream or downstream from transcription start site. Some of these elements stimulate transcription, such as enhancers and LCRs, while others act as transcriptional suppressors, such as silencers. These elements contain recognition sequences for a variety of sequence-specific DNA-binding proteins that are involved in transcriptional regulation. 2.2.2.1. Enhancers and silencers Enhancers can enhance the rate of transcription by increasing promoter utilization. They are the binding sites for specific transcriptional activators. A single enhancer can control the transcription of more than one gene in a position- and orientation-independent manner. Enhancers can be located close to the transcription start site, upstream, downstream, and even within introns. The CAAT box and the GC box described above are enhancer elements that are integral part of the proximal promoter of most genes. Enhancers are thought to bring enhancer-bound transcriptional activators in contact with promoter-bound transcription factors by looping of the DNA. In doing so, enhancers increase the concentration of activators near the promoter and these factors directly or indirectly interact with the promoter to initiate transcription. In yeast, upstream activator sequences (UASs) act as enhancers. Studies on tissue-specific transcription revealed the existence of tissue-specific transcriptional activators. These tissue-specific transcriptional activators, when bound to enhancers, interact with components of the basal transcription machinery. Such interaction is
38
Choudhuri
mediated by other proteins called “coactivators”, which act as a bridge between different transcriptional activators through protein–protein interactions. Some examples of coactivators are as follows: CREB (cAMP-responsive element-binding protein)-binding protein (CBP); p300 (a mammalian transcriptional coactivator closely related to CBP); p300/ CBP-interacting protein (p/CIP), also called “nuclear receptor coactivator 3” (NCoA-3); p300/CBP-associated factor (p/CAF or PCAF); p160; transcriptional intermediary factor 2 (TIF2), also called “glucocorticoid receptor-interacting protein 1” (GRIP1) and “nuclear receptor coactivator-2 (NCoA-2) (TIF2/GRIP1/NCoA-2)”; yeast transcriptional adaptor GCN5; and steroid receptor coactivator-1 (SRC-1), also called “nuclear receptor coactivator-1” (NCoA-1) (SRC-1/NCoA-1). Many coactivators have histone acetylase activity, histone acetylation being a transcription-activating chromatin modification. The opposite of enhancers are silencers, which suppress transcription by binding silencing transcription factors, thereby acting as negative regulatory elements. Silencers can function in orientation-, position-, and distance-independent manner, and they can also be located within introns. Unlike enhancers which recruit transcriptional activators, silencers recruit transcriptional suppressors. An example is the neuron-restrictive silencer element (NRSE), which is a 21-bp sequence found in the regulatory regions of most neuron-specific genes. The transcription suppressor that binds the NRSE is known as “neuron-restrictive silencing factor” (NRSF) or “RE1-silencing transcription factor” (REST), which is highly expressed in nonneuronal tissues. The NRSF interacts with NRSE to suppress the expression of various neuron-specific genes in nonneuronal cells. The mechanism of NRSF action involves the recruitment of corepressor complexes that have histone deacetylase (HDAC) activity, histone deacetylation being associated with transcriptional repression. However, recent evidence suggests that NRSE may play a dual role, acting as a silencer in nonneuronal cells while acting as an enhancer in neuronal cells (79). Many enhancer and silencer elements in vertebrate genes have been reported in the literature. 2.2.2.2. Locus control region Another transcription-enhancing element is called “locus control region (LCR)”. An LCR enhances transcription of a cluster of linked genes by inducing a more open conformation of the chromatin flanking the locus. Thus, the level of activity of a euchromatic region of a chromosome can be strongly influenced by LCRs. LCR was first identified in human β-globin locus that contains a cluster of five functional genes (5′-ε-G γ-A γ-δ-β-3′). The enhancer activity of β-globin LCR is tissue-specific, the expression of globin genes being confined to erythroid cells. However, the tissue specificity is probably not an intrinsic property of LCR itself, but it depends on the LCR and the tissue-specific promoter that interacts with it (80). An LCR consists of many DNAse I-hypersensitive sites (DHSs). Removal of DNA sequences in between these hypersensitive sites does not affect LCR function much, but removal of any of these hypersensitive sites dramatically reduces LCR activity so that expression of the entire locus is affected. Thus, LCRs can be viewed as a collection of these DHSs. The β-globin LCR is located 6–22 kb 5′ to the first globin gene in the locus (ε). It consists of five DHSs, termed 5′DHS1–DHS5. For LCRs, the 5′ hypersensitive sites are primary regulators and those at the 3′ end are of uncertain function. For the β-globin LCR, the enhancer activity of 5′DHS2–DHS4 resides in a 200- to 300-bp core, which contains binding sites for ubiquitous and erythroid-specific transcription factors. A conserved sequence within 5′DHS2 is TGCTGA(C/G)TCA(T/C). This sequence is called the “Maf recognition element” (MARE), and it is critical for strong enhancer activity. The MARE can bind multiple homodimeric and heterodimeric transcription factors in vitro. These factors include Maf homodimers and heterodimers containing a
Eukaryotic Protein-Coding Genes
39
Maf subunit and another subunit of bZIP protein (such as NF-E2, Nrf1, Nrf2, Bach1, and Bach2). The MARE can also bind heterodimers lacking a Maf subunit. The transcriptional activator NF-E2 seems to be a major transactivator that binds to the tandem MAREs of 5′DHS2 and upregulates the globin gene expression (80). The most prominent functional property of LCRs is their ability to confer position-independent, copy number-dependent expression of linked genes. Despite numerous studies on the role of LCR in controlling β-globin gene expression, the mechanism of long-range activation is poorly understood. Various models proposed so far point to the ability of LCRs to alter chromatin configuration and conformation. Besides the β-globin locus in various vertebrates (chicken, mouse, human, etc.), only a small number of other loci have been reported to be regulated by LCRs, such as human α-globin locus and human growth hormone (hGH) locus. 2.2.2.3. Insulator An important gene-boundary element is called “insulator”. Insulators are DNA sequence elements that, when bound to insulator-binding proteins, shield a promoter from the effects of nearby regulatory elements. There are two types of insulator functions: enhancer-blocking function and heterochromatin barrier function. Enhancer-blocking function involves blocking the communication between an enhancer and a promoter when the insulator is located in between these two elements, and thus preventing the enhancer from activating the promoter. Since an enhancer can exert long-range influence on more than one promoter, the blocking function may prevent the indiscriminate effect of an enhancer on multiple promoters and force an enhancer to influence only one specific promoter. Heterochromatin barrier function involves shielding a euchromatic region (containing genes with transcriptionally active promoters) from turning into heterochromatin by the inactivating effect of the invading adjacent heterochromatin. Such heterochromatin barrier function can also protect a stably integrated transgene from local position effects, as well as from a gradual decline of the gene’s expression due to heterochromatin propagation (discussed in detail in Chapter 3 in Section 3.1). Some insulators possess both blocking and barrier functions, while some have only one function. Insulators were first identified in Drosophila. Known insulators in Drosophila include the scs and scs′ (specialized chromatin structure) insulators that flank the 87A7 heat shock locus, which contains two hsp70 genes in divergent orientation. Another Drosophila insulator is the “gypsy” insulator, which is an enhancer-blocking insulator. Gypsy (also known as “mdg4”) is a retrotransposon in Drosophila genome, and it binds the protein “suppressor of Hairy wing” [su(Hw)]; [su(Hw)]-bound gypsy acts as the insulator. Various proteins that bind to the scs, scs′, and gypsy insulator sequences have been identified (see 81 and references therein). Of all known vertebrate insulators, the chicken β-globin insulator (cHS4) is the most extensively studied. It has both blocking and barrier function. It is located in the fourth DHS (5′DHS4) of the LCR of chicken β-globin gene. Initially, the cHS4 insulator was reported to be 1.2 kb long, but subsequent deletion analysis revealed that most of the insulating activity lies in a 250-bp CpG island (the core element) that is highly GCrich (82). The sequence-specific binding of CCCTC-binding factor (CTCF) is required for the enhancer-blocking function of cHS4, but it is not necessary for its heterochromatin barrier function. By deleting the CTCF-binding site, it was demonstrated that cHS4 could still maintain the barrier function, suggesting that the enhancer-blocking and heterochromatin barrier functions are not necessarily interdependent (83). The mechanism of enhancerblocking function of insulators may involve looping, but it is not quite clear. However, the
40
Choudhuri
mechanism of barrier function understandably involves the maintenance of active chromatin configuration through histone modifications at the boundary (84). Not only does the existence of insulators, LCRs, enhancers, silencers, and various promoter elements make the regulation of gene expression a complex process, but the concerted action of these elements also confers precision to the process. 2.3. The 3′ -Flanking Region of the Gene and Transcription Termination The 3′-flanking region of the gene extends far beyond the 3′-UTR, and it contains transcription termination signals. It was realized early on that the maturation of 3′ end of mRNA and transcription termination are closely coupled. 2.3.1. Transcription Termination in Prokaryotes In bacteria, there are two types of terminators: rho-independent or intrinsic terminators and rho-dependent terminators. Rho-independent or intrinsic terminators have two necessary structural features that are both needed for termination: (i) a sequence that can form a stem-loop structure and (ii) a U-rich region at the very end of the stem-loop structure. The stem-loop generally contains a GC-rich region (toward the base of the stem), which is ˜10 bases away from the U-rich region. Formation of the stem-loop apparently causes the RNA polymerase to pause, thus facilitating termination. Rho-dependent transcription termination is observed in about half of the E. coli genes. Rho (ρ) is an RNA-binding termination factor, which is a homohexameric protein with RNA-dependent ATPase and helicase activities. Rho-dependent terminators are typically C-rich and G-poor. During transcription, the rho factor loads onto the elongating RNA at a region that is about 75 nt long and is located upstream of the terminator. Using its ATPase activity, rho translocates along the elongating RNA, probably faster than the polymerase translocates along the template. When the RNA polymerase pauses at the terminator, rho catches up with it and unwinds the DNA–RNA hybrid using its helicase activity, thereby terminating transcription and releasing the RNA and the polymerase. The rho factor terminates transcription but does not degrade the RNA. Rho-mediated transcription termination model is sometimes referred to as the “hot pursuit” model. 2.3.2. Transcription Termination in Eukaryotes Less is known about transcription termination in eukaryotes. However, some generalizations can be made based on the current state of knowledge. Each class of RNA polymerase uses a different mechanism for termination. For pol I and pol III, pausing at the terminator sequence in the 3′-flanking region seems to be important for termination and subsequent release of both the RNA and the polymerase. The factors that aid in pausing may not necessarily be the release factors. Termination signals as well as termination and release factors may be quite different in different species in eukaryotes. 2.3.2.1. Termination of RNA polymerase I-mediated rRNA transcription Work on the mouse showed that transcription of 45S rRNA by RNA pol I terminates at a conserved 18-bp-long terminator element (sense strand sequence: AGGTCGACCAGA/TT/ANTCCG). This element has a Sal I site (italicized) and is therefore called the “Sal box”. The Sal box is located 565 bp downstream of the rRNA coding region, and
Eukaryotic Protein-Coding Genes
41
it binds a nucleolar protein called TTF-I (transcription termination factor for polymerase I). Termination occurs when pol I encounters the Sal box-bound TTF-I and pauses. Additional proteins (release factors) that bind a T-rich sequence upstream of the Sal box help in 3′-end formation and subsequent release of both the transcript and pol I. Various pol I terminators and the terminator-binding proteins studied in the mouse, frog, and yeast are all different. For example, the essential terminator sequence in the frog Xenopus borealis is GACTTGCN, which is much smaller than the mouse Sal box (85–87). 2.3.2.2. Termination of RNA polymerase III-mediated tRNA transcription The termination of pre-tRNA transcription by RNA pol III requires a small run of U’s in a GC-rich region of the RNA (hence a small run of T’s in the sense strand of DNA). This model has some apparent similarity to the prokaryotic intrinsic (rho-independent) termination. However, unlike in bacteria, about four U-residues are sufficient, and the GC-rich region of the RNA need not form a stem-loop structure. The mechanism of transcript release by the pol III termination complex has not been defined yet. Some evidence suggests that the RNA-binding protein “La” is involved in pol III transcription termination (88). La is a nuclear phosphoprotein that has a high binding affinity for the 3′-oligo (U). 2.3.2.3. Termination of RNA polymerase II-mediated mRNA transcription Unlike eukaryotic pol I and pol III or prokaryotic polymerases, eukaryotic RNA pol II in most cases does not terminate transcription at definitive termination signals in the DNA. This lack of dependence on cis-acting sequence signals helps pol II synthesize long transcripts without the possibility of premature termination at similar sequences that may occur elsewhere in the coding region of the gene (89). In most mammalian protein-coding genes, pol II transcribes the template strand 500–2,000 nt beyond the poly(A) addition site. The poly(A) addition site is the pre-mRNA cleavage site and is located 10–30 nt downstream from the poly(A) signal sequence AAUAAA in mRNA (Fig. 1). Transcription of the poly(A) signal sequence triggers the endonucleolytic cleavage of the nascent transcript, degradation of the downstream cleavage product, and termination of transcription; the termination event involves the displacement of pol II from the template. Pausing of pol II downstream from the poly(A) site appears to be an obligatory step leading to termination. In rare cases, pausing may be triggered by intrinsic terminator signals (such as AU-rich sequences); pausing can also be triggered by template-bound proteins (such as MAZ termination factor), both occurring in 3′-flanking region of the gene (90). Once the polymerase slows down and pauses, other factors facilitate release of the transcript and polymerase. Traditionally, there are two major models of termination by pol II: the antiterminator model (also called the “allosteric” model) and the torpedo model. Both models are supported by some experimental evidence. Recently, a unified allosteric–torpedo model has been proposed based on studies in transcription termination in yeast (91). 2.3.2.3.1. The antiterminator (or allosteric) model This model was proposed by Logan et al. (92). This model proposes that cleavage of the nascent transcript at polyadenylation site may trigger a conformational change of transcription elongation complex in such a way that the complex is destabilized; alternatively, the complex may carry an antitermination factor that can leave the complex at the polyadenylation site, thereby marking the nascent RNA for cleavage and simultaneously altering the complex so it is released from the template (Fig. 11A).
42
Choudhuri
A
RNA pol II
Various factors riding on the CTD ORF
3′ -UTR
Antitermination factor leaving the elongation complex and causing allosteric change of the complex Pol II release (Termination)
5′ -UTR
5′ -Flanking region
CTD Cap
AATAAA AAUAAA Poly(A) signal
Cleavage
AAAA
AAAA
AAUAAA
3′ -Flanking region
3′ -Cleavage product being degraded Poly(A) tail
Antitermination/ Allosteric model
Elongating RNA
B CTD 5′ -UTR
RNA pol II
Cleavage/Polyadenylation factors riding on CTD ORF 3′ -UTR
Rat1/Xrn2 (5′ →3′ exonuclease) loaded onto CTD
Pol II release (Termination)
AATAAA AAUAAA 5′ -Flanking region
Cleavage Poly(A) signal
Cap
Torpedo model
AAUAAA
3′ -Flanking AAAA region 3′ -Cleavage product Exonuclease being degraded catching up Poly(A) tail with pol II
AAAA
Elongating RNA
Figure 11 Models of transcription termination in eukaryotes. (A) The antitermination (allosteric) model depicts that the cleavage of the nascent transcript at the polyadenylation site may trigger a conformational change of the transcription elongation complex in such a way that the complex is destabilized; alternatively, the complex may carry an antitermination factor that can leave the complex at the polyadenylation site, thereby marking the nascent RNA for cleavage and simultaneously altering the complex so it is released from the template. (B) The torpedo model depicts that following the endonucleolytic cleavage of the nascent transcript at the polyadenylation site, the downstream (3′) cleavage product is degraded by a 5′→3′ exonuclease while it is still being synthesized and tethered to the polymerase. The exonuclease continues degrading the transcript until it catches up with the polymerase and destabilizes the pol II complex, thereby releasing the enzyme and causing termination.
2.3.2.3.2. The torpedo model This model was proposed by Connelly and Manley (93). This model proposes that following endonucleolytic cleavage of the nascent transcript at the polyadenylation site, the downstream cleavage product is degraded by a 5′→3′ exonuclease while it is still being synthesized and tethered to the polymerase. The exonuclease continues degrading the transcript until it catches up with the polymerase and destabilizes the pol II complex, thereby causing termination (Fig. 11B). Therefore, the torpedo model is analogous to bacterial rho-dependent termination model, the difference being that the rho factor terminates transcription but does not degrade the RNA, whereas the proposed exonuclease in torpedo model degrades the downstream cleavage product RNA and also terminates transcription. The demonstration of such activities in two exoribonucleases, Rat1 in yeast (94) and its homolog Xrn2 (exoribonuclease 2) in humans (95), provided strong support for the torpedo model. Rat1 is a nuclear 5′→3′ exoribonuclease that partners with Rai1 and degrades single-stranded RNA. Cross-linking studies demonstrated that the Rat1–Rai1 complex
Eukaryotic Protein-Coding Genes
43
showed greater accumulation at the 3′ end of protein-coding genes. Inactivation of these exonucleases was found to result in a decrease in termination efficiency. Surprisingly, both these studies also demonstrated that a defect in Rat1 and Xrn2 exonuclease activity did not result in any defect in cleavage, indicating that cleavage of the nascent transcript may not be linked to transcription termination. This is not in agreement with the torpedo model, which assumes that cleavage is required for termination (Fig. 11B). The torpedo model also assumes a cotranscriptional degradation of the downstream cleavage product (Fig. 11B), but direct cotranscriptional degradation of the nascent RNA had not been demonstrated in these two studies. This issue has been addressed by Luo et al. (91), who worked with yeast Rat1 and Xrn1. The Xrn1 (exoribonuclease 1) is mainly cytoplasmic but is also found in nucleus, and it is thought to be the primary 5′→3′ exoribonuclease in yeast and other eukaryotes. It degrades mRNA in a 5′→3′ direction following removal of the poly(A) tail and m7G cap. The authors immunoprecipitated pol II cross-linked to the nascent RNA molecules downstream from the cleavage/polyadenylation site. Attempts to detect this RNA by RT-PCR demonstrated that the nascent RNA was not detectable. The nascent RNA was only detectable when Rat1 or Xrn1 was functionally defective. This demonstrated that degradation of the downstream cleavage product RNA by Rat1 or Xrn1 was indeed cotranscriptional. The authors also concluded that although Rat1 and Xrn1 degraded nascent RNA, this degradation did not explain the mechanism of release of the polymerase from the template. This conclusion does not fit the depiction of the classical torpedo model, which states that after cleavage the degradation of the nascent RNA and the termination of transcription (polymerase release) are intertwined. 2.3.2.3.3. The unified allosteric—torpedo model Neither the allosteric model nor the torpedo model is sufficient to explain the mechanism of termination of pol II-mediated transcription (91). Instead, Luo et al. proposed a hybrid of the two models. In this unified allosteric–torpedo model, the authors suggested that the complex that mediates poly(A) site cleavage consists of pol II, which carries cleavage factors on its phosphorylated CTD along with Rat1. The authors speculated that this complex undergoes one or more transitions that result in (i) cleavage at the poly(A) site stimulated by Rat1 and conventional 3′-end processing factors, (ii) nascent RNA degradation 3′ of the cleavage site, and (iii) an allosteric change that is transmitted to the pol II catalytic site ultimately resulting in its release from the template. 2.3.2.3.4. The revised torpedo model A revised torpedo model of transcription termination has also been proposed (95). According to this model, cotranscriptional cleavage of the nascent transcript occurs close to the transcription termination site. Following cleavage, Xrn2 degrades the downstream cleavage product in a 5′→3′ direction, while the 3′→5′ activity of exosome may degrade the upstream cleavage product back to the poly(A) site. It is clear that the current state of understanding of transcription termination of protein-coding genes is still fluid. Although some of the key factors in the process have been identified, many questions about the mechanism are yet to be answered. It will be interesting to find out whether a specific termination helicase exists (96). 3. CONCLUDING REMARKS Proper identification and accurate annotation of genes is a prerequisite for the success of large-scale genome projects. The success of gene expression studies depends upon accurate
44
Choudhuri
identification of genes so that unique probes can be designed based on unique sequence regions of the genes. Likewise, identification of putative transcription control elements relies on correct identification of transcription start and termination sites. Incomplete or inaccurate gene structure annotation may result in the failure in identifying various genomic variabilities, such as copy number variations (CNVs) and SNPs, which may be important from a clinical genomics perspective. This may also adversely impact molecular evolutionary studies because of the failure to determine (i) genomic divergence between closely related species, (ii) signatures of positive selection in the genome, and (iii) orthologs and paralogs of various genes. Unfortunately, gene structure determination and annotation are particularly difficult for eukaryotic genomes. The depth of this problem is further underscored when the mammoth genes are taken into consideration. For example, the longest eukaryotic protein-coding gene known is human dystrophin gene which is ˜2,400 kbp (i.e., ˜2.4 Mbp) long. It has 79 exons which encode a 14-kb-long mRNA (as a comparison, the human 28S rRNA is 5 kb long). Thus, 99.4% of the dystrophin gene is composed of noncoding sequences. Using quantitative RT-PCR, it was demonstrated that it takes 16 hr to transcribe the dystrophin gene with an average elongation rate of 2.4 kb/min (97), and the dystrophin mRNA has a half-life of ˜16 hr (98). The elongation rate of dystrophin mRNA was found to be different in different regions of the gene; transcription of exon 51–70 was found to have the slowest elongation rate (1.7 kb/min). Splicing of the dystrophin pre-mRNA is cotranscriptional; thus, splicing of exons at the 5′ end becomes complete before transcription is complete. Dystrophin protein has an estimated molecular weight of 427 kDa. Even though the dystrophin gene is the longest known protein-coding gene, its transcript is not the longest known transcript, nor is its protein product the longest known protein. This distinction goes to human titin gene. This gene is 294 kb long; it contains 363 exons, which together encode a 114-kb-long mRNA. The complete predicted titin protein has 38,138 residues with an estimated molecular weight of 4,200 kDa. However, various alternatively spliced tissue-specific isoforms are detected, such as heart muscle-specific N2B isoform (2,970 kDa) and soleus skeletal muscle-specific isoform (3,700 kDa). The gene is located on the long arm of chromosome 2 (2q) in both humans and mice (99). The mammoth genes offer some exceptions to the generally accepted notions about the structure–function relationships of eukaryotic protein-coding genes. Other similar exceptions may complicate proper annotation of such unique, as yet unknown, genes in the genome. An example of such exception is the exon-size rule discussed above. Vertebrate exons are usually less than 300 bp, and exons longer than 800 bp are rare; however, an exon of the titin gene is 6.5 kb long. Nevertheless, the general structure–function relationship and the rules that apply for average eukaryotic genes also apply for these mammoth genes. REFERENCES 1. Choudhuri S. Gene regulation and molecular toxicology. Toxicol Mechan Meth 2005; 15:1–23. 2. Choudhuri S. Some major landmarks in the path from nuclein to human genome. Toxicol Mechan Meth 2006; 16:137–159. 3. Latchman DS. Gene Regulation, 5th ed. New York, NY: Taylor and Francis, 2005:1–374. 4. Perdew GH, Vanden Heuvel JP, Peters JM. Regulation of Gene Expression: Molecular Mechanisms. Totowa, NJ: Humana Press, 2006:1–344. 5. Proudfoot NJ, Furger A, Dye MJ. Integrating mRNA processing with transcription. Cell 2002; 108:501–512.
Eukaryotic Protein-Coding Genes
45
6. Meister G. miRNA gets an early start on translational silencing. Cell 2007; 131:25–28. 7. Ogura K, Choudhuri S, Klaassen CD. Genomic organization and tissue-specific expression of splice variants of mouse organic anion transporting polypeptide 2. Biochem Biophys Res Commun 2001; 281:431–439. 8. Pesole G, Mignone F, Gissi C, et al. Structural and functional features of eukaryotic mRNA untranslated regions. Gene 2001; 276:73–81. 9. Mansilla A, López-Sánchez C, de la Rosa EJ. et al. Developmental regulation of a proinsulin messenger RNA generated by intron retention. EMBO Rep 2005; 6:1182–1187. 10. Jang SK, Wimmer E. Cap-independent translation of encephalomyocarditis virus RNA: structural elements of the internal ribosomal entry site and involvement of a cellular 57-kD RNA-binding protein. Genes Dev 1990; 4:1560–1572. 11. Jang SK, Pestova TV, Hellen CU, et al. Cap-independent translation of picornavirus RNAs: structure and function of the internal ribosomal entry site. Enzyme 1990; 44:292–309. 12. Martínez-Salas E. Internal ribosome entry site biology and its use in expression vectors. Curr Opin Biotechnol 1999; 10:458–464. 13. Kim HY, Klausner RD, Rouault TA. Translational repressor activity is equivalent and is quantitatively predicted by in vitro RNA binding for two iron-responsive element-binding proteins, IRP1 and IRP2. J Biol Chem 1995; 270:4983–4986. 14. Klausner RD, Rouault TA. A double life: cytosolic aconitase as a regulatory RNA binding protein. Mol Biol Cell 1993; 4:1–5. 15. Sudarsan N, Barrick JE, Breaker RR. Metabolite-binding RNA domains are present in the genes of eukaryotes. RNA 2003; 9:644–647. 16. Kozak M. The scanning model for translation: an update. J Cell Biol 1989; 108:229–241. 17. Kozak M. Adherence to the first-AUG rule when a second AUG codon follows closely upon the first. Proc Natl Acad Sci USA 1995; 92:2662–2666. 18. Wang X-Q, Rothnagel JA. 5′-Untranslated regions with multiple upstream AUG codons can support low-level translation via leaky scanning and reinitiation. Nucleic Acids Res 2004; 32:1382–1391. 19. Nett JH, Kessl J, Tina W, et al. The AUG start codon of the Saccharomyces cerevisiae NFS1 gene can be substituted for by UUG without increased initiation of translation at downstream codons. Eur J Biochem 2001; 268:5209–5214. 20. Kozak M. Comparison of initiation of protein synthesis in procaryotes, eucaryotes, and organelles. Microbiol Rev 1983; 47:1–45. 21. Kozak M. Possible role of flanking nucleotides in recognition of the AUG initiator codon by eukaryotic ribosomes. Nucleic Acids Res 1981; 9:5233–5252. 22. Kozak M. Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs. Nucleic Acids Res 1984; 12:857–872. 23. Kozak M. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 1986; 44:283–292. 24. Kozak M. An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 1987; 15:8125–8148. 25. Kay RA, Ellis IR, Jones SJ, et al. The expression of migration stimulating factor, a potent oncofetal cytokine, is uniquely controlled by 3′-untranslated region-dependent nuclear sequestration of its precursor messenger RNA. Cancer Res 2005; 65:10742–10749. 26. Wahle E, Rüegsegger U. 3′-End processing of pre-mRNA in eukaryotes. FEMS Microbiol Rev 1999; 23:277–295. 27. Chen F, MacDonald CC, Wilusz J. Cleavage site determinants in the mammalian polyadenylation signal. Nucleic Acids Res 1995; 23:2614–2620. 28. Gilmartin GM. Eukaryotic mRNA 3′ processing: a common means to different ends. Genes Dev 2005; 19:2517–2521. 29. Gorgoni B, Gray NK. The roles of cytoplasmic poly(A)-binding proteins in regulating gene expression: a developmental perspective. Brief Funct Genomics Proteomics 2004; 3:125–141.
46
Choudhuri
30. Caput D, Beutler B, Hartog K, et al. Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci USA 1986; 83:1670–1674. 31. Shaw G, Kamen RA. A conserved AU sequence from the 3′-untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 1986; 46:659–667. 32. Lagnado CA, Brown CY, Goodall GJ. AUUUA is not sufficient to promote poly(A) shortening and degradation of an mRNA: the functional sequence within AU-rich elements may be UUAUUUA(U/A)(U/A). Mol Cell Biol 1994; 14:7984–7995. 33. Barreau C, Paillard L, Osborne HB. AU-rich elements and associated factors: are there unifying principles? Nucleic Acids Res 2006; 33:7138–7150. 34. McGowan KM, Police S, Winslow JB, et al. Tumor necrosis factor-alpha regulation of glucose transporter (GLUT1) mRNA turnover. Contribution of the 3′-untranslated region of the GLUT1 message. J Biol Chem 1997; 272:1331–1337. 35. Thore S, Leibundgut M, Ban N. Structure of the eukaryotic thiamine pyrophosphate riboswitch with its regulatory ligand. Science 2006; 312:1208–1211. 36. Sylvestre J, Margeot A, Jacq C, et al. The role of the 3′ untranslated region in mRNA sorting to the vicinity of mitochondria is conserved from yeast to human cells. Mol Biol Cell 2003; 14:3848–3856. 37. Hesketh J. 3′-Untranslated regions are important in mRNA localization and translation: lessons from selenium and metallothionein. Biochem Soc Trans 2004; 32:(Pt 6):990–993. 38. Christensen AK, Kahn LE, Bourne CM. Circular polysomes predominate on the rough endoplasmic reticulum of somatotropes and mammotropes in the rat anterior pituitary. Am J Anat 1987; 178:1–10. 39. Roy N, Laflamme G, Raymond V. 5′ Untranslated sequences modulate rapid mRNA degradation mediated by 3′ AU-rich element in v-/c-fos recombinants. Nucleic Acids Res 1992; 20:5753–5762. 40. Wells SE, Hillner PE, Vale RD, et al. Circularization of mRNA by eukaryotic translation initiation factors. Mol Cell 1998; 2:135–140. 41. Gallie DR. A tale of two termini: a functional interaction between the termini of an mRNA is a prerequisite for efficient translation initiation. Gene 1998; 216:1–11. 42. Mazumder B, Seshadri V, Fox PL. Translational control by the 3′-UTR: the ends specify the means. Trends Biochem Sci 2003; 28:91–98. 43. Wilkie GS, Dickson KS, Gray NK. Regulation of mRNA translation by 5′- and 3′-UTR-binding factors. Trends Biochem Sci 2003; 28:182–188. 44. Vilela C, Velasco C, Ptushkina M, et al. The eukaryotic mRNA decapping protein Dcp1 interacts physically and functionally with the eIF4F translation initiation complex. EMBO J 2000; 19:4372–4382. 45. Parker R, Song H. The enzymes and control of eukaryotic mRNA turnover. Nat Struct Mol Biol 2004; 11:121–127. 46. Yamashita A, Chang TC, Yamashita Y et al. Concerted action of poly(A) nucleases and decapping enzyme in mammalian mRNA turnover. Nat Struct Mol Biol 2005; 12:1054–1063. 47. Hawkins JD. A survey on intron and exon lengths. Nucleic Acids Res 1988; 16:9893–9908. 48. Robberson BL, Cote GJ, Berget SM. Exon definition may facilitate splice site selection in RNAs with multiple exons. Mol Cell Biol 1990; 10:84–94. 49. Sterner DA, Carlo T, Berget SM. Architectural limits on split genes. Proc Natl Acad Sci USA 1996; 93:15081–15085. 50. Carlo T, Sterner DA, Berget SM. An intron splicing enhancer containing a G-rich repeat facilitates inclusion of a vertebrate micro-exon. RNA 1996; 2:342–353. 51. Bonen L, Vogel J. The ins and outs of group II introns. Trends Genet 2001; 17:322–331. 52. Roy SW, Gilbert W. The evolution of spliceosomal introns: patterns, puzzles, and progress. Nat Rev Genet 2006; 7:211–221. 53. Jurica MS, Moore MJ. Pre-mRNA splicing: awash in a sea of proteins. Mol Cell 2003; 12:5–14.
Eukaryotic Protein-Coding Genes
47
54. Graveley BR. Sorting out the complexity of SR protein functions. RNA 2000; 6:1197–1211. 55. Wu Q, Krainer AR. AT-AC pre-mRNA splicing mechanisms and conservation of minor introns in voltage-gated ion channel genes. Mol Cell Biol 1999; 19:3225–3236. 56. Black DL. A simple answer for a splicing conundrum. Proc Natl Acad Sci USA 2005; 102:4927–4928. 57. Talerico M, Berget SM. Intron definition in splicing of small Drosophila introns. Mol Cell Biol 1994; 14:3434–3445. 58. Mortillaro MJ, Blencowe BJ, Wei X, et al. A hyperphosphorylated form of the large subunit of RNA polymerase II is associated with splicing complexes and the nuclear matrix. Proc Natl Acad Sci USA 1996; 93:8253–8257. 59. Ibrahim El C, Schaal TD, Hertel KJ, et al. Serine/arginine-rich protein-dependent suppression of exon skipping by exonic splicing enhancers. Proc Natl Acad Sci USA 2005; 102:4927–4928. 60. Smith CWJ, Valcárcel J. Alternative pre-mRNA splicing: the logic of combinatorial control. Trends Biol Chem 2000; 25:381–388. 61. Choudhuri S, Ogura K, Klaassen CD. Cloning of the full-length coding sequence of rat liver-specific organic anion transporter-1 (rlst-1) and a splice variant and partial characterization of the rat lst-1 gene. Biochem Biophys Res Commun 2000; 274:79–86. 62. Cattori V, Hagenbuch B, Hagenbuch N, et al. Identification of organic anion transporting polypeptide 4 (Oatp4) as a major full-length isoform of the liver-specific transporter-1 (rlst-1) in rat liver. FEBS Lett 2000; 474:242–245. 63. Kubodera T, Watanabe M, Yoshiuchi K, et al. Thiamine-regulated gene expression of Aspergillus oryzae thiA requires splicing of the intron containing a riboswitch-like domain in the 5′-UTR. FEBS Lett 2003; 555:516–520. 64. Cheah MT, Wachter A, Sudarsan N, et al. Control of alternative RNA splicing and gene expression by eukaryotic riboswitches. Nature 2007; 447:497–501. 65. Metherell LA, Akker SA, Munroe PB, et al. Pseudoexon activation as a novel mechanism for disease resulting in atypical growth-hormone insensitivity. Am J Hum Genet 2001; 69:641–646. 66. Tuffery-Giraud S, Saquet C, Chambert S, et al. Pseudoexon activation in the DMD gene as a novel mechanism for Becker muscular dystrophy. Hum Mutat 2003; 21:608–614. 67. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315:525–528. 68. Choudhuri S, Klaassen CD. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 2006; 25:231–259. 69. Freiman RN, Tjian R. A glutamine-rich trail leads to transcription factors. Science 2002; 296:2149–2150. 70. Butler JE, Kadonaga JT. The RNA polymerase II core promoter: a key component in the regulation of gene expression. Genes Dev 2002; 16:2583–2592. 71. Choudhuri S, Ogura K, Klaassen CD. Determination of transcription start site and analysis of promoter sequence, splice junction sites, intron sequence and codon usage bias of rat liver-specific organic anion transporter-1 (rlst-1/Oatp-4/Slc21a10) gene. DNA Seq 2002; 13:103–107. 72. Burke TW, Kadonaga JT. Drosophila TFIID binds to a conserved downstream basal promoter element that is present in many TATA-box-deficient promoters. Genes Dev 1996; 10:711–724. 73. Kutach AK, Kadonaga JT. The downstream promoter element DPE appears to be as widely used as the TATA box in Drosophila core promoters. Mol Cell Biol 2000; 20:4754–4764. 74. Vermeulen M, Mulder KW, Denissov S, et al. Selective anchoring of TFIID to nucleosomes by trimethylation of histone H3 lysine 4. Cell 2007; 131:58–69. 75. Tirode F, Busso D, Coin F, et al. Reconstitution of the transcription factor TFIIH: assignment of functions for the three enzymatic subunits, XPB, XPD, and cdk7. Mol Cell 1999; 3:87–95. 76. Hamada K, Kohno S, Iwamoto M, et al. Identification of the human IAI. 3B promoter element and its use in the construction of a replication-selective adenovirus for ovarian cancer therapy. Cancer Res 2003; 63:2506–2512.
48
Choudhuri
77. Ramirez F, Tanaka S, Bou-Gharios G. Transcriptional regulation of the human alpha2(I) collagen gene (COL1A2), an informative model system to study fibrotic diseases. Matrix Biol 2006; 25:365–372. 78. Salguerro S, Pignocchi C, Parry MAJ. Intron-mediated gusA expression in tritordeum and wheat resulting from particle bombardment. Plant Mol Biol 2000; 42:615–622. 79. Roopra A, Huang Y, Dingledine R. Neurological disease: listening to gene silencers. Mol Interv 2001; 1:219–228. 80. Li Q, Peterson KR, Fang X, et al. Locus control regions. Blood 2002; 100:3077–3086. 81. Valenzuela L, Kamakaka RT. Chromatin insulators. Annu Rev Genet 2006; 40:107–138. 82. Chung JH, Bell AC, Felsenfeld G. Characterization of the chicken beta-globin insulator. Proc Natl Acad Sci USA 1997; 94:575–580. 83. Recillas-Targa F, Pikaart MJ, Burgess-Beusse B, et al. Position-effect protection and enhancer blocking by the chicken beta-globin insulator are separable activities. Proc Natl Acad Sci USA 2002; 99:6883–6888. 84. Gaszner M, Felsenfeld G. Insulators: exploiting transcriptional and epigenetic mechanisms. Nat Rev Genet 2006; 7:703–713. 85. Grummt I, Rosenbauer H, Niedermeyer I, et al. A repeated 18 bp sequence motif in the mouse rDNA spacer mediates binding of a nuclear factor and transcription termination. Cell 1986; 45:837–846. 86. Reeder RH, Lang W. The mechanism of transcription termination by RNA polymerase I. Mol Microbiol 1994; 12:11–15. 87. Mason SW, Sander EE, Grummt I. Identification of a transcript release activity acting on ternary transcription complexes containing murine RNA polymerase I. EMBO J 1997; 16:163–172. 88. Gottlieb E, Steitz JA. Function of the mammalian La protein: evidence for its action in transcription termination by RNA polymerase III. EMBO J 1989; 8:851–861. 89. Luo W, Bentley DA. A ribonucleolytic rat torpedoes RNA polymerase II. Cell 2004; 119:911–914. 90. Plant KE, Dye MJ, Lafaille C, et al. Strong polyadenylation and weak pausing combine to cause efficient termination of transcription in the human Ggamma-globin gene. Mol Cell Biol 2005; 25:3276–3285. 91. Luo W, Johnson AW, Bentley DL. The role of Rat1 in coupling mRNA 3′-end processing to transcription termination: implications for a unified allosteric–torpedo model. Genes Dev 2006; 20:954–965. 92. Logan J, Falck-Pedersen E, Darnell JE, et al. A poly(A) addition site and a downstream termination region are required for efficient cessation of transcription by RNA polymerase II in the mouse beta maj-globin gene. Proc Natl Acad Sci USA 1987; 84:8306–8310. 93. Connelly S, Manley JL. A functional mRNA polyadenylation signal is required for transcription termination by RNA polymerase II. Genes Dev 1988; 2:440–452. 94. Kim M, Krogan NJ, Vasiljeva L, et al. The yeast Rat1 exonuclease promotes transcription termination by RNA polymerase II. Nature 2004; 432:517–522. 95. West S, Gromak N, Proudfoot NJ. Human 5′→3′ exonuclease Xrn2 promotes transcription termination at co-transcriptional cleavage sites. Nature 2004; 432:522–525. 96. Rosonina E, Kaneko S, Manley JL. Terminating the transcript: breaking up is hard to do. Genes Dev 2006; 20:1050–1056. 97. Tennyson CN, Klamut HJ, Worton RG. The human dystrophin gene requires 16 hours to be transcribed and is cotranscriptionally spliced. Nat Genet 1995; 9:184–190. 98. Tennyson CN, Shi Q, Worton RG. Stability of the human dystrophin transcript in muscle. Nucleic Acids Res 1996; 24:3059–3064. 99. Bang ML, Centner T, Fornoff F, et al. The complete gene sequence of titin, expression of an unusual approximately 700-kDa titin isoform, and its interaction with obscurin identify a novel Z-line to I-band linking system. Circ Res 2001; 89:1065–1072.
2
The Eukaryotic Genome: A Brief Overview of Structure, Function, and Evolution Supratim Choudhuri U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, OFAS, Division of Biotechnology and GRAS Notice Review, College Park, Maryland, U.S.A.
1. INTRODUCTION—THE SCOPE OF GENOMICS 1.1. Genome Mapping 1.1.1. Genetic Maps of the Genome 1.1.1.1. Principles of genetic mapping were established by research in Drosophila genetics in the early part of the twentieth century 1.1.1.2. Genetic mapping in humans 1.1.2. Physical Maps of the Genome 1.1.2.1. Cytogenetic maps 1.1.2.2. Radiation hybrid maps 1.1.2.3. Sequence maps 2. NUCLEOPROTEIN ORGANIZATION OF THE GENOME 2.1. Chromatin—the DNA-Protein Complex that Stabilizes the Genome and Regulates its Expression 2.1.1. Nucleosome (Chromatin) Assembly 2.1.2. Histone Variants, Deviant Nucleosomes, and Specialized Functions 2.1.3. NonHistone Proteins in the Chromatin—the HMG Proteins 2.1.4. Chromatin Modification 2.1.5. Chromatin Remodeling Complex 2.2. Heterochromatin and Euchromatin 2.2.1. Heterochromatin-Associated Proteins 2.2.2. Heterochromatin Spread and Position Effect Variegation 2.3. Nuclear Matrix, Matrix Attachment Regions, and Chromatin Loops 3. GENOMIC DNA AS A MOSAIC OF ISOCHORES 3.1. Different Families of Isochores and Their Properties—GC-Content, Gene Distribution, and Codon Usage Bias 3.2. In Search of the “Iso” in Isochores
51 51 52
52 52 53 53 53 54 55 55 55 57 59 59 59 60 61 62 62 63 64 65
The opinions expressed in this chapter are the author’s own, and they do not necessarily reflect those of the FDA, the DHHS, or the Federal Government.
49
50
Choudhuri
4. GENOMIC LANDSCAPE AS REVEALED BY GENOME SEQUENCING 4.1. Human Genome 4.1.1. The Protein-Coding Landscape 4.1.2. Gene Birth and Death in Human Lineage 4.1.3. Genomic GC-Content 4.1.4. CpG Islands 4.1.5. Recombination Rate 4.1.6. Repeat Content 4.1.6.1. C-value, C-value paradox, and C0 t analysis 4.1.6.2. Types of repeat sequences in the human genome 4.1.6.2.1. Interspersed (transposon-derived) repeats 4.1.6.2.2. Processed psuedogenes 4.1.6.2.3. Simple sequence repeats 4.1.6.2.4. Segmental duplications 4.1.6.2.5. Tandem repeat blocks 4.1.7. Noncoding RNA (ncRNA) Genes 4.1.8. Human Proteome Analysis 4.1.9. Duplications in the Human Genome and Composite Structure of Human Proteins 4.1.10. Genome-Wide Chromatin Marks and Transcription 4.1.10.1. Pervasive transcription in the human genome 4.1.10.2. Antisense transcription 4.1.11. Human Genomic Variations 4.1.11.1. Single nucleotide polymorphism 4.1.11.2. Copy number variation 4.2. The Chimpanzee Genome 4.2.1. Similarity in Protein-Coding Genes Between Human and Chimpanzee 4.2.1.1. Evolution of the coding sequences 4.2.1.2. Gene expression 4.2.2. Possible Causes of Genome-Wide Nucleotide Divergence Between Human and Chimpanzee 4.2.2.1. Divergence in CpG islands 4.2.2.2. Divergence due to indel mutations 4.2.2.3. Divergence due to transposable elements 4.2.2.4. Divergence due to deletions, repeat sequences, and chromosomal rearrangements 4.2.2.5. Single nucleotide polymorphisms 4.2.3. Positive Selection and Genome Evolution 4.2.3.1. Neutral theory of molecular evolution 4.2.3.2. Signatures of positive selection in the genome 4.2.3.3. Genome evolution in human and chimpanzee 4.2.3.3.1. Molecular evolution of FOXP2 gene 4.2.3.3.2. Molecular evolution of genes regulating brain size 4.2.3.3.3. Molecular evolution of MYH16 gene 4.2.3.3.4. Molecular evolution of CMAH gene 4.3. Rhesus Macaque Genome 4.4. Mouse Genome 5. CHROMOSOMAL SYNTENY AND SYNTENIC MAPS IN COMPARATIVE GENOMICS
67 67 67 68 69 69 70 70 70 71 72 75 76 76 77 78 79 79 80 80 82 82 83 83 84 84 85 85 86 86 86 86 87 87 87 88 88 90 90 91 92 92 92 93 94
The Eukaryotic Genome
51
6. CONCLUDING REMARKS REFERENCES
94 95
1. INTRODUCTION—THE SCOPE OF GENOMICS The goal of the science of genomics is to study the structure, function, and evolution of the genome. An extension of this goal is to understand how environmental factors modulate genome function. This has direct relevance to clinical genomics. The study of genome structure involves an understanding of the genome organization. This includes mapping the location of genes and their regulatory elements in the genome; mapping various single nucleotide polymorphisms (SNPs) in the genes; identifying gene copy number variations (CNVs); identifying various unique sequence elements in the genome; mapping various repetitive sequences, pseudogenes, and retrotransposons; identifying various noncoding RNA (ncRNA)–coding genes; identifying various targets of these ncRNAs and so on. The study of genome function, that is functional genomics, involves studying the expression of the whole genome. This includes studying the expression of protein-coding as well as nonprotein-coding parts of the genome and their interactions. A goal of functional genomics is to compile an atlas of gene expression for various genomes. Detailed functional genomic analyses involve manipulation of genome expression, such as genomewide mutagenesis studies. As Dobzhansky pointed out in his now-famous statement that nothing in biology makes sense except in the light of evolution; the full significance of genomic data of an organism or a species can only be realized when viewed in the light of their evolutionary history. In this respect, evolutionary genomics and comparative genomics have overlapping scopes. The intellectual underpinning of comparative genomics is evolutionary biology. The study of genome evolution involves an understanding of the structure and function of genomes of different species. Therefore, advances in comparative genomics will not only help uncover how genome structure and function in different species evolved over time, but also shed light on how structural and functional divergence of genomes during evolution might have contributed to speciation. Researchers have learned a great deal about various human genes with previously unknown function by comparing them to their counterparts with known functions in other model organisms, such as mouse. Thus, comparative genomics relies heavily on the analysis of sequence similarity and sequence divergence. The following discussion provides a very brief account on certain structural, functional, and evolutionary aspects of eukaryotic genomes, with special emphasis on the human genome. This is by no means an extensive overview; it merely touches on some aspects of genome structure, expression, and evolution.a 1.1. Genome Mapping There are two broad categories of genomic maps: genetic map and physical map. Both these maps for human genome were constructed over time and were refined as newer information about genomic landmarks became available. Genomic landmarks used for mapping are of various types, such as sequence tagged site (STS), expressed sequence a In the following text, many recent reviews that include the original references and earlier important reviews have been cited in order to keep the number of references to a minimum. The expressions kb, Mb, or Gb have been used, and in the context of DNA these mean kbp, Mbp, and Gbp, respectively.
52
Choudhuri
tag (EST), microsatellite, and restriction fragment length polymorphism (RFLP) markers. Microsatellite and RFLP markers are polymorphic markers, whereas STS and EST are nonpolymorphic markers. The following description is a very sketchy account of the principles of some of the common genome mapping techniques. Readers are referred to “Genome Analysis: A Laboratory Manual (Volume 4; Mapping Genomes); Editors: Bruce Birren et al.; CSHL Press, 1999” for the details of human genome mapping and analysis. 1.1.1. Genetic Maps of the Genome Genetic map is also known as “linkage map”. In a genetic map, the relative distance of genes on the chromosome is determined based on the recombination frequency between two genes or two genetic markers located on the same chromosome. The genes in question may have identifiable phenotypes, such as enzyme production, eye color, a physical trait, or a particular clinical symptom. In contrast, the genetic markers flanking the genes may be identified by some nongenic detectable DNA sequences, such as microsatellite, STS, or RFLP. There is one genetic map for each chromosome. 1.1.1.1. Principles of genetic mapping were established by research in Drosophila genetics in the early part of the twentieth century The concept of using recombination frequency between two genes on a chromosome to determine their relative distance and order was first introduced in 1913 by Alfred Sturtevant, a student of Thomas Hunt Morgan. In Drosophila, chromosome maps were made using the relative distance and order of genes along the length of the chromosome, which was determined by three-point (three-loci)-test crosses. The first step involves finding out the middle gene by comparing the noncrossover/parental combination class (highest frequency) with the double crossover class (lowest frequency). Compared to the noncrossover class, the location of only the middle gene is reversed in the double crossover class. Once the middle gene is determined, the next step is to determine the linear distance of the two genes based on recombination frequency. This is a subject discussed in detail in all textbooks of genetics, so it is not repeated here. Nevertheless, it should be emphasized that determination of the recombination frequency between two genetic loci (genes or markers) is of central importance in creating a genetic map. A 1% recombination frequency between two genetic loci means that they are 1 mapunit apart on the chromosome. The map-unit is termed “centiMorgan” (cM). Thus, 1 cM genetic distance between two loci on the same chromosome is equal to a 1% probability that the two loci will be separated by recombination. In other words, 1 cM genetic distance between two loci represents a probability of obtaining one recombinant offspring involving the two loci in 100 progeny. The physical length of DNA that corresponds to 1 cM may vary from species to species. For example, in humans 1 cM = ~1 Mb (=1,000 kb), in mouse 1 cM = ~1.75 Mb (=1,750 kb), in Drosophila 1 cM = ~400 kb, whereas in Escherichia coli 1 cM = ~40 kb. Recombination fractions between two genetic loci never exceed 50% or 0.5, no matter how far apart they are. 1.1.1.2. Genetic mapping in humans The principles of genetic mapping in humans are similar to that of other sexually reproducing diploid experimental organisms. However, the methods used for mapping human genes are different because mating cannot be arranged for experimental convenience and the number of progeny is small.
The Eukaryotic Genome
53
Construction of human genetic maps utilized pedigree analysis and polymorphic genomic markers showing Mendelian segregation pattern. Pedigree analysis was done in many large three-generation families, that is, families with living grandparents and large number of siblings (the more the number of generations and the larger the family size, the better). For polymorphic markers, microsatellite markers [also called “short tandem repeat polymorphisms” (STRPs)] were very useful because they are polymorphic, abundant, and dispersed throughout the genome. Using (CA)n repeat markers in a panel of DNA from eight large families, researchers at the Généthon laboratory in France were able to produce a second-generation linkage map of the human genome. As mapping efforts progressed, subsequent maps were produced with ever increasing numbers of genetic markers (especially microsatellite markers) and ever increasing resolution. In complex pedigree analysis, scoring recombinants simply by examining the phenotype and counting the progeny can be misleading. This problem is circumvented by calculating the likelihood of linkage of two loci. This likelihood is expressed as LOD (logarithm of odds) score denoted as Z. The LOD score compares the likelihood that the test data indicates linkage to the likelihood that the test data indicates no linkage (independent assortment of the two loci). By convention, a LOD score of 3 or greater indicates that the two loci are linked, with a 5% chance of error in the conclusion. The source of the number 3 is the log10 value of 1,000 (103). This means that if the LOD score is 3, the odds that two loci are not linked is 1 in 1,000. To ensure the accuracy of LOD scores, linkage data from related families are often combined with that from unrelated families. 1.1.2. Physical Maps of the Genome A physical map gives the distance from one landmark in the genome to another in terms of DNA base pairs. The importance of physical mapping of the genome becomes apparent when some features of the human genome are considered. Approximately 50% of the genome contains repetitive sequences, and some regions have sequences that are up to 98% identical to one another even though these regions are millions of base pairs apart or are even located on different chromosomes. There is one physical map for each chromosome. Physical maps can be of several types: cytogenetic maps, radiation hybrid maps, and sequence maps, in an increasing order of resolution. 1.1.2.1. Cytogenetic maps Cytogenetic maps have the lowest resolution and are the oldest form of chromosomal physical maps available to scientists for humans and other species. Cytogenetic maps represent specific banding patterns of stained chromosomes that can be observed by light microscopy. Specific banding patterns of chromosomes helped scientists distinguish different chromosomes in the cell and different subchromosomal regions of each chromosome. Using in situ hybridization and the knowledge of cytogenetic map, it has been possible to map the location of genes on specific chromosomes in many mammalian species including humans. 1.1.2.2. Radiation hybrid maps Natural chromosome breaks, such as deletion and translocation, have been useful in the past for mapping the location of genes on specific chromosomes. Radiation hybrid (RH) maps are constructed by inducing artificial chromosome breaks by controlled radiation. In this method, chromosome breaks are induced by measured doses of radiation. The average distance between the breakpoints is controlled by varying the strength of the radiation.
54
Choudhuri
When the markers are known, their separation due to chromosomal breakage can be used to create a RH map that shows the order of markers on the chromosome and their estimated distance. RH mapping can use nonpolymorphic markers. RH mapping was initially done using panels of somatic cell hybrids, that is, hybrids of human and mouse (or hamster) cells containing various human chromosomes, usually a few per cell but preferably only one per cell, as were later obtained in chromosome-specific monochromosomal hybrids. With the discovery of more genomic markers, RH mapping was done by irradiating the whole genome of human diploid cells and fusing the irradiated cells to nonirradiated mouse or hamster cells to create a panel of somatic cell hybrids that represent the whole genome radiation hybrids. In each RH (somatic cell hybrid line), one or more chromosomal fragments are stably incorporated into the recipient genome. Because the hundreds of radiation hybrids thus created are likely to contain different markers and their combinations, and because markers that are closely linked are likely to stay in the same fragment more frequently than markers that are further apart, screening for various markers help place them in proper order on the chromosome and also help estimate their relative distance. However, direct assignment of the location and relative distance of the loci are not possible due to the fact that the number and composition of human DNA fragments within a hybrid are not known. Therefore, the data analysis involves statistical calculation of the likelihood ratio (LOD) as described earlier under genetic mapping. By increasing the radiation dose and causing more breaks, the resolution of RH maps can be increased. RH mapping and genetic mapping are both based on the principle of separation of two genetic loci on the same chromosome: separation through recombination in genetic mapping and separation through chromosome breaks in RH mapping. In both cases, the probability of separation of two loci is directly proportional to their relative distance from each other. As in the case of genetic map unit, the RH map unit is also determined by the frequency of separation of the two loci. The RH map unit is expressed as centiRay (cR); 1 cR represents a 1% probability that two loci on the same chromosome will be separated by radiation-induced breaks. The higher the cR value, the further apart two loci are, and hence the higher the probability of radiation-induced chromosome breaks separating the two loci. 1.1.2.3. Sequence maps Sequence maps are also called “clone contig maps”. To construct a sequence map, the genome is broken down into smaller pieces, and the pieces are cloned into a suitable vector. At the beginning of the human genome sequencing project, yeast artificial chromosome (YAC) was used because very large pieces of DNA (~3,000 kb) could be cloned into a YAC vector. Later it was found that DNA fragments cloned in YAC may undergo spontaneous rearrangement, thereby messing up the true sequence information of the cloned DNA. The discovery of bacterial artificial chromosome (BAC) vectors solved this problem. BAC can easily hold ~300-kb-long DNA fragments, and the cloned fragments are stable. Genomic DNA pieces are cloned into BAC to create a genomic library. The clones are restriction-digested to determine the unique restriction-digestion-pattern fingerprint of each clone. The clones are then sequenced; probes are designed from the known sequence and are hybridized with other clones (genomic library screening) to identify clones that carry the same DNA fragment, and thus can be overlapped. Use of very long probes to screen the genomic library tends to minimize or suppress signals generated due to highly repetitive sequences. Enough overlapping clones (clone contigs) are sequenced to cover the entire genome many times over (about 10 times, referred to as “10 × coverage”) to ensure
The Eukaryotic Genome
55
the accuracy of the map. The overlapping sequences (contigs) are assembled back into an intact and complete genomic sequence using computer software and knowledge of each clone’s map position. Different methods of identifying overlaps between clones have been used, but STS markers, which had previously been identified through sequencing and mapped to various chromosomes, have been particularly useful. Each STS is a few hundred bp-long unique DNA sequence that is found in only one place in the genome. An STS may come from anywhere in the genome, coding or noncoding. When STS markers are identified by sequencing cDNA, they are called “expressed sequence tags”. Once STSs are properly placed on the genome map, the genomic location of any unknown piece of DNA containing an STS can be easily determined. 2. NUCLEOPROTEIN ORGANIZATION OF THE GENOME The structure and organization of the genome can be studied at various levels, from chromatin all the way down to specific sequence characteristics of the DNA. Since the nuclear DNA exists in combination with various proteins which, in turn, determines the spatial structure of the DNA-protein complex and also regulates the replication, repair, and expression of the genome, it is logical to start the discussion of the genome at the level of chromatin. 2.1. Chromatin—the DNA-Protein Complex that Stabilizes the Genome and Regulates its Expression DNA in the nucleus exists mainly in combination with histone proteins; the DNA–histone complex is called “chromatin”. Chromatin can undergo changes in its structure in response to various cellular metabolic demands. Chromatin can be envisioned as a repeat of structural units called “nucleosomes”. The nucleosome core particle is composed of histone octamer plus the DNA that wraps around it. The histone octamer contains two molecules each of histones H2A, H2B, H3, and H4. DNA wraps around the octamer in a left-handed supercoil in about 1.75 turns which encloses about 150 bp. Histone H1 is a linker histone that, along with linker DNA (the DNA in between two nucleosome core particles), physically connects the adjacent nucleosome core particles. The length of linker DNA varies with species and cell types. Usually, nucleosome core particle and linker DNA on both sides of the core encompasses between 180- and 200-bp DNA. Between the nucleosome unit structure and the metaphase chromosome structure containing two chromatids, there are several levels of organization and compaction of the chromatin. Each nucleosome has a diameter of 10 nm; the nucleosomes are compacted into a solenoid fiber structure of 30 nm; the 30-nm solenoid fibers are compacted into a 300-nm filament; and finally, the 300-nm filaments are further compacted into a 700-nm chromosome. During cell division, when the chromosomes duplicate, a 1,400-nm metaphase chromosome is produced containing two chromatids, each chromatid being 700 nm (Fig. 1). During transcription, as the RNA polymerase advances, it introduces right-handed supercoil in the DNA ahead of it. This tends to relieve the left-handed supercoil of the DNA that wraps around the histone octamer. 2.1.1. Nucleosome (Chromatin) Assembly The majority of chromatin assembly is tightly coupled to DNA replication in the cell; thus, the assembly of nucleosomes on DNA occurs during DNA synthesis in S-phase. During DNA replication the preexisting core histones are transferred onto the two nascent
56
Choudhuri
Histone H1 Nucleosome
Chromatin loop
Linker DNA 30 nm solenoid
Extended chromatin filament
300 nm
30 nm
10 nm DNA wraps around the histone octamer in a left-handed supercoil
1,400 nm
Metaphase chromosome
Matrix attachment region (MAR) in the DNA
Nuclear matrix or chromosome scaffold
700 nm
Supercoiled (coiled coil) chromatin filament (chromosome arm)
Figure 1 From nucleosome to chromosome. The histone octamer contains two molecules each of histones H2A, H2B, H3, and H4. The DNA wraps around the octamer in a left-handed supercoil in about 1.75 turns that encloses about 150 bp. Histone H1 is the linker histone that, along with the linker DNA, physically connects adjacent nucleosome core particles. The length of the linker DNA varies with species and cell types. Usually, the nucleosome core particle and the linker DNA on both sides of the core encompasses between 180- and 200-bp DNA. The nucleosomes (10 nm each) are condensed into solenoid fiber structure of 30 nm; the 30-nm solenoid fibers are condensed into 300-nm filament; the 300-nm filaments are further condensed into the 700-nm chromosome. During cell division, when the chromosomes duplicate, a 1,400-nm metaphase chromosome is produced containing two chromatids, each chromatid being 700 nm.
chromatids behind the replication fork, and the other half of the nucleosome complement is made from newly synthesized histones. The first step in the assembly of chromatin is the nuclear import of newly synthesized core histones from cytoplasm. This is mediated by karyopherins (importins) that bind to the nuclear localization signal in the N-terminal domain of each core histone. These newly synthesized histones are acetylated at lysines 5 and 12 of histone H4 (H4K5ac and H4K12ac, and also H3K14ac in Drosophila) prior to their assembly into chromatin. After deposition onto newly replicated DNA, they are rapidly deacetylated by histone deacetylase HDAC1. The functional significance of this specific pattern of histone acetylation and subsequent deacetylation is not understood. Acetylation of newly synthesized histone H3 seems to occur at different sites in different species and has not yet been reported in human cells. In general, the acetylation of H3 and H4 is carried out by Hat1, the only known B-type histone acetyltransferase (B-type HAT), which is distinct from the A-type HATs that acetylate chromosomal histones (1,2). The H3/H4 heterodimers ultimately form the (H3/H4)2 tetramer, which form a stable complex with >120 bp of DNA. During histone deposition onto newly synthesized DNA, the positive charge of histones is shielded by various anionic factors to allow chromatin assembly in a regulated and ordered fashion. Histone H3–H4 tetramers bind to DNA first due to their higher affinity for DNA than H2A–H2B dimers. Subsequent deposition of H2A–H2B dimers is likely to be driven by the higher affinity of H2A–H2B for subnucleosomal particles comprising DNA and H3–H4 (1).
The Eukaryotic Genome
57
Nucleosome core assembly continues with the addition of histones H2A and H2B to the (H3/H4)2 tetramer. Histones H2A and H2B form a stable H2A/H2B heterodimer that binds to either side of the (H3/H4)2 tetramer and extend the wrapping of DNA within the nucleosome to >160 bp. This creates a structure comprised of the four histone dimers linked end-to-end in the sequence (H2A/H2B)–(H4/H3)–(H3/H4)–(H2B/H2A). These precise histone–DNA interactions constrain all DNA sequences, regardless of the inherent sequence-dependent structures to adopt a relatively similar conformation in the nucleosome (3,4). Various histone–chaperone proteins are required for the proper deposition of histones onto DNA and chromatin assembly. A heterotrimeric protein complex termed “chromatin assembly factor-1” (CAF-1) which copurifies with histones was isolated from human cell extracts. The structure and sequence of CAF-1 has been conserved among eukaryotic organisms. CAF-1 appears to deposit newly synthesized histones H3 and H4 onto newly replicated DNA; such histone chaperone activity is coupled to DNA synthesis via its interactions with proliferating cell nuclear antigen (PCNA). Because PCNA is the processivity factor for the replicating DNA polymerase in eukaryotes, the coupling of CAF-1 with PCNA serves to localize CAF-1 to the sites of DNA synthesis. Indeed, in human and mouse cells, CAF-1 is abundantly present at the replication foci (4,5). Another novel histone chaperone, termed “replication–coupling assembly factor” (RCAF), was identified by its ability to facilitate CAF-1-mediated assembly of nucleosomes onto newly replicated DNA. Biochemical approaches have led to the identification of H2A–H2B binding protein termed “nucleosome assembly protein-1” (NAP-1), which is highly conserved among eukaryotic species. The closely related human protein is called “NAP-2”. Both NAP-1 and human NAP-2 bind to histone H2A–H2B, and with the help of karyopherins, aid in their transport from cytoplasm to nucleus as cells progress from G1 to S phase. Although histone chaperones play a crucial role in chromatin assembly, they are not sufficient to generate the typical regular arrays of nucleosomes with 180–200 bp spacing; rather, they lead to the assembly of irregularly spaced nucleosomes. Proper chromatin assembly with regular arrays of nucleosomes requires ATP hydrolysis and ATP-dependent chromatin remodeling factors. Some of these factors have also been identified, such as ATP-utilizing chromatin assembly and remodeling factor (ACF) and chromatin accessibility complex (CHRAC). The catalytic component of ACF and CHRAC is the imitation switch (ISWI) ATPase. Both ACF and CHRAC are members of the ISWI family of chromatin remodeling complex (1). 2.1.2. Histone Variants, Deviant Nucleosomes, and Specialized Functions In higher organisms, all core histone subtypes have variants, with the possible exception of histone H4. These variants are nonallelic primary sequence variants. For the most part, the core histones have only a small number of variants, and the amino acid sequence variations within a subtype are limited. However, there are some highly divergent variants which perform specialized functions. Some examples include CENP-A (histone H3 variant), macroH2A, H2AZ, and H2AX (all are histone H2A variants). The C- or N-terminal regions of all these histone variants have amino acid sequences that are >60% identical with that of their respective normal histone types; in addition, these variants also have unique amino acid sequences. Three well-studied centromeric proteins (CENP) are CENP-A, CENP-B, and CENP-C. CENP-A is the histone H3 variant and is specifically localized to the centromeric chromatin in mammals and yeast. CENP-A synthesis is coordinated with centromeric
58
Choudhuri
replication from mid-S to early G2. Targeted deletion of mouse homolog of CENP-A (Cenpa gene) showed that it is an essential gene for survival. Heterozygous mice were healthy and fertile, whereas homozygous null mutants failed to survive beyond 6.5 days postconception. The affected embryos showed severe mitotic problems, including micronuclei and macronuclei formation, nuclear bridging and blebbing, and chromatin fragmentation and hypercondensation (6). Histone macroH2A, an H2A variant, remains predominantly associated with transcriptionally inactive heterochromatic regions of the genome, such as the inactive X chromosome of female mammals. The association of macroH2A with the inactive X chromosome may be mediated through the interactions of macroH2A and Xist, a ncRNA that is tightly associated with the inactive X chromosome (7). However, the possible role of macroH2A in X-inactivation is unclear since disruption of macroH2A association with the Xist does not affect the maintenance of X-inactivation. It is possible that other proteins, such as HP1 (discussed later), are involved in the maintenance of X-inactivation. Histone H2AZ, a minor H2A variant, is found in a wide range of organisms from yeast to mammals. Swapping experiments using Drosophila H2AZ homolog H2AvD in which regions of H2AvD were replaced with homologous regions from Drosophila histone H2A.1 led to the identification of a distinct region of H2AvD, which was necessary for overcoming the null mutant lethality in null flies (8). H2AX is another histone H2A variant. Following DNA double-strand breaks, H2AX is rapidly phosphorylated forming the gamma-H2AX (γ-H2AX), which accumulates at the site of the double-strand breaks and is associated with the recruitment of various DNA repair proteins. Thus, γ-H2AX is a useful marker of DNA double-strand breaks. In keeping with the proposed role of γ-H2AX in maintaining genomic integrity and stability, H2AXnull mice are radiation-sensitive, growth-retarded, and immune-deficient, and mutant males are infertile. These pleiotropic phenotypes are associated with chromosomal instability, DNA-damage repair defects, and impaired recruitment of various DNA-damage sensor and double-strand break (DSB) repair proteins, such as Nijmegen breakage syndrome protein 1 (Nbs1 or nibrin), p53-binding protein 1 (53bp1), and breast cancer 1 protein (Brca1), but not Rad51 (eukaryotic RecA homologue) (9). The linker histones (H1) are much more variable in structure than the core histones. Metazoan linker histones have a three-domain structure—a central globular domain flanked by N- and C-terminal regions. The preponderance of basic residues within these regions serves to neutralize the polyanionic backbone of DNA, thus facilitating the folding of nucleosomal arrays into higher order structures (3). Among vertebrates, several different types of H1 may exist in the same species at different times of development or in different cell types. In chicken erythrocyte nuclei, for example, the linker histone variant associated with chromatin is H5, whereas in frog erythrocyte nuclei the linker histone variant associated with chromatin is H10 (subtype H10-2) (10). Similarly, in mammals, there are at least six somatic variants (H1a–H1e, H10), a testis-specific variant (H1t), and an oocyte-specific variant (H1oo) (7,11,12). In addition to playing a direct role in stabilizing nucleosomal and higher-order chromatin structure, H1 histones also function as general and specific repressors of transcription by limiting the access of transcriptional activators to chromatin. For example, H1b interacts with the homeodomain protein Msx1, and the complex binds to a regulatory element of the MyoD gene to inhibit its expression (13). For a detailed list and information of histone variants, see the histone database at http://research.nhgri.nih.gov/histones/.
The Eukaryotic Genome
59
2.1.3. NonHistone Proteins in the Chromatin—the HMG Proteins As their name suggests, the high mobility group (HMG) proteins have high electrophoretic mobility in polyacrylamide gels. They are the main nonhistone protein components of the chromatin and are ubiquitous in mammalian cells. However, quantitatively they are much less abundant than histones. They are divided into three families: HMGB (formerly HMG1/-2), HMGN (formerly HMG-14/-17), and HMGA (formerly HMG-I/Y/C) family. Within a family, the gene names are numbered in sequential order (e.g., HMGB1, HMGB2). Splice variants are indicated by small letters (e.g., HMGA1a, HMGA1b, HMGA1c). The HMG functional motifs are as follows: HMG-box for the HMGB family, nucleosomal binding domain for the HMGN family, and AT-hook for the HMGA family. Proteins containing any of these functional motifs are known as the “HMG motif proteins”. HMG proteins bind to DNA and decrease the compactness of the chromatin fiber. In doing so, they enhance the accessibility of various regulatory factors to chromatin. HMG proteins were shown to move very rapidly throughout the nucleus, raising the possibility that following transient displacement of histone H1 from the nucleosomal sites, HMG proteins may rapidly occupy these sites (14). Binding of HMG proteins to DNA can cause significant DNA bending because such interaction weakens the binding of histone H1 to nucleosomes by competing for chromatin binding sites. This is achieved by synergistic binding of HMG proteins to the DNA sites that can potentially serve as H1-binding sites. Thus, a network of dynamic and competitive interactions involving HMG proteins and histone H1, and perhaps other structural proteins, constantly modulates nucleosome accessibility and the local structure of chromatin fiber (14). 2.1.4. Chromatin Modification Chromatin modifications associated with gene expression either activate or repress transcription. Most modifications take place on the N-terminal tails of histones by various chromatin-modifying enzymes. Modifications also take place on the C-terminal tails, and some modifications have been reported in the globular domains of histones (15–17). Various types of posttranslational modifications are acetylation, methylation, phosphorylation, ubiquitinylation, ADP-ribosylation, and sumoylation. The amino acid residues that are subject to modification are specific, thus creating specific “marks” in the chromatin. These modifications help recruit other proteins and aid in either relaxation or further compaction of the chromatin which influence transcription. Lysine is the central amino acid substrate for various modifications on histone. Different lysine modifications may have opposite effects on gene expression. All these modifications are directly relevant for epigenetic regulation of gene and genome expression, and therefore are discussed in more detail in Chapter 3. 2.1.5. Chromatin Remodeling Complex Chromatin modification through histone acetylation, phosphorylation, and so forth can relax and decondense chromatin but cannot completely disrupt nucleosome structure. Without disruption of the nucleosomal core particles, transcription cannot proceed efficiently. Therefore, chromatin modification combined with ATP-dependent chromatin remodeling is necessary for efficient transcriptional activation and completion. A chromatin-remodeling complex is a multiprotein complex with ATPase activity that perturbs nucleosome structure in an ATP-dependent manner, exposes nucleosomal DNA to attack by nucleases, catalyzes histone octamer sliding and transfer, and reduces the supercoiling of DNA circles bearing nucleosomes.
60
Choudhuri
At least four major families of chromatin remodeling complexes are known: SWI/ SNF (SWI/SNF, RSC, Brahma), Mi-2/CHD (Mi-2 complex, NURD), ISWI (ISW1, ISW2, NURF, ACF, CHRAC, RSF), INO80 (18,19). The switching/sucrose nonfermenting (SWI/ SNF) complex was the first chromatin remodeling complex identified and characterized in budding yeast Saccharomyces cerevisiae. The human homolog is referred to as the “hSWI/ SNF”. The ATPase subunit in yeast SWI/SNF complex is known as “SWI2/SNF2”. Mammalian SWI/SNF complex contains either Brahma-related gene-1 (BRG-1) or Brahma (BRM) as its ATPase subunit. Chromatin remodeling factors use the energy derived from ATP hydrolysis to induce a net change in the position of the histone octamer, and it involves the breaking and reestablishment of histone–DNA contacts. Based on various experimental results, two likely mechanisms have been proposed: (i) transfer of histones from one region of DNA to another via a dissociative pathway, and (ii) movement of the histone octamer along DNA by sliding or tracking (20). Because thermodynamic nucleosome repositioning occurs at lower temperatures than that required to disrupt the entire nucleosome, it seems likely that sliding of histone octamer along the DNA will involve the breaking of fewer histone–DNA contacts at any one time (20). During sliding, using the energy from ATP hydrolysis the DNA dissociates from the histone octamer at one edge of the nucleosome, and a neighboring stretch of DNA associates with the octamer to yield a small DNA loop. As this loop spreads along the surface of the octamer, the octamer slides to a new location. Thus, this model depicts that at any given time only a small number of histone–DNA contacts are broken. Chromatin remodeling allows access of the transcriptional activators to DNA. Once transcription begins, the advancement of RNA pol II through chromatin is facilitated by other factors. One such factor, known as “facilitates chromatin transcription” (FACT), has been identified and extensively characterized by Danny Reinberg’s laboratory. FACT is a heterodimer; in humans, the two subunits are hSPT16 and SSRP1. A model of how FACT facilitates the movement of RNA pol II through chromatin shows that it destabilizes the nucleosomal structure so that one histone H2A–H2B dimer is removed transiently during the passage of RNA pol II, thus leaving behind the histone hexamer. After the passage of RNA pol II, FACT redeposits the H2A–H2B dimer using its histone chaperone activity, thereby reassembling the nucleosome traversed by RNA pol II (21). FACT is restricted to transcription that involves nucleosome disassembly mechanisms, but not nucleosome transfer seen with RNA pol III-transcribed genes (22). Importantly, FACT does not require ATP hydrolysis for its action. 2.2. Heterochromatin and Euchromatin The structure of chromatin varies considerably in the nucleus and also in response to cellular metabolic demands. Different levels of chromatin compaction result in the formation of euchromatin and heterochromatin. In general, transcriptionally inactive, highly condensed chromatin that is stained darker is called “heterochromatin”, and transcriptionally active, less condensed chromatin is called “euchromatin”. At the DNA sequence level, heterochromatin contains a great deal of highly repetitive sequence. Heterochromatin and euchromatin can be easily visualized by staining the chromosomes. Constitutive heterochromatin is identified by C banding in which chromosomes are treated with acid (HCl) and base [Ba(OH)2] and then stained with Giemsa stain. Euchromatic chromosome bands are identified by G banding in which chromosomes are subjected to mild proteolysis by trypsin, followed by staining with Giemsa stain.
The Eukaryotic Genome
61
Heterochromatin is classified into two types: facultative heterochromatin and constitutive heterochromatin. Facultative heterochromatin occurs in only one of a pair of chromosomes. The DNA base composition of the facultative heterochromatin is the same as that of its euchromatic counterpart in the homologous chromosome, and that is why facultative heterochromatin has all the characters of euchromatin in terms of the expressible genes present. Facultative heterochromatin is found in the inactive X chromosome (Xi) in the somatic cells of female mammals. In female mammals, one of the two X chromosomes is inactivated so that the females with two X chromosomes do not have twice as much X chromosome gene products compared to that of the males, which possess only one X chromosome. This phenomenon is called “dosage compensation”. The inactivation state of the X chromosomes is reversed in the gonad in primary oocytes (diploid) (23) so that after oogenesis all ova (haploid) contain an active X chromosome. The mechanism of dosage compensation through X chromosome inactivation in mammals is discussed in Chapter 3. Readers are referred to the review by Lucchesi et al. (24) for a better understanding of a comparative account of dosage compensation in Drosophila, C. elegans, and mammals. Unlike facultative heterochromatin, constitutive heterochromatin has DNA sequence characteristics that are radically different from that of the euchromatin; there are a lot of repetitive sequence elements in the DNA. Although constitutive heterochromatin occurs in every chromosome in blocks, they preferentially occur at certain parts of the chromosome, such as at the centromeric and telomeric regions. Heterochromatin is condensed and genetically inert but it is still a dynamic entity and can change in response to the nuclear environment, growth, and differentiation status, as well as the metabolic status of the cell. In Drosophila, about 40 genes have been identified in the heterochromatic regions. These include, among other genes, the 18S and 28S ribosomal RNA genes. The heterochromatin apparently also plays some role in homologous chromosome pairing and chromosome segregation. In general, heterochromatin prevents chiasmata formation and crossing-over in its vicinity (25,26). Centromeric heterochromatin apparently plays a role in sister chromatid cohesion and proper segregation of chromosomes during cell division (27). 2.2.1. Heterochromatin-Associated Proteins A number of proteins have been found associated with heterochromatin. Members of HP1 family (HP1α, HP1β, HP1γ) in mammals represent a class of nonhistone chromosomal proteins that play an important role in establishing and maintaining higher-order chromatin structures and nuclear organization, as well as in chromosome segregation and gene silencing (28). HP1 was first described in Drosophila as a heterochromatin-associated protein with dosage-dependent effects on heterochromatin-induced gene silencing. It was demonstrated that HP1 becomes associated with the inactive X chromosome at the interphase and becomes a component of the Barr bodyb in humans (29). The authors suggested that in humans HP1 might be involved in the maintenance of heterochromatin and X-inactivation. Various HP1-like proteins have since been found in species ranging from fission yeast to humans. The N-terminal region of HP1 is called the “chromodomain”, and the C-terminal region is called the”chromo shadow domain”. The two domains are connected through a hinge region. The chromo shadow domain appears to be important in HP1 b
The inactive X chromosome in female mammals with its facultative heterochromatin stains dark and is called the Barr body. It is explained in more detail in Chapter 3.
62
Choudhuri
dimerization, while the chromodomain actually binds to the heterochromatin through histone H3 dimethylated at lysine 9 (H3K9me2). Establishment of heterochromatin and transcriptional repression involves two successive modifications of the lysine 9 of histone H3: first deacetylation, followed by dimethylation; the latter enables it to recruit HP1. Thus, dimethylation of histone H3K9 and the presence of HP1 serve as chromatin marks for transcriptionally silenced chromatin (30). In addition, the histones in both facultative and constitutive heterochromatin are typically underacetylated. Underacetylation is associated with transcriptional repression. Many other proteins are associated with heterochromatin, but their relevance as legitimate heterochromatin-associated proteins is not established yet (see 31). In addition to HP1, various other proteins associated with heterochromatin also influence the spread of heterochromatin into the adjacent euchromatin. 2.2.2. Heterochromatin Spread and Position Effect Variegation The expression of genes located in close proximity to the heterochromatin, or of transgenes integrated adjacent to the heterochromatin, is sometimes silenced. The silencing is often not complete; the gene is silenced in some cells, but in other cells it is expressed. This results in a mosaic expression, the so-called “variegated (patchy) expression pattern”. Because this expression pattern is brought about by the proximity of the gene to the heterochromatin, the phenomenon is called “position effect variegation” (PEV). Such heterochromatinization of the adjacent euchromatin is a major cause of silencing of transgenes when they are integrated close to the heterochromatin. Indiscriminate expansion of heterochromatin into euchromatin and mass silencing of genes along the length of the chromosome are prevented by various cis-acting elements and trans-acting factors. The most important cis-acting element shielding genes from the silencing effects of heterochromatin is the “insulator” element discussed in Chapter 1. Because heterochromatin spread and PEV are epigenetic effects, it is discussed in more detail in Chapter 3. 2.3. Nuclear Matrix, Matrix Attachment Regions, and Chromatin Loops In the nuclei of eukaryotic cells, the chromatin exists in the “nuclear matrix”, also called “nuclear scaffold”, “chromosome scaffold”, and “nucleoskeleton”. Nuclear matrix is a fibrous network containing various proteins, and it provides structural integrity to the nuclear interior. The chromatin is organized into independent loops that are anchored to the nuclear matrix or chromosome scaffold (Fig. 1). Evidence largely derived from in vitro experiments indicates that nuclear matrix may play a role in genome duplication, RNA synthesis and processing, anchoring of DNA loops, gene expression regulation, protein phosphorylation, mRNA transport, and a variety of other functions (32). An abundant protein in the nuclear matrix is the enzyme topoisomerase II, which is intimately associated with DNA replication. Another important group of proteins is called the “Structural Maintenance of Chromosomes” (SMC) proteins. One type of SMC proteins called “condensins” are essential for normal mitotic chromosome condensation, whereas another type of SMC proteins called “cohesins” are essential for the regulation of sister chromatid pairing (33). For comprehensive information about nuclear matrix-associated proteins in various species, see the nuclear matrix protein-database (NMP-db) at http://cubic.bioc. columbia.edu/db/nmpdb/. The DNA of the chromatin loops that are in physical association with the nuclear matrix contains specific sequences that actually attach to the nuclear matrix. These sequences are called the “matrix attachment regions” (MARs) or “scaffold/matrix attachment regions”
The Eukaryotic Genome
63
(S/MARs). The MARs occur exclusively in eukaryotic genomes. The DNA elements of MARs may range from 300 bp to several thousand bp, and they typically occur every 5–200 kb of sequence. Most known MARs are AT-rich. The suitability of AT-rich island sequences to serve as MARs stems from the fact that AT-rich regions are flexible and easily destabilized so that in their single-stranded form, they can bind to specific DNA unwinding proteins. However, AT-richness alone is not sufficient to confer the matrix attachment property; it is also determined by the specific structure of the AT-rich DNA element, such as strong potential for extensive unpairing when subjected to superhelical strain (34,35). Various MAR-binding proteins (MARBPs) bind to the MARs and mediate MAR function (see 36 for a comprehensive list of MARBPs, their tissue distribution and function). Very large MARs are usually associated with heterochromatin. In general, MARs are vital elements of nuclear organization that are critical for DNA replication, regulation of chromatin structure, transcriptional enhancement or repression, cytosine methylation, and even genomic imprinting (37). MARs appear to be functionally conserved, since animal MARs can bind to plant nuclear scaffolds and vice versa (38). Matrix attachment of the chromatin DNA results in the formation of chromatin loops and folds, creating discrete structural and functional chromatin domains (Fig. 1). Such distinct domains create a microenvironment rich in regulatory proteins and enzymes required for their function. Each domain is also shielded from the effects of the neighboring domains (36). By introducing single and multiple copies of MAR-containing constructs (that contain transcriptionally active genes) in transgenic mouse and transfected cell lines, Heng et al. (39) studied the interaction of MARs with the nuclear matrix. Based on their observation, the authors proposed a model which depicts that structural MARs are physically anchored to the nuclear matrix, whereas functional MARs are located close to the genes and are not anchored to the nuclear matrix. In response to transcriptional demand, the functional MARs become anchored to the nuclear matrix containing the transcription machinery. In doing so, a functional MAR brings the gene close to it in contact with the transcription machinery contained in the nuclear matrix, thereby facilitating transcription. Chromatin loop size in various species, as determined by sedimentation and electron microscopy, shows a great degree of variation; usually between 30 and 120 kb (40). However, larger loop size has also been reported; for example, in human leukemia (HL-60) cells, the average loop size was estimated to be 315 kb (41). 3. GENOMIC DNA AS A MOSAIC OF ISOCHORES Early attempts to describe the organization of vertebrate genomic DNA at a macromolecular level led to the development of the “isochore” concept, the word “isochore” literally meaning “equal regions” (42–44). Isochores have been traditionally defined as >300-kb-long DNA segments in warm-blooded vertebrates (birds and mammals) with their characteristic, relatively homogeneous base composition. In other words, warm-blooded vertebrate genome may be viewed as a mosaic of isochores. The characteristic base composition of an isochore refers to the characteristic GC-content of the isochore, which differs significantly from that of the adjacent isochores. The homogeneity in base composition of an isochore refers to the homogeneity of its base composition compared to that of the chromosome in which it resides. Although isochores are often described as >300-kb DNA fragments, the isochore size may vary between 200 kb and 1.3 Mb (44), and the base composition–homogeneity of the isochores is true above 3-kb level (43,44). Thus, isochores (≥200 kb) are larger than individual chromatin loops, which are on an average 60–70 kb (40), but are usually smaller than chromosomal bands, which are usually 2–3 Mb or larger.
64
Choudhuri
The presence of different classes of isochores makes the genomes of warm-blooded vertebrates nonhomogeneous. This is in contrast to the genomes of cold-blooded vertebrates (fish, amphibians, and reptiles), where the entire genome appears to have homogeneous base composition. The DNA of cold-blooded vertebrates also never attains very high GC levels, whereas the DNA of warm-blooded vertebrates can attain higher GC levels. 3.1. Different Families of Isochores and Their Properties—GC-Content, Gene Distribution, and Codon Usage Bias Mammalian genomes can be fractionated into five families of isochores: L1, L2, H1, H2, and H3. Isochores L1 and L2 are GC-poor, and together they constitute about 62% of the genome, whereas H1, H2, and H3 are GC-rich, and they represent 22%, 9%, and 3% of the genome, respectively. The remaining 4% of the genome is represented by satellite DNA.c In chicken, there is one additional GC-rich isochore, called “H4”. The typical GC-contents of various isochores in humans are as follows: 39% for L1, 41% for L2, 45% for H1, 49% for H2, and 53% for H3. The distribution of genes in isochores is also nonuniform. The GC-poor isochores L1 and L2 have the lowest concentration of genes, while the most GCrich isochore H3 has the highest concentration of genes. The gene concentration (observed/ expected gene frequency) is about 0.55 for the L1 + L2 isochores, 1.2 for the H1 + H2 isochores, and 9.3 for the H3 isochores (45). Because of their higher gene concentrations, the H2 and H3 isochores together have been termed the “genome core”, which makes up about 12% of the genome (9% for H2 and 3% for H3) (43). The genome core contains one gene per 5–15 kb, while the other 84% of the genome consisting of the L1, L2, and H1 isochores (62% for L1 + L2 and 22% for H1) contains one gene per 50–150 kb. The genome core seems to exist in cold-blooded vertebrates as well even though the GC-richness of the genomes of cold-blooded vertebrates is much lower compared to that of warm-blooded vertebrates (46). In the human genome, the least abundant H3 isochore apparently contains 25% of the genes, and the genome core (H2 + H3 isochores combined) contains about 54% of the genes. In contrast, the most abundant GC-poor isochore contains only about 3% of the genes, and the L1 + L2 + H1 isochores combined contain about 46% of the genes (46). Although GC-rich isochores are gene-rich, the genes located in these isochores tend to be smaller in size because of smaller introns. Conversely, the GC-poor isochores are genepoor, but the genes located in these isochores are larger because of larger introns. Comparison of the exon/intron organization of vertebrate genes belonging to different isochore classes, as predicted by their GC-content in the third codon position, revealed that genes coding for long proteins (500 amino acids or longer) are almost twice as frequent in L1 + L2 isochores as in H3 isochores (47). Also, the total intervening sequences (sum of all introns) are on an average three times as long in L1 + L2 isochores as in H3 isochores. This factor varies between species from 2.1 (mouse) to 4 (cow). The authors found these patterns to be true among human, mouse, rat, cow, and even chicken genes, and are therefore likely to be common to all warm-blooded vertebrates. Thus, there is a direct relationship between the GC-richness and gene concentration in an isochore, but an inverse relationship between the GC-richness and gene size. The GC-rich isochores are localized in early replicating, highly transcribing chromatin, suggesting that chromatin has a much more open conformation in the genome core (48). c The completion of human genome sequencing has modified some of these original estimates slightly, and these will be discussed in the relevant sections.
The Eukaryotic Genome
65
Genes that are in GC-rich isochores tend to have a higher GC-content in the third codon position, and genes that are in GC-poor isochores tend to have a higher AT-content in the third codon position (43,49). The AT- or GC-content in the third codon position of the genes within an isochore is generally close to that of the entire isochore. It has also been suggested that this genomic influence extends even to the first and second positions of the codon. Such base-composition bias in the gene sequence, which is driven by the isochore location of the gene often results in codon usage bias. The codon usage bias, in turn, may affect the amino acid composition of the protein. For example, increased GC-content is likely to include amino acids encoded by GC-rich codons (Pro, Ala, Arg, Gly). In contrast, increased AT-content is likely to include amino acids encoded by AT-rich codons (Phe, Ile, Met, Tyr, Asn, Lys) (43,49). While analyzing the sequence of the rat lst-1 (rlst-1) gene (Oatp-4, Slc21a10, Slco1b2), it was observed that the AT-content of the third codon position of rlst-1 coding sequence is about 60%, and that of the entire coding sequence is about 64%. Calculation of the AT-content of the entire locus (NC_005103) from the rat genome sequence database also shows a 60% AT-content for the entire locus. Therefore, a bias toward the usage of ATrich codons is likely. Indeed, of all the codons encoding serine, leucine, and threonine in rlst-1 protein, 61%, 80%, and 73%, respectively, are AT-rich codons, and these three amino acids together account for about 25% of total amino acids of rlst-1 protein (50). For comparison, Choudhuri et al. (50) also analyzed the human LST-1 (hLST-1/ OATP2/OATP-C/SLC21A6/SLCO1B1) gene for its AT-content and codon usage bias. The information on hLST-1 locus (NC_000012) was obtained from the human genome sequence database. The entire hLST-1 locus, located in the short arm of chromosome 12 (12p), is about 109-kb long and has an AT-content of about 65%. When only the exon and intron contents of the hLST-1 gene were analyzed, the AT-content was found to be the same as that of the entire locus (65%). In addition, within the coding sequence, the fractions of AT-rich codons as well as the AT-content of the third codon position were both found to be about 68%. Therefore, the overall sequence of hLST-1 gene is AT-rich, and it shows an AT-rich codon bias similar to that of rlst-1 gene. Because of the base composition-driven codon usage preference, the H3 isochore family has an extremely biased codon usage; a number of codons being absent or very scarce because of very high GC levels in the third codon positions (43). The distribution of isochores in the chromosome also tends to show some relationship with various chromosomal bands. For example, G (Giemsa) bands essentially consist of the GC-poor isochores L1 + L2, T (telomeric) bands consist primarily of the GC-richest isochore H3, while R (reverse) bands are formed almost equally by GC-rich isochore H1 and GC-poor isochores L1 + L2 (48). There are three main views on the origin of isochores. They are selectionist hypothesis, mutationist hypothesis, and recombination hypothesis. None of these hypotheses has been proved to be the only mechanism explaining the origin of isochores; there are evidence for and against each of these hypotheses. A detailed discussion on the origin of isochores is beyond the scope of this chapter. 3.2. In Search of the “Iso” in Isochores The publication of the human genome draft sequence (51) and several other genomes, plus some completely sequenced chromosomes (52), has ignited a debate about the validity of the isochore concept in its current form. The most severe criticism questions the very existence of isochores and claimed that the strict notion of isochores as compositionally homogeneous could be ruled out; hence, “. . . isochores do not appear to merit the prefix ‘iso’ ” (51). Nevertheless, the International Human Genome Sequencing Consortium
66
Choudhuri
(IHGSC) acknowledged that “…the genome clearly does contain large regions of distinctive GC content”, which the authors refer to as “GC content domains” instead of isochores. Even before the completion of the human genome sequencing, Nekrutenko and Li (53) arrived at similar conclusions. They observed that eukaryotic genomes, including mammalian genomes, are compositionally much more heterogeneous than predicted by the isochore model; however, human (or mammalian) genomes still contain long, compositionally homogeneous GC-rich segments (isochores). Interestingly, the other report of human genome sequencing did not come to the same conclusion as the IHGSC (54). They reported: “The most GC-rich fraction of the genome, H3 isochores, constitute more of the genome than previously thought (about 9%), and are the most gene-dense fraction, but contain only 25% of the genes, rather than the predicted 40%. The low GC L isochores make up 65% of the genome, and 48% of the genes.” They also found that chromosomes 17, 19, and 22 have a disproportionate number of H3-containing bands and the highest gene density, whereas chromosomes X, 4, 18, 13, and Y had the fewest H3 bands and the lowest gene density. In subsequent analysis of the human genome sequence by others, the original assertion of IHGSC that the isochore concept could be dismissed has been challenged. In a rebuttal to the notion that “isochores do not merit the prefix iso”, Li et al. (55) published their analysis that “isochores merit the prefix iso” and claimed that the statistical test applied by the IHGSC was not appropriate. A similar argument questioning the methodology used to identify isochores has been put forward by Clay and Bernardi (56) in response to the claim of Cohen et al. (57) that the isochore theory may have reached the limits of its usefulness as a description of genomic compositional structures. Clay and Bernardi (56) claimed that the method followed by Cohen et al. (57) over-fragmented GC-rich isochores (and also many GC-poor isochores) beyond recognition, and thus systematically lost the GC-rich isochore information in their analysis. Recently, using a nonoverlapping 100-kb window-size genome partitioning, an isochore map of the human genome has been created (58). The authors obtained about 3,200 isochores which cover the entire human genome. The reason for using a 100-kb window-size was the finding that the variance of the plots of GC versus window size was high below 100 kb, but tended to plateau beyond 100 kb. The array of GC levels of the 100-kb windows in each chromosome was scanned for jumps (~1%–2%) based on mean GC-content. The isochore map they produced provides information about the size, GC-content, standard deviation, and coordinates of the isochores on the human genome map. The authors found that the isochores are arranged in blocks, and their distribution patterns nicely correspond to the chromosomal bands. The authors suggested that the isochores may constitute the molecular basis of chromosomal bands. In a subsequent publication, the same group (59) expanded and reemphasized the idea that the molecular basis of the classical G and R bands in human chromosomes can be explained by the presence of isochores and isochore boundaries. The authors emphasized that such correspondence between the isochores and the chromosomal bands provides a higher level resolution (100 kb) definition of chromosomal bands than the classical cytogenetic definition with a resolution level of 2–3 Mb. Recent evidence suggests that isochores are gradually disappearing from mammalian genomes. Isochores probably originated in the past due to a strong mutational pressure, which subsequently disappeared leading to the gradual disappearance of the isochores, although the cause of the mutational pressure and its disappearance is not known. A conservative view about the creation of isochore has been that isochores are predominantly the result of accumulation of selection-neutral changes caused by nonuniform mutation or repair biases, such
The Eukaryotic Genome
67
as biased gene conversion (BGC) during homologous recombination (60). Precisely defining isochores in terms of size and composition, as well as isochore boundaries, has remained a major challenge. Nevertheless, there are definite and recognizable GC-rich and GC-poor segments in the genome, and such regional base-composition bias may relate to biological properties that are yet to be understood. As suggested by IHGSC, “The correlation between GC-content domains and various biological properties is of great interest, and this is likely to be the most fruitful route to understanding the basis of variation in GC content” (51). 4. GENOMIC LANDSCAPE AS REVEALED BY GENOME SEQUENCING Genome sequencing and analysis of the sequence can immediately reveal some large-scale features of the genome such as gene content, gene size, and gene distribution; distribution of the GC-content and CpG islands; noncoding genomic landscape; recombination rates; information about the repeat content and genomic parasites; rates of nucleotide substitution and genome evolution and so on. In the following discussion, emphasis will be laid on the details of the human genome, which will be compared primarily with the chimpanzee genome, and to a lesser extent with the genomes of rhesus monkey and mouse. The rationale for choosing chimpanzee genome as the primary comparator is its evolutionary relationship with human. Chimpanzee (Pan troglodytes) is a hominid and the closest evolutionary relative of humans. The chimpanzee–human split occurred about 5–6 million years ago. Rhesus monkey (Macaca mulatta) is an old-world monkey, and the Macaca–human split occurred about 25–30 million years ago. Mouse is a rodent and one of the most widely used eutherian mammals in research. The rodent–primate split from the last common ancestor occurred about 75–95 million years ago. Following completion of the human genome sequencing, a deluge of publications are being added everyday to the public database. Most of these efforts are focused on analyzing the human genome and other genome sequences using various novel statistical tools. The proximate goal is to gain insight into the evolution of genome architecture and organismal complexity and identify various regulatory sequences and molecular entities controlling genome expression and integrity. The ultimate goal is to uncover the molecular basis of humanness, as well as identify genomic hallmarks for specific disease susceptibility in individuals, and finally develop individualized medicine and nutrition. In the following discussion, some fundamental information on the structural, functional, and evolutionary aspects of the human genome will be discussed, and comparisons will be made wherever necessary with other genomes.d 4.1. Human Genome The information discussed below is primarily based on the reports of the international human genome sequencing consortium (51,61). These two references have been cited only when relevant and have not repeated again and again. Other references have been cited as necessary. 4.1.1. The Protein-Coding Landscape Genome sequencing revealed that any two humans are about 99.9% identical in their DNA sequence. Thus, it is through studies of the tiny fraction of the human genome, d
A discussion or even an attempt to summarize the deluge of publications in one chapter is an impossible task. No attempt has been made to capture all relevant references. Rather references have been cited to make a point of discussion.
68
Choudhuri
which constitutes the genetic variation between individuals, that the phenotypic variabilities and disease susceptibilities can be understood in molecular terms (62). The human genome contains about 3 billion base pairs (3 Gb) and is contained in 23 pairs of chromosomes (22 pairs of autosomes + 1 pair of sex chromosomes). The protein-coding sequences comprise about 1.2%–1.5% of the genome. Initial estimates predicted a total of 30,000–40,000 protein-coding genes (51,54), which is about twice as many as in worm or fly. These numbers have since been revised. The current estimate predicts that the human genome contains little more than 22,000 protein-coding genes (61). At least 50% of all human protein-coding genes appear to be subject to alternative splicing involving mainly the coding sequence, each producing two or more alternatively spliced transcripts. About half of the human genome is derived from transposable elements which have contributed dozens of genes. However, there has been a marked decline in the overall activity of both DNA transposons and long terminal repeat (LTR) retrotransposons in the hominid lineage. Hundreds of human genes appear to have resulted from horizontal transfer from bacteria at some point in the vertebrate lineage (51, 54). The average length of human protein-coding genes is about 27 kb (51), and there are an average of nine exons per transcript (61). The average length of 5′-UTR, internal exons, 3′-UTR, and introns is about 300, 145, 770, and 3,365 bp, respectively. On average, the coding sequence in human genome codes for about 447 amino acid residues. The largest number of exons (234) was identified in titin gene (54). For splice site sequence, about 98% of the introns have the canonical GT–AG, while about 0.80% have GC–AG, and 0.10% have AT–AC. The reason AT–AC introns are the least prevalent is probably because they use a completely different splicing machinery than the others (discussed in Chapter 1). More than 40 extremely short exon sequences (less than 19 bp) were detected, and they are all purine-rich (>70% purine) (51). The GC-rich regions are gene-dense containing many compact genes (due to smaller intron size). With an increase in GC-content from 30% to 50%, the relative gene density increases more than 10-fold. 4.1.2. Gene Birth and Death in Human Lineage In the finished sequence of the human genome (61), the birth and death of human genes were estimated. To identify local gene duplication (birth), clusters of nearby homologous gene sequences were searched, and the divergence was assessed at sites that are likely to be selectively neutral. A total of 1,183 genes exhibit such divergence from a neighboring gene. These genes often fall within larger clusters of paralogous genes (genes that are created by duplication). Genes with greater divergence reflect older duplications. Comparison with mouse genes confirms that these genes are more closely related within each species than between the two species in nearly all cases. This is expected for genes arising by duplication after the divergence of the human and rodent lineages. The recent duplications involve genes with immune and olfactory function as well as those likely to be involved in reproductive functions, such as pregnancy-specific beta-1-glycoprotein and choriogonadotropin beta proteins, which may be involved in the extended gestational period in humans. Therefore, either there may have been a true explosion in the rate of gene duplication in the primate lineage, or there may be an ongoing process of gene conversion of older gene duplication events. Gene death is another phenomenon that sheds light on lineage-specific genome evolution. To identify gene death, the genome was scanned for sequences of recent nonprocessed
The Eukaryotic Genome
69
pseudogenes, that is, nearly intact duplicated human genes that have recently acquired inactivating mutation. Database search showed that 27 nonprocessed pseudogenes in humans are also found as nonprocessed pseudogenes in chimpanzee, while five human nonprocessed pseudogenes are functional genes in chimpanzee, indicating that these genes were inactivated in human lineage following human–chimpanzee split about 5–6 million years ago. Of these 32 total nonprocessed pseudogenes fixed in the human population, 10 are derived from olfactory receptors. The remaining 22 include a wide variety, such as genes homologous to a cationic amino acid transporter, a serine-threonine kinase, a calreticulin, a putative G-protein-coupled receptor, and a cystatin. 4.1.3. Genomic GC-Content Average GC-content in the human genome is about 41%, but local GC-contents show wide variations. For example, the most distal 48 Mb, that is, toward the telomere of chromosome 1p (short arm p of chromosome 1) there is an average GC-content of about 47%. In contrast, a 40-Mb region of chromosome 13 has only 36% GC-content. There are also examples of huge variations in GC-content between adjacent chromosomal regions. For example, the average GC-content on chromosome 17q (long arm q of chromosome 17) is 50% for the distal 10.3 Mb, but it drops to 38% for the adjacent 3.9 Mb. Even wider variations were observed in regions less than 300 kb, ranging from 33.1% to 59.3%. The authors tried to look for signatures of isochores originally proposed by Bernardi and colleagues and discussed above. The authors concluded that some of the local heterogeneity in GC-content is attributable to transposable element insertions. 4.1.4. CpG Islands CpG islands are genomic regions that contain a high frequency of cytosine–guanine (CG) dinucleotides. To be recognized as a CpG island, a sequence must fulfill three criteria: (i) have a GC-content of 0.50 or greater; (ii) an observed-to-expected CpG dinucleotide ratio of 0.60 or greater; and (iii) both occurring within a sequence window of 200 bp or greater (63). CpG islands are associated with the 5′ends of many housekeeping as well as regulated genes. Identification of potential CpG islands during sequence analysis thus helps define the extreme 5′ends of genes. Often CpG islands extend into the promoter and sometimes even downstream into the transcription unit. For transcriptionally active genes, the C of CpG is not methylated. A striking feature of the human genome is the dearth of CpG dinucleotides interrupted occasionally by CpG islands. Genes whose promoters are especially rich in CpG sequences tend to be expressed in most tissues. About 72% of human promoters have high CpG content, and 28% have low CpG content (64). The CpG in inactive genes are usually methylated at C to suppress their expression. The methyl-C of methyl-CpG dinucleotides tends to mutate to T by occasional spontaneous deamination, thus methyl-CpG dinucleotides on a DNA strand tend to mutate to TpG. Over evolutionary time, such decay of methyl-CpG accounts for the five times lower observed frequency of CpG islands in the human genome than the expected frequency (observed = 0.8%, expected = 4%; the expected frequency is the product of the frequencies of G and C in the genome). Absence of methylation slows CpG decay because the product of normal cytosine deamination is uracil, which is readily recognized as an aberrant DNA base and is repaired by the DNA repair machinery. Therefore, nonmethylated CpG dinucleotides occur at a predicted frequency.
70
Choudhuri
The human genome contains ~29,000 CpG islands, 65% of which have 60%–70% GC-content. The longest CpG island on chromosome 10 is 36,619-bp long, and 322 of them are longer than 3,000 bp. The role of these large CpG islands remains to be discovered. The number of CpG islands greatly varies among the chromosomes. Most chromosomes have 5–15 CpG islands per Mb (mean = 10.5 per Mb). Chromosome Y has only three CpG islands per Mb, while chromosome 19 has 43 CpG islands per Mb. Interestingly, the relative density of CpG islands was found to correlate with estimates of relative gene density (51). 4.1.5. Recombination Rate Analysis of the recombination rate revealed that the average recombination rate increases as the length of the chromosome arm decreases. Long chromosome arms have an average recombination rate of about 1 cM per Mb, whereas the shortest arms have a rate of 2 cM per Mb. A similar trend has been reported for the yeast genome. Lengthening or shortening of yeast chromosomes results in a compensatory change in recombination rate. The recombination rate is suppressed near the centromeres but is higher in the distal portions of most chromosomes, largely in the terminal 20–35 Mb. Why recombination is higher on smaller chromosome arms is open to conjecture. It should be emphasized in this context that unlike the inverse relationship between recombination rate and chromosome arm length, the relationship between gene-distance and recombination frequency is direct. Within a limit, the closer two genes are, the lower the probability of recombination; similarly, the further apart two genes are, the higher the probability of recombination between them. 4.1.6. Repeat Content Before discussing the repeat content of the human genome as uncovered by genome sequencing, a discussion of some traditional concepts and methods that provided the initial clues to the repeat content of the genome is relevant. 4.1.6.1. C-value, C-value paradox, and C0t analysis An interesting initial observation in genome biology was that genome size does not correlate well with organismal complexity. For example, Homo sapiens has a genome that is 200 times as large as that of the yeast S. cerevisiae, but 200 times as small as that of the single-celled Amoeba dubia. This apparent lack of relationship between the genome size and organismal complexity was termed as “C-value paradox”(65). The term “C-value” is derived from the notation used by Hewson Swift in 1950 to denote the amount of DNA in an organism’s haploid genome. DNA renaturation (annealing) kinetics experiments, known as “C0t” analysis and developed in the 1960s, showed that eukaryotic genomes contain large quantities of repetitive sequence that could bulk-up the genome size (66). The existence of extensive repetitive sequence elements in eukaryotic genomes may provide at least a partial explanation for the C-value paradox. In C0t analysis, samples of sheared genomic DNA are heat-denatured and then allowed to renature over time producing different C0t values [C0t = beginning nucleotide concentration in moles per liter (C0 ) × annealing time in seconds (t) × a buffer factor ( f ) based on the cation concentration that determines the speed of annealing. For example, f = 1.0 for
The Eukaryotic Genome
71
0.12M Na-phosphate buffer and f = 5.82 for 0.5M Na-phosphate buffer.e If genomes that are being compared are annealed in the same buffer condition, then f can be ignored]. For each sample, annealed DNA (dsDNA) is separated from single-stranded DNA (ssDNA) using hydroxyapatite chromatography, and the percentage of the sample that has remained single-stranded (% ssDNA; c/c0) is determined. The logarithm of a sample’s C0t values is plotted against the corresponding % ssDNA (c/c0) values to obtain the C0t curve that shows progression from little or no renaturation to near-complete renaturation over time. Hence, it is a semilogarithmic plot. The shape of the C0t curve is determined by sequence complexity, that is, the proportion of single-copy and repetitive sequences present in the DNA (Fig. 2A). Four classes of sequence are found in eukaryotic DNA: single copy, slightly repetitive ( > 1–10 copies), middle repetitive ( > 10 to many thousand copies), and highly repetitive (~100,000 copies or more). Genomes that contain repetitive sequence anneal differently from genomes with single-copy unique sequences, thereby generating different shapes of C0t curves. By comparing the initial concentration of DNA with the fraction showing annealing characteristics of repetitive sequences, the fraction of repetitive sequences in the genome can be determined. This is how it was initially determined that a large fraction (about 50%) of the genomes of higher eukaryotes including humans contain repetitive sequences. One particular value that is useful in C0t analysis is C0t½, which is the C0t value where half of the DNA has annealed. A higher C0t½ value implies a slower annealing reaction. Slower annealing occurs due to greater sequence complexity, that is, due to the occurrence of higher fraction of unique sequences, as well as due to bigger genome size. In prokaryotes where the DNA does not contain much repetitive sequences, C0t½ values are directly related to genome size. For eukaryotes, highly repetitive nature of DNA adds one more layer of complexity in annealing kinetics. In general, the larger the genome size, the longer it takes for any one sequence to encounter its complementary sequence in the crowd of DNA fragments and anneal (higher C0t½ values). Also, the more complex the genome, that is, the higher the proportion of unique sequences in the genome, the longer it takes for any two complementary sequences to encounter each other and anneal (higher C0t½ values). In contrast, if the genome is full of repetitive sequences, a sequence will encounter its complementary sequence faster and the annealing reaction will go faster (lower C0t½ values). Sometimes two genomes may yield similar-shaped C0t curves indicating similar nature of sequence complexity, but the difference in genome size can be understood based on their C0t½ values (Fig. 2B). With the advent of molecular cloning and sequencing techniques, C0t analysis has become an experimental approach of the past. However, C0t analysis provided the first insight of both prokaryotic and eukaryotic genome structure, including sequence complexity and the repetitive nature of higher eukaryotic genomes. 4.1.6.2. Types of repeat sequences in the human genome Repeat sequences account for at least 50% of the human genome. There are five classes of repeats: (i) Interspersed repeats — transposon-derived; (ii) Processed pseudogenes — retroposed copies of cellular genes; (iii) Simple sequence repeats — (A)n, (CA)n, or (CGG)n, etc.; (iv) Segmental duplications — blocks of ~1–200 kb (or longer) sequences that have been copied from one region of the genome and integrated into another region; and (v) Tandem repeat blocks — various blocks of sequence, such as at centromeres, telomeres, the short arms of acrocentric chromosomes, and ribosomal gene clusters. e
Source: www.mgel.msstate.edu/pdf/cot.pdf
72
Choudhuri
A 100 Highly repetitive DNA C0t ½ = ~ 0.12
% ssDNA (c /c 0)
80 60
Middle repetitive DNA C0t ½ = ~ 10
40
Single-copy sequence C0t ½ = ~ 400
20
10–1
100
101
102
103
Log C0t
B 100
DNA 2
% ssDNA (c /c 0)
DNA 1 80 60
C 0t ½ = 0.1
C0t ½ = 10
40 20
10–2
10–1
100
101
102
103
Log C0t
Figure 2 Hypothetical C0t curves. Figure 2A shows a hypothetical C0t curve of a mammalian DNA. The shape of the C0t curve is determined by sequence complexity, that is, the proportion of single-copy and repetitive sequences present in the DNA. The C0t½ values demonstrate the speed with which various types of sequences, such as highly repetitive, middle repetitive, and single-copy sequences anneal. Figure 2B shows two different DNA samples that yield almost identical-shaped C0t curves, suggesting similar nature of sequence complexity of these two DNA samples. However, DNA 1 anneals 100 times faster than DNA 2, indicating that DNA 1 represents a smaller genome size than DNA 2.
Repeats were traditionally described as “junk”. However, recent findings suggest that they actually represent an extraordinary trove of information about biological processes. In addition to providing a rich paleontological record holding crucial clues about evolutionary events and forces, repeats can be used as markers; they can reshape a genome by causing ectopic rearrangements creating entirely new genes, modifying and reshuffling existing genes, and modulating the overall GC content. The human genome was the first repeat-rich genome sequenced. 4.1.6.2.1. Interspersed (transposon-derived) repeats Most human repeat sequences are derived from transposable elements, which constitute about 45% of the human genome.
The Eukaryotic Genome
73
In mammals, there are two main types of transposable elements: DNA transposons (class II) and retrotransposons (class I). Retrotransposons are of two types based on the presence or absence of long terminal repeats (LTRs), such as LTR retrotransposons and non-LTR retrotransposons. The non-LTR retrotransposons have two major types: long interspersed elements (LINEs) and short interspersed elements (SINEs). All retrotransposons transpose through RNA intermediates, while the DNA transposons transpose directly as DNA. Transposable elements that carry out their own transposition are called “autonomous”, such as LTR retrotransposons and LINEs, whereas those that cannot are called “nonautonomous”, such as SINEs, and they need the help from autonomous elements for transposition. An at-a-glance classification of transposon-derived repeat elements is presented in Fig. 3. I. DNA transposons: These are autonomous transposable elements, making up about 3% of the human genome. The distribution of DNA transposons does not show any significant bias toward AT- or GC-rich regions of the genome. DNA transposons resemble bacterial transposons; they have terminal inverted repeats and they encode a transposase enzyme that binds near the inverted repeats and mediates mobility through a cut-and-paste mechanism. The transposase makes a staggered cut at the target site of the genomic DNA producing sticky ends, cuts out the transposon, and ligates it into the target site. Following the ligation of one end of the transposon to the target DNA in each strand, DNA polymerase fills in the gap by extending the ssDNA on the other end of each strand, and DNA ligase seals the gap (Fig. 4). The human genome contains at least seven major classes of DNA transposon. II. LTR retrotransposons: These are autonomous transposable elements, making up about 8% of the human genome (~ 450,000 copies). Exogenous retroviruses seem to have arisen from endogenous retrotransposons by the acquisition of a cellular envelope (env) gene. Like DNA transposons, the distribution of LTR retrotransposons (or LTR retroposons) does not show any significant bias toward AT- or GC-rich regions of the genome. LTR retroposons are flanked by direct LTRs, that is, long terminal direct
Transposon-derived repeats
DNA Transposon (Class II)-derived (direct transposition, autonomous)
LTR Retrotransposon-derived (contains LTR, autonomous e.g., HERV)
LINE (autonomous e.g., L1)
Figure 3 genomes.
Retrotransposon (Class I)-derived (transposition through RNA intermediate)
Non-LTR Retrotransposon-derived (does not contain LTR)
SINE (nonautonomous e.g., Alu)
Various types of transposon-derived repeats in the human genome and other eukaryotic
74
Choudhuri
Target DNA
Transposon
AACGG TTG CC
DNA polymerase fills the gap and ligase seals the nick Transposon AACGG
TTGCC
Transposase-mediated staggered cut and transposon integration DNA polymerase fills the gap and ligase seals the nick
Transposon AACGG TTG CC
AACGG TTG CC
Direct repeat created flanking the transposon insertion site
Figure 4 DNA transposons have terminal inverted repeats. They encode a transposase that binds near the inverted repeats and makes staggered cuts at the target site of the genomic DNA producing sticky ends. The transposase also cuts out the transposon and ligates it into the target site. Following the ligation of one end of the transposon to the target DNA in each strand, DNA polymerase fills in the gap by extension on both strands and ligase seals the nick. Transposon insertion creates direct repeats that flank the inserted transposon.
repeats that contain all the necessary transcriptional regulatory elements. They contain gag and pol genes, which encode a protease, reverse transcriptase, RNAse H, and integrase. Reverse transcription, primed by a tRNA, occurs in the cytoplasm (in contrast to the nuclear location and chromosomal priming of LINEs as described below). Although there are a variety of LTR retrotransposons, only the vertebrate-specific endogenous retroviruses (ERVs) appear to have been active in the mammalian genome. About 85% of the LTR retrotransposon-derived elements in the genome consist only of isolated LTR where the internal sequence has been lost by homologous recombination between the flanking LTRs. III. Line elements: These are autonomous transposable elements, making up about 20% of the human genome and occurring at much higher density in AT-rich regions of the genome. In humans, the LINEs (L1) are about 6 kb long. L1 is a primate-specific LINE, which is also the major LINE in human genome constituting about 17% of the genome (~ 520,000 L1 elements). A LINE contains a pol II promoter and two open reading frames (ORFs), one encoding the endonuclease and the other encoding the reverse transcriptase. LINE activity proceeds as follows: RNA pol II transcribes the LINE DNA into LINE RNA; the LINE RNA is translated into proteins; the proteins and RNA join together and reenter the nucleus; the endonuclease cuts a strand of the target genomic DNA, often in the intron of a gene; the reverse transcriptase copies the LINE RNA into LINE DNA which is inserted into the target DNA forming a new LINE element there. The length of LINEs may vary because transcription may continue downstream into additional DNA sequence producing a longer transposed element, or reverse transcription of LINE RNA may conclude prematurely producing a shortened transposed element. The LINE machinery is believed to be responsible for most reverse transcription in the genome, including the retrotransposition of the nonautonomous SINEs and the creation of processed pseudogenes. Three distantly
The Eukaryotic Genome
75
related LINE families are found in the human genome: LINE1, LINE2, and LINE3. Only LINE1 (L1) is still active. IV. Sine elements: These are nonautonomous transposable elements that need the help of L1 elements for transpostition. SINEs occur at much higher density in GC-rich regions of the genome and they make up about 13% of the human genome. SINEs are short sequences (about 100–400 bp) and they contain an internal pol III promoter but do not encode any proteins. All currently known SINEs are derived from tRNA and 7SL RNA genes. Most nonautonomous SINEs share the 3′ end with a resident LINE. The only active SINE in the human genome is the Alu element, which is the major SINE constituting about 11% of the genome (~1 million Alu elements). Alu elements are primate genomic-specific SINEs, which are derived from the small cytoplasmic 7SL RNA. Each Alu sequence is a dimer of two 7SL RNA-derived monomer units, connected by an A-rich linker. It is surprising that SINEs depend on LINEs for their insertions but they show opposite insertion bias: Alu in GC-rich regions but LINE in AT-rich regions. One explanation is that SINEs had been initially inserted in AT-rich DNA along with LINEs, but the distribution was subsequently reshaped by evolutionary forces. This is evidenced by the observation that recent Alu elements show a preference for AT-rich DNA like that of LINEs, whereas progressively older Alu elements show a progressively stronger bias toward GC-rich DNA. V. Variations in interspersed repeat density: There is wide variation in repeat density in the genome. Some regions are extraordinarily dense in repeats, such as a 525-kb region on chromosome Xp11 (X chromosome, short arm p, region 1, band 1), with an overall transposable element density of 89%. This region contains a 200-kb segment with 98% density as well as a segment of 100 kb in which LINE1 sequences alone comprise 89% of the total sequence. In contrast, some genomic regions are nearly devoid of repeats. The four regions with the lowest density of interspersed repeats in the human genome are the four homeobox gene clusters: HOXA, HOXB, HOXC, and HOXD. The near absence of repeats may be a sign that sequence disruptions cannot be tolerated in this gene cluster. Each locus contains regions of about 100 kb containing less than 2% interspersed repeats. A similar trend is also true for the HOX clusters in mouse, rat, and baboon. Transposons contributed to the birth of many genes as well as various parts of the gene. For example, 20 human genes had already been recognized as transposon-derived. These include the genes encoding RAG1 and RAG2 recombinases and the major centromere-binding protein (CENPB). From the draft human genome sequence 27 more genes were identified bringing the total to 47. All but four are derived from DNA transposons. The transcription terminators of many genes are derived from LTR retroposons. Other genes employ regulatory elements derived from repeat elements. 4.1.6.2.2. Processed psuedogenes There are three types of pseudogenes in the genome: unitary pseudogene (cellular gene inactivated by acquiring mutations); duplicated pseudogene (a gene born by tandem duplication of a cellular gene, then becoming inactivated by acquiring mutations, while the other copy functions normally); and processed pseudogene (retrotransposed pseudogene or retropseudogene). Processed pseudogenes are retrotransposed copies of mRNAs (in the case of protein-coding genes). Because they are reverse transcribed from mRNAs, they are characterized by one or more of the following structural features: (i) presence of a poly(A) tail, (ii) no introns, (iii) loss of upstream regulatory sequences, and (iv) disabled ORF. The ORF can be disabled in one of the following ways: (i) from premature stop codon, (ii) from accumulating various mutations, and (iii) from ORF truncation.
76
Choudhuri
In the human genome build34, the total number of pseudogenes (processed plus nonprocessed) seems to be around 17,000 (refer to Gerstein group database http://www. pseudogene.org/human/ and links therein), although the reports from various sources vary significantly depending on annotation. Processed pseudogenes are made through LINE-mediated mRNA retrotransposition. In humans, LINEs are the major source of insertional mutagenesis. In addition to its own reverse transcription and transposition, the LINE enzymatic machinery can sometimes be diverted to direct the same (retroposition) of cellular mRNA transcripts. When LINEs are active, mRNA transcripts that are in the vicinity can be swept up and retrotransposed. This results in the creation of processed pseudogenes in the genome (67). Many processed pseudogenes are transcribed even though they do not encode any functional protein. It has been estimated that the human genome contains 166–233 transcribed processed pseudogenes, which represent about 4%–6% of all pseudogenes in the genome (68). Recent evidence indicates that transcribed processed pseudogenes may actually perform some regulatory functions. Hirotsune et al. (69) provided evidence that the transcribed pseudogene Makorin1-p1 in mice stabilizes the Makorin1 mRNA. Based on their experimental results, the authors hypothesized that the first 700-nt region of Makorin1 mRNA contains a recognition site for a putative destabilizing factor. Because this 700-nt region is shared by both the normal gene-encoded Makorin1 and pseudogene-encoded Makorin1-p1 mRNAs, the expression of the pseudogene provides a means of titrating out the destabilizing factor by direct competition. Although Makorin1 is not found in humans, other such examples may be reported in the future. 4.1.6.2.3. Simple sequence repeats Simple sequence repeats (SSRs), also known as “simple sequence tandem repeats” (SSTRs), are perfect or slightly imperfect tandem short repeat sequences. SSRs with shorter repeat units (n = 1–13 bases) are called “microsatellites”, whereas those with longer repeat units (n = 14–500 bases) are called “minisatellites”. SSRs are thought to arise by replication slippage or unequal crossing over (discussed in Chapter 1). SSRs comprise about 3% of the human genome with the greatest contribution coming from dinucleotide repeats (0.5%). There is approximately one SSR per 2 kb of the human genome and the number of nonoverlapping tandem repeats is 437 per Mb. Of the dinucleotide repeats, the share of the AC dinucleotide repeat is the highest (50%), followed by AT (35%), AG (15%), and GC (0.1%). Similarly, the frequencies of the trinucleotides repeats are AAT (33%), AAC (21%), ACC (4.0%), AGC (2.2%), ACT (1.4%), and ACG (0.1%). When the dinucleotide and trinucleotide repeats are combined, the fraction of AC is still the highest (28%) followed by AT (19%), AG (8%), AAT (4%), AAC (2.5%), AGG (1.5%), AAG (1.4%), and the rest being less than 1% each. Thus, trinucleotide SSRs are much less frequent than dinucleotide SSRs. SSRs have been extremely important in human genetic studies because they show a high degree of length polymorphism in human population due to frequent replication slippage, and hence can serve as polymorphic markers in the genome. The repeat CAG in the ORF (encoding glutamine) has been implicated in many “trinucleotide repeat expansion disorders” (discussed in Chapter 1). 4.1.6.2.4. Segmental duplications Segmental duplication involves the transfer of 1–200 kb (or greater) blocks of genomic sequence to one or more locations in the genome. Hence segmental duplications create paralogous loci (loci created by duplication) that may result in gene CNVs; CNVs result
The Eukaryotic Genome
77
in altered gene dosage between individuals. The duplicated regions represent low-copy repeats and have >90% identity. Such strong sequence identity suggests that they are relatively recent in origin. The finished sequence of the human genome reported about 5.3% of the genome as segmental duplications with a possibility for further increase because many of the remaining euchromatic gaps are associated with segmental duplications (61). Various other publications that followed have reported slightly higher percentage of segmental duplications in the human genome. Segmental duplications can be of two types: interchromosomal and intrachromosomal duplications. In interchromosomal duplications, segments are duplicated among nonhomologous chromosomes. Many interchromosomal duplications map near the centromeric and telomeric regions. Intrachromosomal duplications occur within a particular chromosome. It involves several duplicated segments that mediate chromosomal structural rearrangements, which is often associated with genetic disease. Intrachromosomal duplications are more frequent (~3.5%) than interchromosomal duplications (~2%). In humans, chromosomes 7, 9, 15, 16, 17, 19, 22, and Y are significantly enriched in both inter- and intrachromosomal duplications (70). There seems to be a strong association between the location of segmental duplications and regions of chromosomal instability. Segmental duplications predispose the regions containing these to recurrent rearrangement by nonallelic homologous recombination (paralogous recombination), resulting in deletion, duplication, or inversion. Segmental duplications have been implicated in >25 human genetic diseases, such as Smith-Magenis syndrome, Charcot-Marie-Tooth syndrome 1A, and Prader-Willi/Angelman syndrome. Segmental duplications provide raw materials for the evolution of genome and are also responsible for interindividual variations because they contribute to large-scale CNVs within the human population. Segmental duplications have apparently contributed more to the genetic difference between chimpanzee and human than single-base mutations (71,72). 4.1.6.2.5. Tandem repeat blocks This class includes large tandem repeat blocks of sequence known as “satellite DNA”, so named because they form a second or satellite band when genomic DNA is separated on a density gradient. There are various types of satellite DNA, such as alpha, beta, and gamma satellites, satellites I, II, and III. In general, satellite DNA shows a great degree of variability among individuals, particularly with regard to the number of repeats at a given locus. The most common satellite DNA type is the alpha satellite (alphoid DNA) with a repeat unit size of 171 bp. It is the major sequence element in centromeric heterochromatin of all human chromosomes and is involved in centromere function, such as microtubule attachment. Some of the 171-bp units contain a 17-bp binding site called the “CENP-B box” that binds the centromere-specific protein CENP-B. The consensus sequence of the CENP-B box is 5′-(C/T)TTCGTTGGAA(G/A)CGGGA-3′. The 171-bp monomer units are arranged in higher order repeats ranging in length from several hundred to several thousand kilobases. The C